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Abstract 
 
In chapter one the biology of cancer is introduced along with a brief history of drug 
treatment and the status quo of cancer therapeutics. This includes a general overview of 
cancer prevalence, carcinogenesis, and biochemistry. The main targets for cancer therapeutics 
are introduced along with in-depth look at cancer vasculature, tubulin binding agents and 
their mechanisms of action. 
In chapter two the development of the routes to the dibenzo[c,e]oxepine target compounds 
are described. The optimisation of a key biaryl precursor molecule for these analogues is 
described. This includes a brief overview of palladium catalysed coupling chemistry and a 
screen for suitable catalytic systems.  
In chapter three the development of an intramolecular ring closing process for 
dibenzo[b,d]oxepine is described. This includes investigation into non-phenolic oxidative 
coupling and a screen for oxidants. Palladium/phosphine catalysed intramolecular arylation is 
also discussed.  
In chapter four the synthesis of the target compounds is described along the development of 
routes to further analogues. 
In chapter five the biological testing of compounds is discussed. This features an 
introduction to biological evaluation methods for anti cancer compounds. The results for all 
of the MTT and tubulin binding assays (MA) are presented, revealing a fluorinated 
dibenzo[c,e]oxepine analogue with cytotoxicity within the  nanomolar range  (MTT K562 - 
IC50 60 nm, MA - 1.2 µM). Furthermore a link has also been established between the 
cytotoxic activity profiles of a series of simple biaryl compounds and Combretastatin A-4.  
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What is cancer? 
Understanding the genesis of cancer is an ongoing process. Extraordinary progress has been 
made over the past 30 years in determining the most fundamental basis of the process at a 
molecular level. The decoding of the human genome has led to the identification of several 
genetic precursors to cancer. This, along with the identification of several efficacious natural 
compounds, has led to research into several targets areas  
“Cancer” is a generic umbrella term that covers over 150 different conditions that affect most 
tissues in the body. Tissues that are susceptible to malignancies (most are) can present them 
in various grades and types. Even though each type has unique features, the basic 
mechanisms in tumour formation are quite similar. 
Cells in a healthy human body exist as a complex interdependent system that regulates each 
other’s proliferation. Healthy cells only reproduce under instruction of cells in their 
proximity; this system of collaboration ensures the maintenance of an appropriate tissue size 
and structure. Cancer cells exist in stark contrast to this in that they over-proliferate, affecting 
tissue structure and avoiding controls on growth.   
Cancer growth is determined by a set of basic principles that have been identified over the 
past 30 years. The cells of a tumour began as a single cell at one point, usually years before 
the tumours inception stimulated by inappropriate reproduction. The changes that lead to 
cancer occur through a build up of mutations in specific genes within the cell. The 
understanding of these genes is paramount to the formation and development of cancer 
treatments. 
All eukaryotic cells contain genes; these are sequences of DNA arranged on chromosomes 
located in the nucleus of the cell. Each gene codes for a specific sequence of amino acids 
from which proteins are made. Mutations in genes can cause changes in the activity or the 
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quantity of the protein. Cancer is determined by two types of gene, proto oncogenes and 
tumour suppressor genes. These genes, when non-mutated, are important in the regulation of 
cell life cycle. Proto oncogenes encourage the growth of a cell before cell division, tumour 
suppressor genes inhibit this. Mutation of proto oncogenes can lead to excessive 
multiplication causing either the formation of too much protein product or an overactive 
version of it. Conversely, mutation in a tumour-suppressor gene inactivates its control over 
growth leading to uncontrolled cell proliferation. 
Cancer in essence is caused by DNA mutation/damage. During the process of cell division, 
any damaged/mutated DNA is either repaired or destroyed by the various cellular DNA repair 
mechanisms. Cancer cells are neither destroyed nor repaired by these mechanisms because 
the repair mechanisms have been deactivated by mutation. When the DNA damage in a cell 
exceeds its repairing capability the mutation is passed on to the next cell. When this mutation 
is on a gene related to DNA repair mechanisms, further replication will increase the rate of 
mutation at other sites. This concept is known as the mutator phenotype (Fig 1) and evidence 
of this is shown in the fact that cancer cells show thousands of DNA mutations (Loeb. 2001).  
 
Figure 1 Diagram showing the concept of the mutator phenotype from the initial point of DNA damage to point of clinical 
detection (Loeb. 2001). 
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The causes of cancer are varied and many. Several environmental factors have been 
identified. These include tobacco, red meat, numerous chemicals, environmental pollutants, 
UV-light and radiation. Microbial infections have also been shown to cause cancers such as 
aflatoxin from the fungus Aspergillus flavus from certain nuts and the human papilloma virus 
which can cause cervical cancer. Genetic factors also apply to causes of cancer with 
approximately 10% of cancers being entirely hereditary (Gopie et al. 2012). 
Instances of cancers differ between the sexes with men more likely to develop cancer, this 
increases over the age of 64. This phenomenon has been documented in a recent study on 
brain/central nervous system cancers over 37 years (1975-2007). Kohler’s group commented 
that male nervous system cancers accounted for 90/100000 cases in 1990 whereas cases of 
female nervous system cancers was less than half of this (40/100000) in 1995 indicating a 
gender–specific factor for CNS cancers (Kohler et al. 2011).      
Cancer can also be described as a disease of the elderly as cases in both sexes increase 
rapidly from the age of 55 (Fig 2), (Bassily et al. 2010) this is due the natural process of 
ageing at the cellular level and a lifetime accumulation of mutations. Treatment of the 
condition amongst the elderly is complicated by functional decline, low haematopoietic 
reserve and a high prevalence of co morbidities (Bassily et al. 2010). 
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Figure 2 Graph showing cancer mortality as a function of age (Bassily et al. 2010). 
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Cancer causes and metastasis  
Tumours are classed as benign, pre-malignant or malignant. Benign tumours are not classed 
as cancerous; they do not invade neighboring tissues, metastasize or grow abnormally. 
Metastasis occurs when cancerous cells break away from the primary tumour, and travel to 
other parts of the body through either the circulatory or lymphatic system. This process 
complicates treatment and is sometimes referred to as haematogenous or lymphatic spread 
(Lorusso & Rüegg 2012). 
Metastatic or secondary tumours arise when the breakaway cancer cells arrive at a distant 
site, penetrate through the epithelial cells and begin to proliferate. The process of local 
metastasis is also possible where primary tumour cells permeate through local tissue and 
form secondary tumour sites within close proximity to the initial tumour (Oppenheimer 
2006). Ability of cancer to metastasize is classed as one of the six hallmarks of cancer. 
Hanahan and Weinberg concluded in the early 2000s that all malignant cancer growth is a 
manifestation of six abilities of a cancer cell:  
Tissue invasion and metastasis  
Self-sufficiency in growth signals 
Insensitivity to growth inhibitory signals  
Evasion of apoptosis 
Potential for unlimited replication  
Angiogenesis 
Ten years later the group defined the above six hallmarks, they suggested the addition of two 
more (Hanahan & Weinberg 2011): 
Reprogramming of energy metabolism  
Evading immune destruction 
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Growth and proliferation in normal cells are instigated by external signals, whereas cancer 
cells do not require these signals from surrounding tissue and proliferate uncontrolled. This is 
due to the production of their own hormone signals or the induction of their own internal 
stimulus.  
Cancer cells also have the ability to ignore the signals that regulate growth allowing them to 
avoid the normal mechanism of growth inhibition to proliferate. 
Immortality or avoidance of apoptosis is another hallmark of cancer. Cell life in normal cells 
is determined by repetitive nucleotide sequences at each end of the chromosomes called 
telomeres. In normal cells each time a cell divides, the telomeres get shorter. When the 
telomeres get too short the cell will cease growth, enter senescence, or begin programmed 
cell self-destruction (apoptosis), this depends on the cell's genetic background. Cancer cells 
evade the mechanisms normally in place to induce the previously mentioned consequences of 
ageing. Apoptosis provides space for new cells and avoidance of this allows the damaged or 
altered genetic information to pass to the next generation of cells. 
Cancer cell cycle 
The growth of cancer is not only caused by break down in the cell signaling pathways, it also 
causes disruption of the cell cycle. The cell cycle clock (fig 3), is made up of an arrangement 
of proteins that interact with each other in the nucleus. These proteins integrate various 
stimulatory and inhibitory pathway information, if the stimulatory messages are in greater 
numbers the cell can advance through its growth cycle. There are four stages in the cell cycle 
and advancement through them is driven by changing levels of cyclin proteins. 
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Figure 3 diagram showing the 4 phases of the cell cycle (G1, S, G2, M) and how this is regulated by cyclin (Dehay & 
Kennedy. 2007). 
The G1 phase is crucially important as it is this that decides if the cell will continue into the S 
phase. This is activated by a molecular switch. 
 
Figure 4 diagram showing advancement from G1 to S phase via the activation of a molecular switch (Machaca.  2011). 
The process (Fig 4) begins with a rise in the levels of cyclin D, followed by an increase in the 
levels of cyclin E. Combination of these proteins leads to the activation of cyclin dependent 
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kinase enzymes (Fig 4, 1). These enzymes transfer phosphate groups from ATP molecules to 
a pRB protein, this is also known as the master brake of the cycle. If this protein lacks 
phosphate groups it blocks the cycle through the sequestering of various transcription factors. 
The brake on cycling is removed (Fig 4, 2) when the pRB receives enough phosphates from 
the cyclin-kinase complex freeing the transcription factors to act on genes (Fig 4, 3). This 
leads to the induction of the various proteins needed for further progression through the cell 
cycle. The overall effect of any change in the levels of the proteins is deregulation of the 
cycle clock and hence excessive cell proliferation (Machaca. 2011). 
Types of cancer     
As mentioned there are several different types of cancer, a broad system of classification 
exists based either on type of cell or tissue that the cancer has come from. 
Carcinoma – this is the most common type of cancer. It occurs at epithelial cells, usually in 
older people. Common types are breast, prostate, lung, colon and pancreas.   
Lymphoma / Leukaemia – these tumour classes come from hematopoietic cell. They tend to 
include cancer of the lymph nodes and various tissues of the immune system. 
Sarcoma – these are tumours’ of the connective tissue. All sarcoma originate from 
mesenchymal cells from bone marrow. Susceptible tissues include cartilage, bone, muscle 
and fat. 
Blastoma – these cancers are more common in children as they are derived from embryonic 
cells.  
Germ line – cancers derived from sperm or ova (Pluripotent cells) from testicle or ovary. 
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Cancer chemotherapy 
This is the use of pharmaceutical agents to kill cancer cells through several different 
mechanisms. The main drug target areas are interference with the cell division process and 
damage to the DNA of cancerous cells. The principle behind chemotherapy is to damage 
rapidly dividing cells, this includes both cancerous and healthy cells with the knowledge that 
cancerous cells cannot repair themselves against the cytotoxicity but normal cells can. This 
type of treatment is typically used to deal with metastasis as it affects rapidly dividing cells 
throughout the body. 
In principle this treatment works because the cancer cells replicate quicker than most normal 
cells. This means that it affects mainly cancer cells and a small number of healthy cells as a 
lower number of healthy cells replicate before the drug is passed from the body. 
Treatment is usually given in cycles, this is to give the patients time to recover from the side-
effects caused by damage to normal cells. These usually include; hair loss, diarrhea, fatigue 
and nausea. The drugs are normally given in combinations to reduce cancer resistance. 
There are several chemotherapeutic drug classes in use; treatment is usually tailored for each 
patient depending on type and class of malignancy. 
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Antimetabolites  
These are compounds that mimic biochemical molecules. They usually bind to proteins 
(receptors or enzymes) causing inactivation of a biological response. For this to occur the 
compounds are usually very similar in structure to the compound they are mimicking. The 
main process that these drugs interfere with is the production of nucleic acids. This is done in 
various ways such as inhibiting the production of deoxyribonucleoside triphosphates, this is 
an immediate precursor in the synthesis of DNA - so failure to produce this halts replication. 
This usually requires a long duration of interference to cause cell death. Many anti-
metabolites are so similar in structure to pyrimidine or purine bases that they can successfully 
substitute for them in the anabolic nucleotide pathways and compete with /inhibit the normal 
substrates for the enzymes. Nucleotide anti-metabolites are so similar in structure to their 
normal counterparts that they can be also be incorporated into DNA and RNA even with the 
highly selective nature of polymerases. This leads to the initiation of various DNA repair 
mechanisms and cell death. Five main groups of anti-metabolite are in use (Fig 5, 1- 5); 
Pyrimidine antagonists – i.e. 5-Fluorouracil (1) (Mader et al. 1997) 
Purine antagonists – i.e. 6-thioguanine (2)  (Nelson. 1990) 
Folate inhibitors – i.e. Methotrexate (3) (Obasaju et al. 1993) 
Sugar modified nucleoside analogues – i.e. cytarabine (4) (Mehta et al. 2011) 
Ribonucleotide reductase inhibitors – i.e. Triapine (5)  (Sigmond et al. 2007) 
 
                                                               Figure 5 Common anti-metabolite cancer drugs 
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Alkylating agents 
This is the most widely used class of anticancer drugs. These compounds are electrophiles 
that form covalent bonds with biological macromolecules. The most common targets are 
nucleophilic sites at DNA bases (NH2, OH etc) and will usually result in the attachment of an 
alkyl group to DNA. The main sites for alkylation (Fig 6) are nitrogen atoms at guanine (6), 
adenine (7) and cytosine (8). 
 
Figure 6 Main sites for alkylation on DNA base guanine (6), adenine (7) and cytosine (8). 
Alkylation causes damage in various forms as the helical structure of the DNA is rendered 
defective. The usual disruption caused is DNA breaks or incorrect links within or between the 
strands of the molecule. The lethal lesions are usually caused by the interstrand link or less 
frequently intrastrand cross-linking as caused by e.g. cis-platin (Fuertes et al. 2003). 
Apoptosis occurs if the damage caused is not fixed by any of the various DNA repair 
mechanisms. Examples include (Fig 7).  
 
Figure 7 Structures of commonly used alkylating agents Chlorambucil (9), bischloroethylnitrosourea (BCNU) (10), 
temozolomide (11), lomustine (CCNU) (12) and chlormethine (13). 
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DNA intercalating agents 
These compounds are geometrically flat or contain flat regions. They stack between paired 
DNA bases to form a DNA-drug interaction that is vital for cytotoxicity. The compounds 
bond to the DNA through Van der Waals forces and hydrogen bonding; due to this they are 
usually aromatipolycyclic and planar. The drug is positioned rigidly in a perpendicular 
fashion to the DNA helical axis. 
The interaction between the drug and base is more energetically favored and so stronger than 
the interaction between base pairs. Intercalating agents tend to be used against fast growing 
cancer cells such as Hodgkin’s Lymphoma, for which Daunorubicin (Fig 8, 14) is used in the 
clinic (Tulpule et al. 2001). The antibiotic dactinomycin (Fig 8, 15)  has also been used for 
the treatment of children’s cancers such as Ewing’s Sarcoma (Balamuth and Womer. 2010) 
and Wilm’s tumour (Ehrlich et al. 2006). 
    
                                     
Figure 8 Daunorubicin (14) and dactinomycin (15), two commonly used DNA intercalating drugs 
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Angiogenesis and tumour vasculature 
When a tumour grows to roughly 1-2 mm in diameter, the process of angiogenesis, formation 
of new blood vessels begins. At this size vasculature is required for further growth and 
metabolism. The supply of blood to cancer cells is essential for providing oxygen and 
nutrients and removing the cytotoxic waste produced.  
 
Figure 9 Diagram showing the induction (a) and resolution (b) steps for the process of angiogenesis for tumour vasculature 
It has been shown that the establishment of a blood vessel network directly correlates with 
survival, growth and development of a tumour (Hinnen and Eskens. 2007). 
This process begins (see FIG 9) when regular blood circulation becomes inadequate and the 
oxygen supply to cells is restricted. Various angiogenic proteins are activated to stimulate the 
production of new blood vessels. Vascular endothelial growth factor (VEGF) and fibroblast 
growth factors (FGF) are released by a signal cascade to instigate differentiation of the 
endothelial cells that constitute blood vessels In addition, further proteins are recruited to 
VBM – Vascular Basement 
Membrane 
MMP – Matrix 
metalloproteinases 
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remodel the extracellular matrix, stabilize the blood vessels and regulate the differentiation of 
cells to form capillaries, veins and arteries (Eskens and Verweij. 2006). 
The vascular network formed in solid tumours is distinct when compared to non-cancerous 
tissue. This is due to a process called neovascularisation. This process involves parallel 
proliferation of endothelial cells that cover the inner surface of blood vessels. This process 
differs from angiogenesis in that angiogenesis mainly deals with the growth of sprouts and 
capillary buds from existing vessels (Raja et al. 2012).  
Cancer cells have a faster rate of proliferation than normal cells. Due to this 
neovascularization lags behind cell growth resulting in the formation of vasculature that 
varies greatly from normal vessels in both structure and morphology. 
The difference in cancer vasculature is different at a cellular level as tumour vessels express 
proteins that are either not present or at a low concentration in non-cancerous cells. Examples 
of these proteins are angiogenic growth factor receptors and αvintegrins, the presence of 
which has been identified from human breast carcinoma xenografts on mice using an in vivo 
phage library. This phage library also allowed the identification of cancer cell specific amino 
acid motifs including the RGD motif (arginine, glycine and aspartic acid) which can 
selectively bind to the integrins αvβ3 and αvβ5. The group reported that the motif is expressed 
in several cancers including sarcoma, melanomas and carcinomas (Jussila and Alitalo. 2002). 
The importance of blood supply in the development and growth of solid tumours has not been 
overlooked and compounds that specifically target vasculature have been developed. These 
compounds have been broadly classified as anti-angiogenic agents and care needs to be taken 
to distinguish between them. Anti-angiogenic compounds target proteins involved in the 
generation of new vessels preventing vasculature growth whereas vascular targeting agents 
actively target and cause physical damage to pre-existing blood vessels. Some agents both 
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prevent the formation of new vessels and cause disruption to existing vasculature. In this case 
the classification of said compound is based on the primary mode of action (Hinnen and 
Eskens. 2007). 
Normal (non-cancerous) tissues in the body have a well maintained blood supply provided by 
an efficient and orderly vascular network (Fig 10, a). This is regulated by a demand driven 
metabolic balance between pro and anti-angiogenic factors and a complex network of 
lymphatic vessels that remove the subsequent metabolic waste products. The normal 
microvascular architecture is hierarchical with an even distribution of mature vessels to allow 
the appropriate transport of oxygen and nutrients to cells. 
 
Figure 10   (a) An SEM image showing the microvascular structure of normal lung tissue. (b) An SEM image showing the 
microvasculature of adenocarcinoma. The arrows show abnormal structures, arrows point to blind ends. 
In tumours, rapid expansion of cell population and related over expression of angiogenic 
factors lead to the formation of a disordered and inefficient network of blood vessels that 
differ drastically from healthy blood vessels (Fig 10, b). This vasculature is characterised as a 
tangled, disorganised maze of immature, permeable vessels without a hierarchy (Konerding 
et al. 2001). Tumour vasculature tends to be uneven in shape and non-uniform in diameter 
with dead ends. They can also have shunts between arterioles and venules. The 
complementary lymphatic system is equally disordered, uniform and leaky causing fluid 
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engorged vessels (Padera et al. 2002). These structural flaws massively reduce the 
vasculature’s ability to both deliver required nutrients through the blood and remove waste 
through the lymph system. Compared to normal vasculature tumour vessels are much more 
permeable. As they are immature vessels that are lacking in smooth muscle cells leaving 
them with an abnormal basement membrane caused by gaps in the endothelial lining (Gee et 
al. 2003). This hyperpermeability leads to inadequate osmotic force causing a build up in 
interstitial pressure (Vaupel et al. 1987). The irregular shape of the vessels causes geometric 
resistance that often leads to insufficient amounts of oxygen reaching tumour cells, this is 
evident the presence of micro regional hypoxia (Vaupel and Hockel. 2000). 
Anti-angiogenic Agents 
The aim of anti-angiogenic therapies is to target and inhibit the key molecular factors in a cell 
that are required to develop new vessels for tumours. Without the development of sufficient 
vasculature to deliver oxygen and remove waste, tumour growth is limited to a few 
millimetres in diameter and the tumour remains benign and metastasis is avoided (van der 
Bilt et al. 2012). 
The process of angiogenesis is complex (Fig 11) and depends heavily on regulation of 
biochemical signals, receptors and various cell types to manage what is known as the 
“Angiogenic cascade”. Many signaling molecules have been identified as crucial to the 
process but the target deemed most important and therefore heavily investigated is the protein 
vascular endothelial growth factor (VEGF). This pro angiogenic factor incites the growth of 
vasculature as a response to certain stimuli such as hypoxia, the lack of or reduced levels of 
oxygen (Dibbens et al. 1999). 
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Figure 11 Diagram showing the complexity of the VEGF biochemical pathway leading to angiogenesis (Sabioscience,  
2012) 
VEGF is vital for the proliferation of endothelial cells and therefore new vasculature but it is 
also important in the regulation of vasculature transport by inducing an increase in 
permeability. It has also been shown that the rate of angiogenesis as a function of VEGF 
secretion can be affected by oncogene activation or tumour suppressor deactivation.(Lennard 
et al. 2001) Several therapeutic approaches have been developed to directly target both 
VEGF (Jubb et al. 2006) and VEGFR (VEGF receptor). Inhibition of tyrosine kinase 
(VEGFR) using small molecule pharmaceuticals have had promising results in the 
cliniespecially the use of these compounds in combination with established therapeutic agents 
(Madhusudan and Ganesan. 2004). Several other angiogenic factors exist and have been 
researched as targets (Dong et al. 2007). Despite the potential in the area it should be noted 
that several cellular angiogenic pathways exist, all with highly sophisticated regulation 
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mechanisms with this in mind targeting one factor is very unlikely to cause enough disruption 
to cease formation of vasculature.  
Tubulin and microtubules 
Microtubules are important proteins that make up part of the cell cytoskeleton. These 
compounds are long protein polymer filaments that have a tube like shape and are essential 
for cell division in eukaryotic cells. The main building block for microtubules is tubulin, this 
protein is found in almost all differentiated cells in the body (Ludueña. 1997). 
Microtubules are made up of repeating units of α-tubulin and β-tubulin heterodimers, with a 
mass around 50,000 Daltons per dimer (Fig 12, a). These structures can measure up to 
several micrometres in length with the tubulin heterodimers maintained in an equilibrium  
The structures of both the α and β tubulin subunits are very similar, this is reflected by the 
fact that they share a 40% sequential homology (Aylett et al. 2011). 
Microtubule arrays are used to physically separate chromosomes during cell division. As the 
cell divides the microtubules maintain the direction and plane of cleavage of the genetic 
material. These tasks require the dynamic assembly and disassembly of the microtubules 
especially during the process of mitosis. The presence of microtubules is also important for 
cell shape maintenance, movement of vesicles through the cell, cell signaling and 
morphogenesis (Dupuis-Williams et al. 1996). 
The tubulin sub-units polymerize to create a robust polymer that possesses an essential 
resistance to bending, compression and stretching. These properties along with the various 
mechanical properties of transitional filaments and actin filaments give the cytoplasm its 
strength and shape; this in turn forms the cytoskeleton which dictates the spatial organization 
of the cell. The formation of these cytoskeletal polymers exist in a highly dynamic 
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equilibrium in which they polymerize, depolymerize and move through the cytoplasm with a 
timescale of seconds to minutes (Castro et al. 2010). 
 
 
Figure 12 a - Diagram of a fully formed microtubule. b - Diagram showing the 3 stages of microtubule dynamic assembly 
(Conde & Caceres 2009), (http://www.nature.com/nrn/journal/v10/n5/box/nrn2631_BX1.html. 2012b) 
The process begins with the gathering of the α and β tubulin subunits forming a short 
microtubule nucleus (Fig 12, a). This nucleus is then elongated at both ends resulting in the 
formation of a hollow cylindrical shaped structure composed of a head to tail layout of 
subunits arranged as 13 protofilaments. These filaments have a helical arrangement 
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(sometimes referred to as a super helix.) The ends of the microtubules are designated as a 
plus end in which a β-subunit is at the end or a minus end in which a α-subunit is at the end 
(Lai et al. 1994). 
 
 The stabilization/destabilization of microtubules is associated with the binding interactions 
of a group of proteins called microtubule associated proteins (MAPs). These proteins can 
bind to other proteins or small molecules to change dynamics classing them in a regulatory 
role (Brun et al. 2009). 
The cycle of tubulin polymerization/depolymerization (Fig 12, b) begins with the binding of 
GTP at the β-subunit causing its activation. This begins the formation of a several 
consecutive monomers of GTP known as a “Cap” at the end of a microtubule, the presence of 
which is essential for growth to continue. When tubulin is polymerized, GTP irreversibly 
hydrolyses to GDP.        
As a precautionary measure to prevent all of the GTP converting to GDP the microtubule is 
briefly destabilized to allow detachment of the tubulin-GDP complex. It is believed that the 
essential dynamic instability is driven by the competition between the attachment of GTP to 
tubulin and the hydrolysis of GTP (Fig 13). This important property allows the interruption 
of slow growth periods with a rapid disassembly. With this in mind, compounds that interfere 
with the formation/deformation of microtubules can potentially act as chemotherapeutic 
agents (Nawrotek et al. 2011). 
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Figure 13 Image of GDP-bound tubulin (Chen et al. 2008). 
Tubulin as a drug target 
Owing to their ubiquitous nature, the presence of tubulin in the cytoskeleton is essential for 
eukaryotic cells and of vital importance in various cell processes, in particular mitosis. The 
tubulin assembles to make microtubules and in turn form the mitotic spindle that is required 
to pull apart the chromosomes into each subsequent daughter cell. They have key roles 
forming cell shape during angiogenesis, cell proliferation and migration. In the context of 
cancer, microtubule-motor proteins are crucial in the transport of vital onco proteins.  
Microtubules are highly dynamic polymers by nature, constantly changing length during 
various phases of elongation/shortening. This dynamic property makes tubulin an excellent 
target for anti-cancer drugs. 
There are two main drug classes that bind to tubulin causing microtubule inhibition. These 
are compounds that either stabilize (Microtubule stabilizing agents MSAs) or destabilize 
(Microtubule destabilizing agents MTAs) microtubules. MSAs stabilize the polymer and 
promote polymerization whereas MTAs prevent polymerization and promote 
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depolymerization. The presence of MSAs allow the polymerization of GDP- bound tubulin 
into microtubules, an action that doesn’t happen under normal conditions. Many MAPs have 
been shown to act as MSAs but none of them bind as well as non-indigenous compounds 
allowing for a more stabilized polymer (Aylett et al. 2011).  
The precise mechanism for MSA induced mitotic arrest and subsequent apoptosis has not 
been fully elucidated, however it is generally accepted that the stabilization causes 
interference with cellular spindle dynamics. This causes the cell to fail at mitotic check points 
causing an arrest at the G2/M phase. Failure at this stage of the cell cycle is a hallmark of 
tubulin binding agents. Microtubules also play a role in endothelial cell migration. Therefore 
targeting tubulin also has an inhibitory effect against angiogenesis and vascularization in 
tumours (Jordan and Wilson. 2004).  
Both classes contain a vast range of structurally diverse molecules that vary from large 
complex natural products to small simple drug analogues. Compounds are classified based on 
their effects on tubulin polymer mass at high concentration. Both classes at low concentration 
cause inhibition of microtubule dynamic stability leading to mitotic arrest with little effect on 
overall polymer mass (Jordan et al. 1993).  
Target selectivity comes from the fact that these drugs disrupt immature proliferating tumour 
endothelial cells which replicate 20 times faster than in healthy vasculature (Denekamp 
1982). This occurs either through direct apoptosis or effects caused by endothelial cell 
reliance on a tubulin/microtubule-based cytoskeleton to maintain cellular shape. The 
disruption of an oxygen supply causes ischemia that induces a cascade of secondary tumour 
cell death (Dark et al. 1997). 
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Microtubule stabilizing agents 
Microtubule stabilizing agents stop the disassembly of GDP bound tubulin forming stable 
polymers. These compounds bind to either the taxoid or laulimalide/peloruside sites located 
on the luminal and external faces of the β-subunit respectively. Activation of either site 
causes the stabilization of an important β-subunit loop resulting in the stabilization of the 
microtubule lattice. This class of compounds represents most of the clinically used 
treatments. Most of these compounds are large, complex structures with a massive diversity 
in shape.  
 
 
Taxoid binding site 
The taxoid binding site was first discovered over 20 years ago by Rao (Rao et al. 1992). The 
site was detected on the β-subunit by using [3 H] taxol to directly radiolabel tubulin. Taxol 
binds to the site with 1:1 stoichiometry, effecting protofiliment interaction. The site is located 
on the luminal face of β-tubulin, the same location on α tubulin is occupied by 8 extra amino 
acid residues. Most of the bonding interactions occur at the taxane ring and most MSA 
compounds reversibly compete with taxol. The taxol binding pocket itself consists of the S9-
S10 loop and parts of the core helix of the β-subunit. When taxol is bound it sits on the N-
terminus of the microtubule loop protruding from the protofiliment, this acts as a secondary 
structure for microtubule stabilization (Sui and Downing. 2010), (Nogales et al. 1995). As 
mentioned taxol binds to the luminal site of β –tubulin. When polymerized the molecule is 
facing the inside of the microtubule and the corresponding location on α-tubulin is occupied 
with eight extra residues. These amino acids help to stabilize the M-loop and it had been long 
suspected that taxol/taxanes replicate this action on the β-subunit. This loop is located 
between strand 7 (S7) and helix 9 (H9). It provides important lateral interactions to the taxol 
binding pocket. (Löwe et al. 2001). A recent study confirmed this through X-ray 
crystallography (Prota et al. 2013). 
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Figure 14 Image showing paclitaxel bound to the taxoid binding site on tubulin (Chen et al. 2008). 
The binding pocket (Fig 14) is located inside a hydrophobic cleft and binds to taxol through 
hydrogen bonds and numerous hydrophobic interactions. Several amino acid residues directly 
interact when taxol is bound. These interactions have been further validated by Snyder 
(Snyder et al. 2001) through the use of molecular docking. A model of the taxol bioactive 
conformation was constructed using data from crystallographic density analysis. The model 
showed 3 H-bond interactions and confirmed the hydrophobic interactions. 
Paclitaxel (FIG 15, (16)) was one of the first compounds of this class discovered and over the 
years along with its semi-synthetic analogue (docetaxel) paclitaxel has been heavily 
researched as anticancer therapeutics. Paclitaxel was first identified in 1971 (Jordan et al. 
1993) in a US National Cancer Institute screening program for anticancer agents as an isolate 
from the bark of the Pacific Yew (Taxus brevifolia). A major problem with the compound 
was acquiring a supply of it as it required material from the bark of two trees to provide a 
dose for a single patient. Several total synthesis have been achieved (Nicolaou et al. 1994) 
but with multiple steps and low yields, other sources were required. The problem was 
overcome by semi-synthesis of taxol and its analogues from other natural products from yew 
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needles, an overall better method as needle harvesting doesn’t kill the tree. Paclitaxel and its 
analogues have been termed taxoids and the method of action is the selective binding to β 
tubulin subunits. The binding of taxoids causes microtubule stabilization through the 
acceleration of tubulin polymerization leading to a halt in cell division (Horwitz. 1994). 
 
Figure 15 the natural product Paclitaxel (16) 
Many changes to the “Top” face of the pharmacophore of taxol led to increased aqueous 
solubility and better pharmacokinetic properties leading to the development of two 
compounds BMS 188797 and BMS 184476. Further modifications to the taxol structure 
resulted in an overall effect of increasing the potency by a magnitude of 3.  The more 
substantial changes involved changing aromatic groups with more hydrophobic moieties; this 
also showed a serendipitous activity against drug resistant cancer strains. Further 
modification to the structure has resulted in the first orally active taxol, ortataxel. The 
compound showed increased activity due to increased restriction to rotation in the 
pharmacophore. 
 
The Laulimalide/Peloruside Binding Site 
Tubulin has another binding site that induces microtubule stabilisation; the location of this 
site was greatly debated with evidence suggesting its presence on both α and β subunits. The 
binding of laulimalide (Fig 16, (17)) was first thought to be localised to a loop region (S9-
S10) on the α subunit (Nguyen et al. 2010). This was supported by NMR data for peloruside 
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(Fig 16, (18)) bound to the α-subunit in its bioactive conformation, in particular the 
interactions at the αM-loop (Pineda et al. 2004). Nogales proposed a limitation to this theory 
in that the S9-S10 loop has 8 extra amino acid residues that would obstruct the site and 
strengthen the links between the α subunits and the protofilaments making the binding of a 
MSA unlikely (Löwe et al. 2001). Almost 10 years later Huzil determined that the peloruside 
site was in fact located on the β-subunit’s exterior surface close to the subunit interface (Fig 
17) (Nguyen et al. 2010). The proposed site is quite close in sequence to the taxoid binding 
site but structurally distant. 
 
Figure 16 Image showing the structures of Laulimalide (A) and Peloruside (B) 
Using a different technique, Chen identified the same region as an almost identical match. 
The group used digital signal processing to search for binding hot spots (Chen et al. 2008). 
The site was further supported by modelling work and radiolabelling studies that gave further 
insight into the structure, binding and electrostatic/hydrophobic interactions that strengthen 
the case for the presence of the laulimalide/peloruside site on the β subunits as opposed to the 
α-subunit (Nguyen et al. 2010). The study agreed with Huzil’s location for the binding site 
but uncovered more complex bonding than originally proposed. This involved an 
intramolecular H-bond that gives peloruside a more rigid orientation allowing a hydroxyl 
group to interact with an arginine residue. 
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Figure 17 Image of Peroruside bound at the lau/Pel tubulin binding site (Chen et al. 2008) 
 
Another study based on laulimalide used molecular docking and mass shift perturbation 
analysis to show that the molecule binds to the external surface of the microtubule, making 
the laulimalide/peloruside site unique in that all of the other known tubulin binding sites are 
located inside the microtubule (Bennett et al. 2010). As it stands there is more evidence to 
suggest a single site located on the β-subunit as opposed to the α subunit. Simultaneous 
binding at both proposed sites is possible but not supported as Pera’s (Pera et al. 2010) 
studies show a 1:1 stoichiometry. An x-ray crystal structure is required to fully elucidate the 
structure.  
Microtuble Destabalising Agents 
These molecules bind to the vinca domain or the colchicine binding site, two distinct sites 
located at a distance from each other on tubulin. Nevertheless the actions of both classes of 
ligands share a common effect; they inhibit the formation of microtubules, therefore 
triggering disassembly. 
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Binding at the vinca binding region 
 
Figure 18 Structure showing Vinca alkaloid core R = CH3:  (+) – Vinblastine (19), R = CHO:  (+) – Vincristine (20) Drugs 
that target the Vinca binding domain 
Several known natural products competitively bind to tubulin at the vinca binding domain. 
The compounds vinblastine (19) and vincristine (20) (Figure 18) were the first antimitotic 
compounds to be approved for clinical cancer therapy. Both compounds cause microtubule 
destabilisation. At low concentrations vinblastine inhibits mitotic progression and at high 
concentration causes depolymerisation of microtubules (Jordan et al. 1992). This leads to 
apoptosis and is followed by cell death. The compound binds to the β-subunit of tubulin at 
the positive end of microtubules - this feature is specific to vinca domain binders, Fig 19 
shows vinblastine bound to polymerised tubulin. Vincristine can bind to tubulin both in its 
polymerised and unpolymerised forms.  Vinca domain agents bind fast and in a reversible 
manner, causing a conformational change to allow better contact. These drugs cause a 
slowing of the dynamic assembly/disassembly of microtubules. This inhibits the assembly of 
the mitotic spindle creating tension at the kinetochores that renders chromosomes at the 
spindle poles too short to reach the spindle equator blocking progression to anaphase thus 
causing mitotic arrest (Ehrlich et al. 2006). 
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Figure 19 Image of vinblastine-bound tubulin(Chen et al. 2008) 
Dolastatins 10 and 15 also bind to the tubulin vinca binding domain. These peptide 
compounds extracted from sea slugs (Dolabella auricularia) act as non-competitive 
inhibitors of tubulin  with vincristine and vinblastine. Both compounds have a much higher 
binding affinity to tubulin than vincristine and vinblastine and this is evident from the much 
higher cytotoxicity exhibited. Dolatstatins are retained in the vinca binding site much longer 
than vinca compounds which are removed from the cells quickly (Verdier-Pinard et al. 2000). 
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Colchicine binding site 
Since the original discovery that tubulin was the biological target for colchicine (Fig 20, (21)) 
in the sixties (Weisenberg et al. 1968), little progress was made in elucidating the ligand-
protein structural relationship until a study was published by Bai 30 years later (Bai et al. 
2000). The study attempted to identify the colchicinoid binding site location in tubulin using 
both molecular modelling and biochemical techniques. The group also showed that the site of 
interaction for podophyllotoxin (another MTA) overlapped partially with that of colchicine. 
The location of site was finally validated by X-ray crystallography (Ravelli et al. 2004). This 
study showed the structure of tubulin complexed with a colchicine analogue (DAMA-
colchicine) and the stathmin like domain of the RB3 protein. Another tubulin crystal structure 
was subsequently reported featuring a double tubulin heterodimer complexed to the stathmin-
like domain of the RB3 protein; the structure was free from any ligands.   
 
Figure 20 Diagram showing the structure of colchicine and its ring naming system 
 
Several other crystal structures of tubulin complexed MTAs have since been published 
suggesting a slightly different mode of action, causing a change in the microtubule structure 
from linear to curved (Dorléans et al. 2009). 
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The colchicine binding site is located in a deep pocket at the interface between the tubulin 
heterodimers. Due to the hindered location, major conformational changes need to occur to 
allow inhibitors to enter the site. The binding region should be referred to as a “Domain” 
instead if a site due to its complexity.  
 
Figure 21 Image of Colchicine-bound tubulin(Chen et al. 2008) 
Colchicine binds to tubulin in its non-polymerised form in two steps. Fig 21 shows a image 
of colchicine-bound tubulin. The MTA first forms a weak, reversible complex with tubulin. 
This causes a conformational change in the protein that leads to the formation of a stronger 
pseudo-irreversible complex (Skoufias and Wilson. 1992).  
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Vascular Targeting Agents 
 Podophyllotoxin 
Podophyllotoxin (22) binds to the colchicine binding site on the tubulin β-subunit. The 
compound is a competitive inhibitor of tubulin, binding more rapidly and with more affinity 
in a reversible manner than colchicine. This compound has a unique mechanism of action in 
that it doesn’t interfere with the tubulin GDP/GTP exchange; instead the compound disrupts 
tubulin dependant GTP hydrolysis (Cortese et al. 1977). Molecular docking studies on 
podophyllotoxin and colchicine showed that even though both compounds bind at the binding 
site on the  tubulin β-subunit, they don’t fully overlap in their bonding interactions and 
therefore show quite different biological binding profiles (Stanton et al. 2011). The full 
mechanism of the compounds antimitotic action hasn’t fully been elucidated but it known 
that it interrupts microtubule dynamic instability (Jordan et al. 1992). 
Unfortunately podophyllotoxin was unsuitable for further development into a useful clinical 
drug. However etopside and teniposide, two analogues of the compound were further 
developed into clinically used drugs to treat lung and testicular cancer respectively. Strangely 
both analogues show poor binding affinity to tubulin compared to the parent molecule but 
exhibit a strong inhibition of DNA topoisomerase-II, an enzyme used in the relaxation of 
super coiled DNA during cell division (Pommier et al. 2010). 
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Figure 22 structure of Podophyllotoxin 
Combretastatin A-4 
More recently some small molecule vascular targeting agents have shown promise in clinical 
trials. Combretastatin A-4 phosphate (CA-4, (23)) is a prodrug salt of a natural compound 
found in the South African willow (Combretum caffrum). Many analogues of combretastatin 
have been tested and all have a common two ring structure bridged by an ethene unit 
(Gaukroger, K. et al. 2003a), (Galli, U. et al. 2015). The rings are commonly referred to as the A-
ring and B-ring (Fig 23). The A ring in almost all of the analogues contains the characteristic 
3,4,5-trimethoxy motif.  The Z-isomer of CA-4 (23) is more biologically active than the E- 
isomer (25) as it is also cytotoxic. Changing R groups on the B-ring of combretastatin has 
been shown to improve anti-tumour activity (Ohsumi et al. 1998). CA-4  is currently in the 
stage 3 human cancer clinical trials.  
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Figure 23 Diagram showing the ring labelling system of CA-4 (23), CA-4 phosphate (24) and the structure of the Trans 
configuration of CA-4 (25) phosphate (26). 
Phenstatin (27) is a related vascular disrupting agent that resulted from a SAR analysis of 
CA-4; bearing a close structural similarity to its parent molecule - it is a potent inhibitor of 
mitosis. This compound and its more water soluble prodrug have almost identical biological 
profiles to combretastatin in terms of cytotoxicity and potency (Pettit et al. 1998). The 
compound is currently in clinical trials for human solid tumours. 
 
 
Figure 24 structure of Phenstatin 
CA4 (23) has a close structural relationship with colchicine with which it competitively binds 
to the colchicine binding site with a higher binding affinity causing inhibition of microtubule 
formation (McGown and Fox 1989). The compound binds to tubulin in the low µM range 
causing it to be highly cytotoxic with typical IC50 values in the low nM range. Unfortunately 
CA-4 (23) has poor water solubility and the drug in its basic form wasn’t developed further. 
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This problem was overcome in the mid 1990s by Pettit’s group through the development of 
the CA-4 (23) sodium phosphate prodrug  (CA-4-P (24), fostrabulin
™
) (Pettit et al. 1995). 
The compound in its prodrug form has an improved biovailability profile but is inactive until 
it is converted to the active CA-4 (23) through the action of non-specific phosphatase 
enzymes in vivo. 
Even though CA-4-P (24) has entered clinical trials the exact mechanism by which vascular 
disrupting agents work is still not fully understood. Various in vitro studies on several cell 
types have been performed. Between a concentration range of 0.1 to 1.0 µM in HUVEC cells, 
the drug causes complete disruption of the microtubules within 30 minutes (Galbraith et al. 
2001) This depolymerisation of microtubules causes a rapid transformation of the cellular 
structure, remodelling the cytoskeleton and morphology of focal adhesions, resulting in the 
phosphorylation of myosin fibres causing them to interact with myosin. This leads to 
improved contractibility and formation of actin stress fibres. This depolymerisation was 
shown to be directly proportional to the sequence of phosphorylation and myosin fibre 
formation (Kanthou and Tozer. 2002) 
Activation of ROCK (Rho kinase) through the upstream interactions of Rho A (GTPase) have 
been shown to regulate these alterations to cytoskeletal structure and morphology (Fig 25). 
The exact mechanism by which microtubule disruption triggers activation of RhoA has not 
yet been fully elucidated. It has been postulated that a set of guanidine nucleotide exchange 
factors (GEF) are released from the microtubule disruption activating RhoA and causing  in 
GTPase activation (Krendel et al. 2002). 
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Figure 25  diagram showing the complexity of the ROCK RHOA pathway (Kloc et al. 2005) 
Another trait of CA-4-P (24) treated cells is membrane blebbing. The cells become more 
rounded in shape as f-actin accumulates in blebs on the cell surface, forming a spherical 
network that engulfs the cytoplasm causing focal adhesions to appear deformed. Endothelial 
cells treated with CA-4-P (24) rapidly become more permeable to numerous macromolecules; 
this is due to increased contractibility and interruption of cell-cell connections. Tozer found 
that this increased permeability can be reduced through the inhibition of ROCK and RhoA. 
This points to a link between CA-4-P  activated signal pathway induction and the structural 
and morphological changes to treated endothelial cells (Dark et al. 1997). 
Disruption to adherens junctions also occurs when endothelial cells are treated with CA-4-P.  
These sites are the point where the actin cytoskeleton is linked to the cytoplasmic face. This 
disruption also causes increased permeability of endothelial cells (Vincent et al. 2005). Many 
factors contribute to dysfunctional cell division. Depending on the concentration and 
exposure to CA-4-P along with cell type, microtubule disruption can result in phase arrest at 
G2/M and subsequent apoptosis (Dark et al. 1997). It has also been found that the changes to 
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endothelial changes caused by CA-4-P can be reversed. Twenty-four hours after cellular drug 
clearance endothelial cells can rebuild cellular structure to a level similar to pre-treatment. 
This is unusual compared to the disruption caused by colchicine which is non-reversible. It 
has been postulated that differing effects may be caused by differences in binding kinetics for 
each molecule as CA-4-P binds faster and with a larger affinity to tubulin than colchicine. 
CA-4-P also dissociates over 100 times quicker (Lin et al. 1989). 
Several animal studies have been performed to assess the selective and rapid action of the 
compound on tumour vasculature using both xenograft targets.(Dark et al. 1997), (Chaplin et 
al.), (Pedley et al. 2001). Initial signs of anti-vascular activity are evident from as little as 10 
minutes after administration. Complete vascular shutdown occurs after 30 minutes along with 
a marked increase in vasculature permeability. This extensive collapse in vasculature results 
in haemorrhagic necrosis within an hour, which is largely located in the tumours’ centre 
(Chaplin et al. 1999). This may be the reason that the viable rim can repopulate after only 1 
dose (Grosios et al. 2000). 
 
 
ZD6126 
As previously mentioned, colchicine is the oldest known tubulin –binding agent. It is a 
secondary plant metabolite that has been used medicinally in traditional medicine for 
hundreds of years. The alkaloid was first isolated from the plant autumn crocus Colchicum 
autumnale in 1820. By the end of the 1930s the compound’s anti-vascular properties were 
discovered.(Boyland and Boyland. 1937) and initial results from studies on animal and 
human tumours showed promise but the compound’s toxicity stopped further clinical studies 
by 1950.(Ludford et al. 1948) A derivative of colchicine, ZD6126 showed almost identical 
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antivascular activity to that of CA-4-P on endothelial cells. The compound itself is unable to 
bind to tubulin; however it is converted to N-acetylcolchinol (NAC) by various serum 
phosphatases. NAC is an active metabolite of colchicine that binds to the colchicine binding 
site in a more rapid fashion and in contrast, a reversible manner (Kang et al. 1990). Some 
colchicine analogues contain an unsaturated oxepine B-ring. These compounds show the 
same anti-vascular and antimitotic activity in vitro as NAC (29) but this only occurs at a 
higher dose (Joncour et al. 2008). 
 
Figure 26 Diagram showing the ring labelling system and structures for colchicine (21), its metabolite NAC (29) and its 
analogue ZD6126 (28) 
 
ZD6126 (28) is structurally similar to colchicine in that both contain a 6-membered A-ring 
with a trimethoxy motif and a 7 membered B-ring. The compounds differ in the C-ring in 
which ZD6126 (28) has a smaller 6 membered ring as opposed to the 7-membered ring in 
colchicine (21) (Fig 26) both compounds selectively bind to the colchicine binding site on the 
β-subunit of tubulin. When bound to the tubulin, the polymerization of tubulin/formation of 
microtubules is inhibited leading to cell cycle arrest and apoptosis. The entire mechanism for 
binding and inactivation at the colchicine site has yet to be fully elucidated but SAR analysis 
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has verified that the trimethoxy motif on the A ring in is essential to biological activity 
(Zefirova et al. 2011). 
ZD6126 also exhibits a specific cytotoxic effect against tumour cells whereas colchicine does 
not, leading to damage of normal cells. ZD6126 was shown to cause increased hypoxia and 
decreased tumour volume when tested against murine xenographs (Wachsberger et al. 2005). 
ZD6126 was able to show total disruption of microtubules in endothelial cells  40 minutes 
after administration. This led to the induction of actin stress fibre resulting in cellular 
contraction and cell blebbing (Micheletti et al. 2003). These morphological changes occurred 
selectively at a non-toxic dose and predominantly in proliferating endothelial cells as opposed 
to quiescent endothelial cells. Clearance of ZD6126 resulted in the endothelial cells reverting 
to their orginal cell shape within 3 hours implying that the effect of NAC is reversible. The in 
vivo activity of the drug was investigated through preclinical screens against various solid 
tumour models (mouse and human) (Davis et al. 2002). ZD6126 as a single administration in 
mice at a well tolerated dose induced retraction of endothelial cells resulting in increased 
permeability, platelet activation, coagulation and basement membrane exposure. This 
compound exhibited characteristic VDA effects resulting in stoppage of blood followed by a 
quick onset (within 1 hour) of tumour necrosis (Goertz et al. 2002). 
Doubling the dosage to 100 mg/kg improved the retardation of tumour growth when 
administered over 5 days. The study revealed that the maximum tolerated dose of ZD6126 in 
mice was 400 mg/kg with significant necrotic effect shown at doses as low as 25 mg/kg. A 
pharmacokinetic study was also performed and revealed that, when mice received a well-
tolerated single dose (61 mg/kg), the drug rapidly hydrolyses to NAC which is subsequently 
cleared from the plasma with an approximate half-life of 1 hour (Davis et al. 2002) The drug 
entered clinical trials in the early 2000s. The initial aim of testing was to determine dose 
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limitations, the maximum tolerated dose and efficiency of a single dose. All participants had 
advanced stage solid tumours and after a 21 day regime it was determined that the maximum 
tolerated dose was 112 mg/kg when given once a day for a week with a drug half-life of 1-3 
hours (Beerepoot et al. 2006), (LoRusso et al. 2008). 
Reported side-effects included nausea, vomiting, headache, and pain, which were thought to 
be dose related. At this stage there were minor signs of cardiotoxicity in the form of a 
reduced cardio ejection fraction (Beerepoot et al. 2006). Interestingly, at tolerated doses the 
compound didn’t show any vascular damage to normal tissue in an MRI study confirming the 
drug’s specificity to tumour vasculature (Evelhoch et al. 2004). The compound was entered 
into phase II clinical trials as three different combination therapies wih 5-fluorouracil, 
leucovorin and oxaliplatin. The drug failed at this stage due to the presentation of cardiotoxic 
side-effects resulting in a number of patients requiring the dose to be limited due to QT 
prolongation (Lorusso & Rüegg 2008), (Hollebecque et al. 2012). 
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Oxepines 
More recent research in the area of vascular targeting agents has focused on dibenzoxepines 
(Fig 27), whose structures are similar to NAC (29) with a 7- membered central heteroatom 
ring with an oxygen in the central [c,e] position. Several analogues have been made, mostly 
consisting of a trimethoxy containing A-ring and varied R groups on the C-ring. It is believed 
but still not confirmed that these targets also bind to the colchicine site on tubulin β-subunits. 
In vitro studies on these compounds have revealed that the basic pharmacophore requires the 
basic 3-ring structure with a trimethoxy A-ring to effect VTA activity (Colombel et al. 2010). 
 
 
Figure 27 Structures of the VTA compounds NAC and dibenzoxepines 
As previously mentioned, colchicine is too toxic to use as a VTA, but as the colchicine 
binding site can accommodate a number of different pharmaceutical motifs, various groups 
have been performing pharmacophore based design to try and produce a compound that has 
maximum efficacy as a VDA, excellent pharmacokinetics and reduced cardiotoxicity. 
Edwards et al, while working on the axial chirality of colchicine binding analogues, analyzed 
the dihedral angle of various oxepine type compounds and discovered that the degree of 
helicity at the biaryl core of dibenz[c,e]oxepines resembles closely that of colchicine 
(Edwards et al. 2011).  
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This led to the formation of several dibenzo[c,e]oxepine derivatives that had structural 
elements of both ZD6126 (28) and CA-4 (23). One of the compounds 3,9,10,11-
tetramethoxy-5,7-dihydrodibenzo[c,e]oxepin-4-ol (30) showed an excellent cytotoxic activity 
against K562 leukaemia  cells (IC50, 2.2 nM). The compounds also successfully bound to 
tubulin as determined by a tubulin binding assay. Similarily a number of hybrid type 
NAC/phenstatin like compounds have been evaluated. They all have in common the single 
carbon bridge of phenstatin with the conformational stability provided by a central 6 or 7 
membered ring. 
 
Figure 28 The structure of 4 benzosuberene type analogues 
A series of potent suberene type combretastatin like analogues have been reported to show 
excellent inhibitory activity against cancer cell lines (Tanpure et al. 2013). The group made a 
series of analogues varying the pattern of methoxy groups and functional groups (Fig 28). 
Impressive IC50 values in the picomolar range were reported along with synthesis of water 
soluble prodrugs.Further analysis of the benzosuberene type fused ring system was reported 
in the synthesis of a series of combretadiazepine compounds. The series featured a 1,4-
benzodiazepin-2-one fused ring system, a so called privileged structure that improves 
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conformational stability by locking in the Z-conformation of CA-4. The compounds show a 
similar biological profile to CA-4 in tubulin binding and cytotoxicity (neuroblastoma cells) 
with an improved pharmacokinetic profile (Galli et al. 2015). 
Project aims 
 
The aim of this project was to further develop oxepine analgues as potential antivascular 
agents. Building on previous investigations (Edwards et al. 2011; Gaukroger et al. 2003b; 
McGown & Fox 1989) into tubulin binding, a series of dibenzoxepines  was synthesised and 
biologically evaluated. 
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Design rationale  
 
In the area of colchicine binding vascular targeting agents hundreds if not thousands of 
compounds have been investigated over the past 20 years. Dichotomising compounds further 
into combretastatin or colchicine type structures can be difficult due to the massive structural 
diversity of studied molecules.  
 
Figure 29 Diagram showing the target oxepine compounds 
 
 46 
 
 
Figure 30a Diagram showing a structure activity relationship analysis on colchicine 
 
 
One constant in the criteria for activity in the colchicine binding site is the presence of the 
trimethoxy motif will feature in all compounds. 
SAR analysis of both compounds (Fig 30a) shows the importance of the trimethoxy moiety. 
What is unusual is the variation in location of the motif (Fig 31). In NAC (29) the pattern is 
2,3,4 on the A ring but in both Phenstatin (27) and combretastatin derivatives  the pattern is 
3,4,5, even though the distance between the main rings are different (Fig 31 red lines).  
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Figure 30b Diagram showing the relationship between NAC (29), CA-4 (23) and Phenstatin (27) 
Analogues with an altered seven-membered rings containing sulphur and nitrogen were 
synthesised. The conformation of the synthesised oxepine analogues changes the angle 
between the two aryl rings and alters the interaction of the molecules with tubulin.  
McNulty (McNulty et al. 2015) recently reported low µM activity from a simplified 
NAC/Combretastatin hybrid (31) with a similar methoxy substitution to the Edwards 
(Edwards et al. 2011) oxepine analogues and CA-4 (Fig 32).   
 
Figure 31 Diagram showing the similarities between Edwards Oxepine (30), Mc Nulty’s NAC/ Combretastatin hybrid (31) 
and CA-4 (23) 
A simplified series of biaryls without a central heterocyclic ring have also be synthesized and 
tested. These molecules will be analogous to dibenzoxepines, they will be tested to further 
explore the colchicine pharmacophore.  
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Figure 32 Diagram showing the target biaryl compounds 
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Chapter 2: Development of a 
route to the desired 
analogues 
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Introduction  
The central theme for this chapter is carbon- carbon cross coupling. In a coupling reaction 
two molecular fragments are combined leading to the formation of a new bond. This process 
is often catalyzed by a transition metal (Pd, Cu, Ni). The explosion of research in this area 
since the 1970s has generated powerful, practical and robust methodologies that have been 
recognised with a Nobel prize and feature as a valuable tool throughout research from 
academia to industry. Previous work on dibenzo[c,e]oxepine compounds (30) by Edwards 
(Edwards et al. 2011) utilized Ullmann coupling to synthesise a series of compounds similar 
to our target molecules. Ullmann coupling is one of the earliest examples of coupling and 
serves as a good example of homo coupling (Fig 33), in which 2 equivalents of an aromatic 
halide (32) react to form a symmetrical or homocoupled product (33).  
 
Scheme 32  shows a general reaction scheme for an Ullmann reaction involving the homocoupling of an aromatic halide in 
the presence of copper at high temperature to form a biaryl product. 
 
The Ullmann reaction used by Edwards (Fig 33) shows that when 2 different aromatic halides 
(34) and (35) are used, a mixture of hetero and homo coupled products are produced. In this 
case the heterocoupled product (36) is the desired compound. Ullmann coupling is 
traditionally utilised in synthesis requiring symmetrical molecules as the major product is 
usually homocoupled. 
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Scheme 33 Reaction scheme for an Ullmann reaction used by Edwards to form a central biaryl precursor (36) to a 
dibenzoxepines analogue 
The mechanism for the Ullmann reaction has been has been well investigated in the literature 
but has yet to be fully elucidated. A thorough investigation by Paine (Paine 1987) involving 
several sources of copper revealed that a single copper ion (Cu(I))  species was the 
intermediate, ruling out the presence of a radical. The work also alluded to the large 
variability in yield suggesting that availability of surface copper ions and the ease at which 
they dissolve for homogenous catalysis was an important factor. Ullmann coupling is quite 
robust but lacks selectivity when cross coupling is required. In an attempt to remedy this, 
Ziegler (Ziegler et al. 1980) published a modified Ullmann procedure which has been shown 
to successfully cross couple sterically hindered aryl halides, including precursors for natural 
compounds with a similar trimethoxy motif  (Fig 35, (39)) (Stark et al. 2010), (Nelson & 
Meyers 1994). Encouragingly, this method has also been reported in the synthesis of NAC 
(29) (Broady et al. 2007). 
 
Scheme 34 Diagram showing the modified Ullmann coupling used by Ziegler to synthesise a central biaryl precursor in the 
synthesis of steganacin (39)  
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The Zeigler-Ullmann reaction works particularly well with electron rich aryl halides. The 
process requires the presence of directing groups (cyclohexylimine, acetal, thioacetal) groups 
in the position ortho to the halide group in each aryl coupling partner. This serves both to 
protect carbonyl groups from reaction with butyl lithium and to direct the oxidative insertion 
of copper. Ziegler proposed a mechanism (Fig 36) in which the electron rich ring is first 
lithiated (40) through halogen-lithium exchange and reacted with CuI
.
P(OEt)3 to form an 
organocuprate compound (41), aided by the coordination effect of the nitrogen. Addition of 
the coupling partner (42) results in an oxidative addition at the copper resulting in an increase 
in formal oxidation state from (I) to (III) (43 to 44), coordination by nitrogen ligands 
followed by reductive elimination to give biaryl (45).
 
Scheme 35 Reaction scheme showing the proposed mechanism for the modified Ziegler cross coupling reaction 
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Palladium-catalysed cross- coupling 
An obvious starting point for this was palladium catalysed cross-coupling. Since its discovery 
in the late 1970’s (Miyaura et al. 1979), Suzuki–Miyaura cross-coupling has become a 
widely used carbon-carbon bond forming reaction. This involves the palladium catalysed 
coupling of an aryl/alkyl halide with an aryl/alkyl boronic acid. Numerous examples and 
reviews have been published reporting high yields and excellent functional group tolerance 
along with an ever growing selection of ligand / catalyst systems. 
 
Reaction X Y Reference 
Kumada I, Br, MgX (Tamao, Sumitani, & 
Kumada, 1972) 
Negishi I, Br, ZnX (King, Okukado, & 
Negishi, 1977) 
Stille I, Br, Triflate Sn(Alkyl)3 (Stille & Lau, 1977) 
Suzuki I, Br, Triflate B(OH)2, BF3K, BPIN (Miyaura, Yamada, 
& Suzuki, 1979) 
Hiyama I, Br, Triflate Si(OMe)3 (Hatanaka & 
Hiyama, 1988) 
Figure 36 Scheme showing a general palladium catalysed cross coupling reaction between an aryl halide and a partner 
xdnucleophile to generate a biaryl, the table indicated the required X and Y group for commonly used name processes. 
Fig 37 shows the most frequently used biaryl forming coupling reactions. The most 
commonly utilised reactions are Suzuki and Stille in which organic halides (or pseudo 
halides) are “coupled” with nucleophilic coupling partners (boronic acids and stannanes). Fig 
38 is focused on the state of palladium during carbon-carbon bond formation. The catalytic 
cycle is common to all C-C processes (Kumada, Negishi, and Hiyami etc) in which the halide 
undergoes an oxidative addition to form a Pd
(II)  
species that transmetalates a coupling partner 
to remove the halide. This new Pd
(II) 
species undergoes reductive elimination to form the 
coupled product and regenerate the  Pd
(0) 
catalyst for further cycles. 
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Figure 37 Shows the catalytic cycle for palladium during a Suzuki cross coupling reaction. X is a halide and Y is the 
nucleophilic coupling partner 
The reaction mechanism for the catalytic cycle (Fig 38) is generally accepted and typically 
described around the oxidation state of palladium.  This begins with the oxidative addition of 
the palladium catalyst to the alkyl/aryl halide forming an organopalladium complex. 
Palladium (0) is oxidized to Palladium (II) in the process resulting in the breaking of the 
carbon – halogen bond meaning that palladium is bound to both halide and ligand. This is the 
rate determining step for the reaction (Casado & Espinet 1998). 
This is followed by a transmetallation step which involves the transfer of ligands from one 
organometallic species to another. This occurs during the reaction but the exact mechanism is 
uncertain and greatly disputed. The general consensus is that the alkyl/aryl component of the 
nucleophilic coupling partner is transferred to the palladium species and replaced with 
previously added base.  Apart from Stille coupling, Pd catalysed C-C reaction doesn’t occur 
in the absence of base and often 2-4 eq is required suggesting that the role of base is to both 
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activate the nucleophilic species and facilitate formation of the new palladium (II) species. 
(Fig 39) shows 2 proposed pathways (Path A and Path B) for transmetallation in Suzuki 
coupling (Matos and Soderquist. 1998). Both proposed pathways result in the same 
organopalladium transition state from which reductive elimination gives the desired carbon – 
carbon bond. 
 
 
Figure 38 Shows two proposed actions of base in the transmetallation step in Suzuki cross coupling.  Path A shows a 
hydroxylation of the boronic acid coupling partner and subsequent coordination of this molecule to the palladium centre. 
Path B shows the substitution of X on the initial oxidative addition product with OH which in turn reacts with the boron 
from the boronic acid. 
Reductive elimination is in essence a reverse of oxidative addition, in which a bond is created 
between two metal (palladium) bound anionic ligands (Ar
1
 and Ar
2
 in Fig 40) causing a 
reduction in formal oxidation state of the metal by 2, in this case palladium (II) to palladium 
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(0) resulting in the reformation of the catalyst. In order for the biaryl product to be eliminated 
the Ar
1
 and Ar 
2
 groups must both be coordinated cis to each other therefore trans 
coordinated complexes will isomerise to this preferred configuration. The tetravalent 16-
electron palladium species generated by transmetallation eliminates from its square planar 
complex unassisted followed by formation of the Ar
1
-Ar
2
 sigma bond yielding the desired 
coupled product.  
 
Scheme 39 Scheme showing the reductive elimination of a tetra-substituted Pd (II) intermediate to form a biaryl product and 
regenerate the Pd (0) catalyst. 
It has been reported that some reactions can have a slow transmetallation step, in which case 
formation of a T- shaped 14- electron intermediate through the dissociation of a ligand can 
enhance the process (Fig 41). It is believed that through a further rearrangement to a Y 
shaped species accelerated reductive elimination can occur (Espinet and Echavarren 2004). 
Addition of an extra ligand to this complex forms the common 18 electron species that allows 
elimination of the Ar
1
-Ar
2
 biaryl product.  
 
Scheme 40 Scheme showing the rearrangement of a Pd(II) intermediate from a T-shape to a Y-shape to allow the 
complexation of a free ligand to allow reductive elimination. 
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Pinacol boronate esters 
The popularity of boronate esters in Suzuki coupling has increased 
dramatically over the past 10 years. Boronic acids can reversibly react with 
diols to form stable boronic esters that can release the active acid in situ. 
Boronic esters are more stable to air and chromatography, making them easier 
to store, purify and characterise than boronic acids. Another attractive feature is alternative 
routes of synthesis that avoid lithium- halogen exchange/ directed ortho metallation. These 
include Miyuara borylation (Ishiyama, Murata, & Miyaura, 1995), a palladium catalysed 
reaction with Bis(pinacolato)diboron  (B2Pin2) and Musada borylation (Murata, Watanabe, & 
Masuda, 1997) that uses pinacol borane directly (Fig 42) 
 
 
Scheme 41 Scheme showing 2 routes to boronate esters. Miyuara borylation (Red) uses B2Pin2 with the Pd(dppf)Cl2. Masuda 
borylation (Green) utilises pinacol borane with various phosphine based ligands. 
The mechanism for Masuda type borylation was much disputed until Lam (Lam et al. 2010), 
using Density Functional Theory (DFT), calculation elucidated the correct pathway.  
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Fig 43 shows that the oxidative insertion step remains the same for both mechanisms. Lam 
proved through calculation that the original idea that triethylamine deprotonates pinacol 
borane isn’t possible due to the hydridic tendency of B-H bonds. Lam’s transmetallation 
stage involves ionisation of the oxidative addition product to generate a 14 electron aryl 
palladium carbonation that subsequently reacts with pinacol borane through a sigma bond 
metathesis regenerating Ln2Pd(0)
 
and forming the borylated aromatic product 
 
Scheme 42 Scheme showing both the original proposed Masuda mechanism (Left) and the correctly elucidated Lam 
mechanism (right), with a newly discovered Ionisation / metathesis process. 
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Buchwald ligands  
Until the late 90s catalytic systems used for Suzuki type coupling featured predominantly 
triarylphosphine ligands. Around this time focus changed to more bulky, electron rich 
phosphine type ligands mostly created by Buchwald’s group at MIT. These ligands can 
dramatically improve the selectivity and efficiency of C-C (Martin and Buchwald. 2007), 
(Denmark and Kallemeyn. 2006), C-N (Biscoe et al. 2007) and C-O (Anderson et al. 2006)  
coupling reactions  
 
Ligand R
1 
R
2
 R
3
 R
4
 R
5
 
MePhos Cyclohexyl Cyclohexyl Me H H 
DavePhos Cyclohexyl Cyclohexyl N(Me)2 H H 
CyJohnPhos Cyclohexyl Cyclohexyl H H H 
JohnPhos t-Butyl t-Butyl H H H 
SPhos Cyclohexyl Cyclohexyl OMe H OMe 
XPhos Cyclohexyl Cyclohexyl O  i-Pr O  i-Pr O  i-Pr 
RuPhos Cyclohexyl Cyclohexyl O  i-Pr H O  i-Pr 
Table 43 Diagram showing the general structure of Buchwald ligands and a table showing the appropriate substitutions for 
each ligand. 
These compounds (Fig 44) are easily prepared in a one-pot procedure involving the addition 
of an aromatic Grignard reagent to a benzyne intermediate (generated in situ) and the 
subsequent intermediate is trapped with a substituted chlorophosphine on a 10 kg scale (Fig 
45) (Kaye et al. 2001). 
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Scheme 44 Scheme showing the general method used for synthesizing Buchwald ligands. 
The popularity of these ligands can be attributed to the fact that they are: air stable, 
crystalline solids, thermally stable, operationally simple to use and commercially available. 
Fig 46 summarizes the role of the structural features of this ligand series.  
 
Figure 45 General diagram showing the function of each substituent and the effect than changing these groups has. 
The combination of steric and electronic properties can be fine tuned to enhance the rates at 
each step of the catalytic cycle giving the catalytic species formed their excellent activities.  
With specific reference to sterically hindered biaryls, Wolfe (Wolfe et al. 1999) reported 
success in the synthesis of tri-ortho substituted biaryls using both DavePhos and CyJohnPhos  
catalysed Suzuki reactions in excellent yields. 
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Bauduoin’s (Joncour et al. 2006) group has developed Suzuki conditions for the synthesis of 
tri-ortho substituted biaryl molecules that are structural hybrids of NAC / Steganacin 
featuring the desired trimethoxy A ring motif (Fig 47). The group screened a series of ligands 
and bases, determining that either S-Phos or DavePhos in combination with barium 
hydroxide worked best in dioxane at 100 
o
C in moderate yield (55%). This catalytic system 
was also reported for the synthesis of a biaryl precursor (48) to steganacin (Baudoin et al. 
2003) from  an  aryl halide (46) and protected trimethoxy aromatic boronate ester (47)  
 
Scheme 46 Scheme showing the Pd/ Phosphine catalysed coupling reaction utilised in Baudoin’s synthesis of Steganacin. 
N-Heterocyclic carbenes (NHC) 
A carbene is a compound of neutral charge that contains a divalent carbon with a 6 electron 
valence shell. Typically the lack of a full electron octet makes free carbenes unstable and 
until the late 1980s they were viewed as reaction intermediates unable to be isolated. This 
changed with the seminal work by Bertrand (Igau et al. 1988) who published the first 
isolatable carbene (Fig 48, (49)), stabilised by adjacent  silicon and phosphorus atoms.  
 
Figure 47 scheme showing both Bertrand’s (49) and Arduengo's (50) carbenes. 
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Following this Arduengo (Arduengo et al. 1991)  reported the first nitrogen heterocycle 
carbene (50). This compound was easily prepared and isolated This discovery started a rapid 
growth in the area of carbene metal complexation resulting in vast libraries of NHC 
compounds that proved excellent ligands for transition  metal catalysis. 
There has been a rapid growth in the use of N-heterocyclic carbenes (NHC) as ancillary 
ligands in transition metal catalysis.  In particular, in the area of palladium catalysed coupling 
reactions as an alternative for phosphine ligands. Reasons for this include a more facile, less 
expensive synthesis that doesn’t require air free preparation and produces non-toxic by-
products. Phosphine ligands can also suffer from degradation of the P-C bond at higher 
temperatures resulting in catalytic deactivation.  
These nucleophilic NHCs are neutral ligands that can donate 2 electrons without π – back 
bonding making them more effective donors than bulky phosphine groups meaning that they 
are more stable from ligand dissociation from the palladium centre (Huang et al. 1999). 
The use of NHCs as ligands for Suzuki type cross coupling has been reported (Huang et al. 
1999), (Organ et al. 2009). Ozdemir reported high yields and substrate versatility from a 
series of tetrahydropyrimidinium NHCs for both Suzuki cross coupling and direct arylation of 
benzaldehydes (Ozdemir et al. 2005a).  The group chose 6 membered rings over 5- 
membered ring geometry as they have a stronger ortho donating capability.  
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Discussion of results 
Previous work on dibenzo[c,e]oxepine compounds by Edwards (Edwards et al. 2011) utilized 
Ullmann coupling to synthesise (Fig 49) a series of compounds similar to our target 
molecules. This method was initially used to synthesise the central biaryl precursor (56) for a 
series of fluoro dibenzo[c,e]oxepine derivatives.  
 
Scheme 48 Reaction scheme showing the synthesis of precursor (56) via Ullmann coupling and preparation of two 
brominated benzaldehydes (52 and 55) from commercially available starting material 
The A ring coupling partner 2-bromo 3,4,5-trimethoxybenzaldehyde (52) was prepared in 
good yield (68%)  by the dropwise addition of bromine to  3,4,5-trimethoxybenzaldehyde 
(51) in chloroform. (52’) was also made from (51) via periodic acid catalysed iodination 
(83%). Synthesis of the B ring coupling partner, 6-bromo 2-fluoro 3-methoxybenzaldehyde 
(55) was produced in 2 steps from 2-fluoroanisole (53). Bromination of 2-fluoroanisole 
generated (54) (84.3%). Formylation of this compound proceeded in moderate yield (57%) 
via directed ortho metallation of the 2 position by the fluoro group.  
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Figure 49 Diagram showing both hetero (56) and homo (57) coupled products from the Ullmann reaction. 
The Ullmann coupling was attempted using conditions suggested by Edwards (Edwards et al. 
2011) giving the desired heterocoupled dialdehyde compound (56)  in poor yield (22%) along 
with a mixture of  homocoupled (57) product (55%) and  3,4,5-trimethoxybenzaldehyde (51). 
Overall the reaction required 3 eq of 2-bromo 3,4,5-trimethoxybenzaldehyde (52) starting 
material and 10 eq of copper. Changing the coupling partner from bromide to the more 
reactive 2-iodo 3,4,5-trimethoxybenzaldehyde  (56) had negligible effect on the reaction 
outcome.  
Ziegler-Ullmann coupling was utilized in an attempt to improve the yield of the desired biaryl 
(56). Both aldehyde coupling partners (52’, 55) required protection in the form of 
benzylimine groups. The imine moieties also function as directing groups for Ziegler 
coupling. 
Preparation of the imines (58, 59) was achieved in two easy steps from the aryl halides (52’ 
and 55). The conversion of the 2-iodo 3,4,5-trimethoxybenzaldehyde (52’) to the imine (59) 
was achieved in quantitative yield by reaction of benzaldehyde (52’) with benzylamine and 
para-toluenesulfonic acid under Dean Stark conditions. Formation of the (E)-N-(6-bromo 2-
fluoro 3-methoxybenzylidene) cyclohexylimine (58) was first attempted using this method 
with poor results (17% yield). The reaction was tried at room temperature in methanol and 
gave a significant increase in yield (67%). Synthesis of the cuprous iodotriethyl phosphite 
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complex CuI·P(OEt)3 was achieved in one step in good yield (67%) from the reaction of 
cuprous iodide and triethyl phophite. Lithiation of (E)-N-(6-bromo 2-fluoro 3-
methoxybenzylidene)cyclohexylimine was followed by transmetallation with CuI·P(OEt)3 
and addition of (Z)-N-(2-iodo 3,4,5-trimethoxybenzylidene)cyclohexylamine. Treatment with 
with acid removed the cyclohexylimine groups to afford the desired dialdehyde (56) in 
moderate yield (50%) 
 
Scheme 50 Scheme showing the Ziegler modified Ullmann coupling of cyclohexylimine functionalised aromatic halides to 
for a central precursor for oxepine analogues  
The Zeigler-Ullmann coupling gave the highest overall yield for the formation of the biaryl 
dialdehyde (56). The work up and purification was much more simple compared to the 
Ullmann reaction and gave an improved yield of the desired product and reduced yield of 
homocoupled product. 
 
A limitation to Ullmann Ziegler coupling is the requirement of 1 directing auxiliary in the 
ortho position to the halide on each coupling partner. Various alternatives to cyclohexylimine 
have been reported including diethylamine, oxazoline, acetals (Broady et al. 2007) and 
thioacetal but all ultimately are removed to give an ortho benzylic carbonyl (aldehyde or 
ketone) on each ring. This is unsuitable for the synthesis of biaryl[b,d]oxepines for which 
alternative routes were investigated.  
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Figure 51 scheme showing a series of 5 membered hetero cyclic protection direction groups for Ziegler coupling 
Previous work on these compounds has focused on disconnecting these structures either at 
the biaryl bond (Oxidative coupling (Sawyer and Macdonald. 1988), Stille/Peir coupling 
(Edwards et al. 2011) or the central ring tether (Aldol reaction (Besong et al. 2008)).  
 
Figure 52 Diagram showing the pints of disconnection investigated for both [b,d] and [c,e] oxepines 
Initial investigations focused on disconnecting at the heteroatom-containing tether first with 
the rationale that a universal method for both [b,d] and [c,e] oxepines could be established 
that involved shared biaryl precursors to improve efficiency (Fig 53).  
An obvious starting point for this was palladium catalysed cross-coupling, Suzuki –Miyaura 
cross-coupling (Miyaura et al. 1979) was choosen due to its robustness and high functional 
group tolerance. This involves the palladium catalysed coupling of an aryl/alkyl halide with 
an aryl/alkyl boronic acid. Numerous examples and reviews have been published reporting 
high yields and excellent functional group tolerance along with an ever growing selection of 
ligand / catalyst systems. 
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Results: Synthesis of coupling precursors 
The Suzuki coupling was the obvious choice as its use has been widely reported for biaryl 
coupling (Heravi and Hashemi. 2012), (Wójtowicz-Rajchel and Koroniak. 2012). Acetal 
protection of the aldehyde (52) giving (60) required was required before formation of the 
boronic acid (61) was attempted (Fig 54). This was attempted with both the classical ethylene 
glycol, Dean Stark method and a recent method using triethyl orthoformate (Molander and 
Ellis. 2007).  
 
Scheme 53 Reaction scheme showing an acetal protection of an aldehyde followed by a failed attempt at synthesising a 
boronic acid through lithium halogen exchange followed by electrophile quench (trimethly boronate ester) 
As the trimethoxy motif is common to all of the desired analogues 6-formyl-2,3,4-
trimethoxyphenylboronic acid (61) was chosen as a starting point for synthesis of a common 
precursor. Synthesis of this has already been described in the literature (Besong et al. 2008) 
in two steps from 3,4,5-Trimethoxybenzaldehyde as a precursor to (–)-N-acetylcolchinol 
(29). The 3,4,5-Trimethoxybenzaldehyde (51) was brominated in the 2-position and the 
aldehyde subsequently protected as a 1,3 acetal. Attempted boronic acid formation via 
lithium halogen exchange (Fig 55) followed by acetal deprotection failed to afford the 
desired product. The reaction was also attempted with fresh t-BuLi, distilled trimethylborate 
ester and increased equivalency of t-BuLi but to no avail. Increasing lithiation time and 
temperature (-40 
o
C) had no effect as did the addition of the lithiation promoting agent 
TMEDA. The reaction was attempted in diethyl ether and TBDME All of the mentioned 
methods produced only 3,4,5-trimethoxybenzaldehyde (51). This indicated that the lithiated 
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species was being formed and protonated or the boronic acid was forming and 
protodeborating. With this in mind, the reaction was attempted again with the solution of the 
electrophile in THF added dropwise for a slower addition, this again only produced the 3,4,5-
trimethoxybenzaldehyde (51) starting material. Different electrophiles were also employed 
via canula addition (tri-n-butylborate and tri-isopropyl borate) with no success.  
 
Scheme 54 Scheme showing the attempted formation of a boronic acid through lithium halogen exchange. 
 
Attempted Stille coupling 
 
Besong (Besong et al. 2008) also reported the synthesis of 3,4,5-trimethoxy-2-
(tributylstannyl)benzaldehyde (63) for use in Stille coupling, again using lithium-halogen 
exchange but quenching the organolithium with tributyltin chloride (Fig 56). However, in our 
hands this only produced dehalogenated product (51).  Labruére reported the palladium 
catalysed direct stannylation of 2-bromo 3,4,5-trimethoxybenzaldehyde (52) using  Pd(PPh3)4  
with hexa-n-butylditin in refluxing toluene (Labruére et al. 2012) This was attempted, 
successfully affording the desired stannane (63) in high yield (72%). 
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Scheme 55  Reaction scheme showing the successful Pd catalysed stannylation of (52) to generate the desired stannane (63)  
Attempts to form biaryl (96) using the method described by Besong did not work in our 
hands giving less than 10% yield of desired biaryl. Fig 57 summarises the unsuccessful 
efforts to optimise the cross coupling of the stannane with 6-bromo 2-fluoro 3-
methoxybenzaldehyde (53) by trialling different catalysts and conditions.  
 
 
 
 
 
 
 70 
 
 
 
 
 
Pd Catalyst  Ligand Additive 
1 
Additive 
2 
Solvent Temp 
(
o
C) 
Yield (%)  
 
Pd(PPh3)4  CuI        DMA 50 - 
  CuI       CsF DMF 100 - 
 PPh3 CuI    CsF DMF 100 < 10  
 PPh3 CuI CsF DMF 120 - 
Pd(dba)2  CuI  Dioxane 80 - 
  CuI  Dioxane 80 - 
PdCl2 P-tBu3 CuI       CsF DMA 50 - 
 P-tBu3 CuI       CsF DMF 50 - 
 P-tBu3 CuI       CsF DMF 80 < 10  
 P-tBu3 CuI       CsF DMF 100 - 
Pd(OAc)2 DABCO  KF Dioxane 80 - 
 DABCO  KF Dioxane 100 - 
Table 56 Reaction scheme showing the attempted synthesis of dialdehyde (56) via Stille coupling and a table summarising 
the various catalytic systems, bases and conditions trialled. 
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Baudoin (Baudoin et al. 2002) developed a Musada type borylation of this type of electron 
rich aromatic ring. This method was used to synthesise two trimethoxybenzyl alcohol 
derivatives with different hydroxyl protecting groups to further investigate Suzuki coupling.    
 
Scheme 57 Scheme showing the synthesis of both silyl and MOM protected benzyl coupling partners for Suzuki coupling. 
Iodination of 3,4,5-trimethoxybenzaldehyde (51)  occurred in excellent  yield (83%)  using 
iodine and periodic acid to give (52’).  Reduction with sodium borohydride in methanol 
afforded the benzyl alcohol (64) in excellent yield (90%). Triethylsilyl (65) and methoxyl 
methyl (67) protection groups were added in excellent yield (81% and 92% respectively) 
through base catalysed SN2 reaction with TES triflate and methoxymethyl chloride 
respectively. Subsequent borylation of the protected iodides occurred in good yield giving 
TES (66) and MOM (68) protected pinacol boranes (72% and 66% respectively).     
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Results: Attempted Suzuki coupling 
Suzuki coupling was attempted on both MOM and TES protected borylated A ring precursor 
with benzaldehyde 70, Fig 59 summarises the conditions used and the halide coupling partner 
trialled.  Overall the only suggestion of formation of (71) occurred when the reaction of (68) 
was carried out in refluxing toluene. Adding more catalyst did not improve the yield, 
changing solvent to DMF and increasing reaction temperature to 150 
o
C also resulted in no 
reaction 
.  
 
 
 
 
 
 
 
 
 
Pd Catalyst  catalyst Additive  Solvent Temp 
(
o
C) 
Yield 
(%) 
  (68) Pd(PPh3)4  EtOH 80 - 
  (68)  LiCl EtOH 80 - 
  (68)  LiCl DME 80 - 
  (68)  LiCl Toluene 120 < 10  
  (68)   DMF 150 - 
  (66) Pd(dba)2  EtOH 80 - 
  (66)  LiCl EtOH 80 - 
  (66)  LiCl DME 80 - 
  (66)  LiCl Toluene 120 - 
  (66)  LiCl DMF 150 - 
Table 58 Scheme showing the attempted palladium catalysed Suzuki coupling of a trisubstituted biaryl and a table showing 
the reagents and conditions trialled 
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Results: Attempted  phosphine catalysed Suzuki reaction 
Direct reduction of the commercially available 3,4,5-trimethoxyphenylacetic acid (72) with 
LiAlH4 was low yielding (30%) but conversion of the acid to methyl ester (73) was high 
yielding (79%). Reduction to the alcohol (74) was acheived in good yield (75%). This 
compound was iodinated (75) in good yield (74%). Both Methoxyl methyl (76) and 
triethylsilyl (TES) (78) protection groups were added in excellent yield through base assisted 
SN2 reaction with TES triflate and methoxymethyl chloride (90% and 87% respectively).    
 
Figure 59 Scheme showing the synthesis of both MOM (77) and Silyl (79) protected phenyl ethanol coupling partners for 
Suzuki coupling. 
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Borylation was first attempted with the TES protected compound (78) giving the product as 
an inseparable mixture of the desired boronate with deiodinated starting material (3:1, 
approximately 65% determined by 
1
H NMR). The MOM (77) protected iodide was 
synthesised and borylated in high yield (75%). Several unsuccessful attempts (Fig 61) were 
made to couple aromatic halides (81) to both of the borylated (80) products using the 
DavePhos (83) / Pd(OAc)2  system described by Baudoin (Colombel et al. 2010) in an attempt 
to form the trisubstituted biaryl (82). Again in all cases deiodinated starting material was 
recovered indicating that oxidative addition of  palladium is occurring at the C-I site 
suggesting that the reaction is failing at either the transmetallation or reductive elimination 
stages. 
 
R Y Yield % 
OMOM CHO NR 
OMOM C(=O)Me < 10 
OMOM OMOM NR 
OMOM OBn < 10 
OTES CHO NR 
OTES C(=O)Me < 10 
OTES OMOM NR 
OTES OBn NR 
Table 60 Scheme showing the attempted formation of trisubstituted biaryl via Baudoin’s conditions and a table indicating the 
substituents on each ring (R and Y). A TLC analysis was performed after 6 hours and the concentration of Pd(OAc)2 and 
DavePhos tripled. 
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Attempted Suzuki coupling using a Pd/ N-heterocyclic carbene (NHC) catalytic system 
 As an alternative to phosphine ligands, an N-heterocyclic carbene (NHC) was also 
synthesised (Fig 62) and trialled as a catalytic system for biaryl coupling. The NHC precursor 
chosen was a tetrahydropyridinium salt (87) described by Ozdemir (Özdemir et al. 2005b) as 
a ligand for palladium catalyzed Suzuki coupling. This compound was synthesised in 3 steps 
from mesitaldehyde (scheme 62)  
 
Scheme 61 Scheme showing the synthesis of the tetrahydropyridinium salt ligand (87) from mestitaldehyde (84). 
The first step involved the formation of a diimine (85) and was poor yielding (17%). NaBH4 
reduction of this diamine occurred in excellent yield (92%) to give secondary diamine (86) 
followed by formation of the chloride salt (87) (72%) in high purity by melting point. 
Suzuki coupling was attempted between the (88) (Fig 63, 68) and the iodide coupling partner 
(70 )using the Pd(OAc)2 / 87 catalyst system under the conditions described by Ozdemir. This 
was unsuccessful, producing a mixture of dehalogenated and deborated starting materials. 
Increasing the temperature and catalytic loading failed to give the desired biaryl. 
 76 
 
 
Scheme 62 Scheme showing the attempted formation of a trisubstituted biaryl (89) via a Pd/carbene catalysed Suzuki 
coupling. 
 
Changing the halide coupling partner to 4-bromoanisole under the conditions described by 
Ozdemir (scheme 63) gave excellent conversion to the desired product (90%), again 
indicating that steric hindrance was the limiting factor when an ortho substitution is present 
on the B-ring coupling partner.  
 
Attempt to form biaryl using Pd/ NHC catalysed direct arylation 
 
Ozdemir also reported the use of this Pd/NHC system to catalyse the direct arylation of 
electron rich benzaldehydes (Özdemir et al. 2005b).  This was replicated in our hands 
resulting in successful direct functionalisation of the 2 position of 3,4,5-
trimethoxybenzaldehyde (51) with 4 –iodoanisole (91). This proceeded in high yield, 
affording the biaryl product o(Fig 64) (91%). We also attempted the direct functionalisation 
of 3,4,5-trimethoxybenzaldehyde (51) with 6-iodo 3-methoxybenzaldehyde (70) (Fig 64). 
This was unsuccessful generating only 3,4,5-trimethoxybenzaldehyde and dehalogenated 
starting material. 
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Scheme 63 Scheme showing both the successful formation of a disubstitiuted biaryl (left) and unsuccessful formation of a 
trisubstituted biaryl (Right) through Pd/carbene catalysed direct arylation. 
The reaction was also attempted with 2-iodobenzaldehyde (70) and 2-iodoacetophenone (70’) 
but in both cases a mixture of starting material and deiodinated starting material where 
produced suggesting that oxidative addition at least occurred. So far, attempts have been 
unsuccessful in the synthesis of the required tri -substituted biaryl precursor (92). 
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Investigation into the effects of changing groups ortho to the coupling carbons 
 
R R1 
Conditions A Yield 
(%) 
Conditions B Yield 
(%) 
Conditions C Yield 
(%) 
CHO  70            CHO NR NR NR 
CHO  71            C(=O)Me < 10 NR NR 
CHO 105           CH2 OMOM NR NR NR 
CHO 112           OBn NR NR NR 
CHO H 88 92 90 
OMOM  70            CHO NR NR NR 
OMOM  71            C(=O)Me NR NR NR 
OMOM 105           CH2 OMOM NR NR NR 
OMOM 112           OBn NR NR NR 
OMOM H 67 61 52 
Table 64 Diagram showing a general scheme for a Suzuki reaction and a complementary table that shows the various R and 
R1 substituents. Conditions A (Pd(PPh3)4, Na2CO3, DME 80 
oC sealed tube). Conditions B (Pd(OAc)2, DavePhos, Ba(OH)2
.8 
H2O, Dioxane/H2O, 100 
oC), Conditions C (Pd(OAc)2, 87, K2CO3, DMF/H2O, 50 
oC). 
 Various types of palladium catalysed cross-coupling have been attempted to no avail. 
Several methods have been attempted and have either failed or produced tiny amounts of 
desired product (<10%) that did not improve through optimisation.  Various combinations of 
the groups ortho to the coupling moieties (Boronate ester on A ring (93), iodide on B-ring 
(94) have been trialled (Fig 65). On every occasion the only successful coupling occured 
when the ortho group to the halide is hydrogen, further confirming steric hindrance as being a 
problem. In all cases, deiodinated starting material was recovered indicating that oxidative 
addition had occurred. Switching the halide group to the A- ring and vice versa for the 
boronate B-ring had no effect on reaction success, ruling out protodeboronation due to the 
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electron donating trimethoxy moiety. Sneickus’ group encountered this issue with steric 
hindrance during the total synthesis of the natural product  Gymnopusin (Wang et al. 2012). 
The compounds required the formation of a tri-substituted biaryl (Fig 66) with a similar 
substitution pattern to our desired precursor. 
 
Scheme 65 Scheme shows two examples of alternative retrosynthetic routes to trisubstituted biaryls due to failed cross 
coupling. 
The group attempted several Suzuki conditions to form the biaryl directly but abandoned this 
method due to the low yields caused by steric hindrance and electron donating nature of the 
substituents. An alternative route was utilised that involved formation of a di-substituted 
biaryl followed by a rearrangement. Labruere (Labruere et al. 2012) reported a similar 
problem when dealing with tri-substituted biaryls. The original route was attempted but the 
Stille coupling failed, fortunately the electron donating substituents on (99) allowed for 
regiospecific nitration to give the desired product (98).  
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A Friedel Crafts approach  
 
 
Scheme 66 Retrosynthetic route to [b,d] oxepines utilizing an intramolecular Friedel Crafts ring closure 
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As directly preparing a tri-substituted biaryl directly through cross coupling has proven 
unsuccessful due to steric hindrance a different approach was attempted. Having shown that 
disubstitiuted biaryl can be formed in excellent yield, this was chosen as a starting point for 
oxepine construction. The retrosynthesis (Scheme 67) shows that a Friedel Crafts acylation 
ring closure is the key step to form the oxygen containing central ring. This route is 
exclusively for [b,d] oxepines and the electron donating groups present on both the A and C 
rings should allow for sufficient selectivity in a Friedel Crafts electrophilic ring closure.
 
Scheme 67 Scheme showing the synthesis of both a-ring and b ring phenol precursors in 2 steps via a Suzuki reaction and 
Dakin oxidation. 
 Initially aldehydes were chosen to generate appropriate starting phenols (101, 104) using 
Dakin/ Baeyer Villiger chemistry (Scheme 68).  Both biaryl aldehydes (90, 103) were 
synthesised with via Suzuki coupling in excellent yields. Both acid and base-catalysed Dakin 
reactions were attempted with H2O2 giving poor yields. A boric acid / H2O2  system has been 
reported to increase yield in the oxidation of benzaldehydes to phenols (Roy et al. 1999), so 
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this was also attempted and also gave disappointingly low yields. Using m-CPBA followed 
by base hydrolysis, again gave poor yields as did urea/ H2O2 (Varma and Naicker. 1999).  An 
attempt was made to oxidise the aromatic benzaldehydes (Fig 69) to phenols before Suzuki 
coupling. Again the desired phenol (105) was formed in poor yield (14%) with the major 
component being an aromatic formate (106). Several attempts to hydrolyse this formate failed 
even using hot concentrated base (NaOH (50%). As direct Suzuki coupling of 2-iodo 5-
methoxyphenol with 2,3,4-trimethoxyphenylboronic acid proceeded in low yield (24%), a 
series of phenol protecting groups were considered.
 
Scheme 68 Scheme showing the attempted Dakin oxidation of benzaldehyde (70) to generate the desired phenol (105) in 
poor yield and unwanted formate (106) as the major product. 
Synthesis of 2-iodo 5-methoxyphenol (107) by direct iodination of 3-methoxyphenol (105) 
has been described in the literature. The method described by Das (Das et al. 2007) using 
molecular iodine in acetonitrile with catalytic ceric ammonium nitrate produced a complex 
mixture of iodinated aromatics with approximately 15% (by crude  
1 
H NMR) of the desired 
product in our hands unlike the 85% reported.  Using silver trifluoroacetate (Fig 70) in 
chloroform gave (107) an unimpressive yield of 32%. An optimized yield of 68% was 
achieved using silver nitrate with a slow canula addition of iodine in chloroform (0.1 g /500 
mL) over 24 hrs. 
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Scheme 69 Scheme showing the iodination of 3- methoxyphenol generating 6-iodo 3-methoxyphenol as the major regiomer 
(68%) and 4-iodo 3-methoxyphenol 
Alkylation of 2-iodo 5-methoxyphenol (105) with methyl bromoacetate resulted in the 
desired acid (109) in excellent yield (76%). An attempt to couple 2,3,4-
trimethoxyphenylboronic acid (102) directly with (109) generated (110) in  disappointing 
yield ( <10%) (Scheme 71). 
Increasing the amount of catalyst and increasing reaction time did not improve the yield of 
(110). The reaction was also unsuccessfully attempted at 150 
o
C in DMF. 
 
Scheme 70 Scheme showing the alkylation of phenol (105) to form acid (109). Reaction of this compound with boronic acid 
(102) was unsuccessful. 
2-Iodo-5-methoxyphenol (105) was protected with a MOM group through base catalysed 
nucleophilic substitution using Hunigs base and MOMCl in DCM in excellent yield (91%) 
(Scheme 92). Suzuki coupling of this compound with 2,3,4-trimethoxyphenylboronic acid 
(102) was unsuccessful. Alkylation of 2-iodo 5-methoxyphenol (105) with benzyl bromide 
succeeded in moderate yield (43%), but a Mitsunobu reaction with benzyl alcohol gave a 
clean conversion to the desired benzyl protected phenol (112) in excellent yield (86%) 
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Figure 71 Scheme showing the Mitsunobu reaction between phenol, and benzyl alcohol to generate (112). Suzuki coupling 
of this compound with boronic acid (102) and subsequent palladium catalysed hydrogenation to give the desired phenol 
(104). 
The subsequent Suzuki coupling of (112) with 2,3,4-trimethoxybenzeneboronic acid (102) 
proceeded to generate (113) in excellent yield (88%). The benzyl protecting group was 
removed via palladium catalysed hydrogenation in excellent yield (87%) to give the desired 
biaryl phenol (104).  The isomer of this phenol was also required (101). The synthesis is 
described in Fig 73. 
 
Scheme 72 Reaction scheme showing the preparation of coumpounds (101 and (116). (115) through the bromination of phenol (114) with 
NBS. A Mitsunobu reaction of the product (115) with benzyl alcohol (110) produced coupling partner (116). A Suzuki coupling of this 
compound (116) with boronic acid (102) using general proceedure 1 generated benzylated biaryl (117), hydrogenation of this compound 
generated the desired phenol (101) in excellent yield. 
Bromination of 3,4,5-trimethoxyphenol (114) using NBS proceeded in excellent yield (87%) 
following a procedure described in the literature (Jinno et al. 1999). Benzylation of the 
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phenol (115) was best achieved through Mitsunobu reaction with benzyl alcohol (110) in 
excellent yield (92%). Suzuki coupling of this bromide (116) with 4-methoxybenzeneboronic 
acid (102) generated the desired biaryl (117) in excellent yield (90%)  Removal of benzyl 
protection via Pd catalysed hydrogenation generated the desired phenol (101) in excellent 
yield (94%). Attempts to directly synthesise the required acid (118) from this phenol (101) 
with potassium carbonate and 2-bromoacetic acid in methanol was low yielding (25%) and 
attempts to improve this by changing solvents failed.  Using bromoacetic acid methyl ester in 
ethanol followed by a basic work up gave the desired acid in high yield (85%)  (Fig 74). The 
Friedel Crafts ring closure proceeded in good yield (73%) using a mixture of trifluoroacetic 
acid and trifluoroacetic anhydride (50:50) to generate oxepin-7(6 H)-one (119).   
 
 
Scheme 73 Scheme showing the alkylation of phenol (104) with 2-bromoacetate followed by acidic work up to generate acid 
(118). Intramolecular Friedel Crafts of this compound generated dibenzo[b,d]oxepin-one in good yield with (120) as a minor 
product. 
Attempts to improve the yield of desired oxepin-7(6 H)-one (119) and reduce the presence of 
the benzofuran-2(3H)-one side product (120) were attempted. Changing the Lewis acid 
(TiCl4, BF3
.
(OEt)3 and AlCl3)  resulted in overall lower yields for the reaction. 
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Lewis acid Time (H) % yield of 119 % yield 120 
TFA/TFAA 50:50 24 73 15 
TFA/TFAA 75:25 36 60 15 
TFA/TFAA 25:75 36 51 10 
TFA 36 27 - 
TFAA 36 - - 
Table 74 Table showing the conditions attempted to optimise the formation of (119) and reduce the formation of impurity 
(120) 
Alkylation of the phenol (101) with bromoacetic acid methyl ester in ethanol followed by a 
basic work up gave the desired acid (121) in high yield (74%) (Scheme 76). Friedel Crafts 
ring closure again generated oxepin-7(6 H)-one (122) in high yield (75%) and this was easily 
separated from the benzofuranone (123) side product. 
 
Scheme 75 Scheme showing the alkylation of phenol (101) with 2-bromoacetate followed by acidic work up to generate acid 
(121). Intramolecular Friedel Crafts of this compound generated dibenzo[b,d]oxepin-one in good yield with (123) as a minor 
product. 
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Conclusion 
 
The substitution pattern of the methoxy groups on these molecules (Fig 77) supply 
appropriate directing effects for intramolecular Friedel Crafts ring closure. This is true if the 
acid is located on either ring. In both cases (74, 76) a small amount of unwanted indanone 
side product (120, 123) was produced but was easily removed by chromatography. The 
ketone moiety on the ring closed products (119, 122) can serve as a useful functionality for 
further derivation or can be removed via reduction. A potential issue with the robustness of 
the method is outlined in Fig 77. If the ring closure was attempted on a molecule (124) with a 
substitution meta to the biaryl carbon on the B-ring, depending on the directing nature of the 
substituent a mixture of regiomers (125, 126) will form. The ratio of compounds will depend 
on the directing ability of R.      
 
Figure 76 A diagram showing potential issues of regioselectivity when using an intramolecular Friedel Crafts ring closure on 
an unsymmetrical ring (124). The red arrows indicate the sites of reaction. 
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Introduction  
Attempts were also made to synthesise oxepines through different routes in which the final 
step was the formation of the dihedral biaryl bond. Disconnecting the molecule at this bond 
has the advantage of being thermodynamically favoured and having fewer steps. The 
disadvantage is the lack of a common precursor in the preparation of a library of compounds.  
Edwards (Edwards et al. 2011) used an intramolecular CuCl oxidative coupling (Scheme 78) 
first described by Piers (Piers et al 2000) to synthesise a series of dibenzo[c,e]oxepine 
colchicine binding analogues (128) from distannylated precursor (127). This method required 
two steps involving toxic stannane reagents, and gave poor to moderate yields. 
 
Scheme 77 Reaction scheme showing the copper chloride catalysed intramolecular ring closure of a distannane (127). 
Due to the previously mentioned lack of success with Ullmann coupling an intramolecular 
version wasn’t attempted. Miyano reported an Ullmann coupling method that utilised tethers 
in trying to control atropisomerism of bridged biaryls, again this suffered from low yields. If 
a sterically hindered bond was formed and would require an extra step (Miyano et al. 1984). 
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Intramolecular oxidative coupling 
Intramolecular phenolic oxidative coupling is a key process in several natural product 
biosynthetic pathways, not least in the biosynthesis of colchicine (Maier and Zenk. 1997). 
This has been an area of great interest as the process allows the formation of carbon-carbon 
bonds without the necessity of installing coupling functionalities such as halogens or boronic 
acids/stannanes and can proceed without transition metal catalysis. Initial research into the 
process involved highly toxic heavy metal oxidants such as thallium or vanadium complexes 
(VOCl3, VOF3). Thallium(III) trifluoroacetate  (TTFA) was in fact utilised (Scheme 79) as an 
oxidant in the phenolic oxidative coupling stage in synthesis of racemic NAC (29) (Sawyer 
and Macdonald. 1988). Several other metal oxidants including FeCl3 and Pb(OAc)4 were also 
trialled.  
 
Scheme 78 Reaction scheme showing an intramolecular phenolic oxidative coupling ring closure used in the synthesis of 
racemic NAC (130) from phenol precursor (129). 
  The seminal work of Kita (Kita et al 1996) in the mid 1990s involved the development of 
PIFA (Phenyliodine bis(trifluoroacetate) (131), a metal - free hypervalent iodine (III) species 
for Lewis acid activated oxidative coupling reactions. The group also reported the first non-
phenolic oxidative coupling reaction using a non –metal oxidant. Besong (Besong et al 2008) 
reported the asymmetric synthesis of S-(-)-NAC (29) via phenolic oxidative coupling. The 
group directly compared oxidants. PIFA (131) offered a better yield (50% over 30%) and 
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required much lower equivalency of BF3
.
(OEt)2 (1.5 eq reduced from 35 eq) compared to 
TTFA as a solvent. 
Both suggested mechanisms for phenolic (Fig 80) and non-phenolic (Fig 81) oxidative 
coupling resulted in a similar charged pseudo diquinone species that re-aromatised through 
resonance stabilisation to yield products. 
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Scheme 79 Scheme showing the proposed mechanism of Lewis acid catalysed intramolecular phenolic oxidative coupling 
with PIFA (131) used as an oxidant to convert a tethered phenol (132) to a ring closed product (133). 
 
Scheme 80 A reaction scheme showing the proposed mechanism for a Lewis acid catalysed non-phenolic oxidative coupling 
reaction involving single electron transfer, converting (134) to (135) 
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Results 
This process was attempted in the synthesis of dibenzo[b,d]oxepines. The B-ring precursors 
(Fig 82 (138), (139)) were synthesised in one pot from 2-fluoroanisole (136) (63%). Directed 
ortho metallation with n-BuLi followed by quenching with triiospropyl borate generated 
boronic acid (137) and addition of hydrogen peroxide and acetic acid gave the phenol (139) 
via an oxidative cleavage. The boronic acid wasn’t isolated. Both ether precursors (141, 142) 
for oxidative coupling were formed using Mitsunobu chemistry in good yield.  
 
 
Scheme 81 Scheme showing the synthesis of phenol (139) from 2-fluoroanisole (136). Also featured is the formation of 
ethers (141, 142) from Mitsunobu coupling of appropriate phenol (138, 139) with alcohol (75). 
In our hands non-phenolic oxidative coupling was unsuccessful. Several conditions were 
attempted (Fig 83) using both PIFA and TTFA as oxidant. Following the Kita procedure 
(Kita et al. 1996) with  compound (141) gave approximately 5% (By H
 1
 NMR) of the desired 
product (143) in a complex mixture. Changing temperature or oxidant resulted in quantitative 
recovery of starting material. With compound (142), again a multi component mixture was 
produced with no evidence of (144). This may be due to in an imbalance in electro potentials 
between rings with initial formation of cation intermediates followed by the reforming of 
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starting material through resonance stabilisation. This could also be due to the position of the 
ether leading to a competing intermediate ortho to the b-ring methoxy.  
 
R [O] Solvent Temp (oC) Yield % 
H PIFA BF3
.(OEt)2 -40 < 10 
   -78 NR 
   0 NR 
  TFA/TFAA -40 < 10 
   -78 NR 
 TTFA BF3
.(OEt)2 -40 NR 
   0 NR 
F PIFA BF3
.(OEt)2 -40 < 5 
   -78 NR 
   0 NR 
  TFA/TFAA -40 < 5 
   0 NR 
 TTFA BF3
.(OEt)2 -40 NR 
   0 NR 
Table 82 Scheme showing the attempted non-phenolic intramolecular oxidative coupling reaction on (141,142) to form 
oxepines 143 and 144. The table shows all of the oxidants, Lewis acids trialled at various temperatures. 
 
Direct arylation 
Since the early 2000s there has been shift in research away from traditional cross coupling and 
heterocyclic chemistry towards C-H functionalisation in general but in particular for the formation of 
biaryl compounds (Deprez et al. 2006), (Lane and Sames. 2004), (Kakiuchi et al. 2003).   
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Scheme 83 Diagram showing a general reaction scheme for a palladium catalysed intramolecular arylation. The red bond in 
halide (145) is the site of palladation. The red line in (146) shows the newly formed biaryl C-C bond. 
Palladium catalysed arylation (Fig 84) of (hetero) aromatic compounds is a more direct route than 
classical cross coupling as it requires fewer steps and in the case intramolecular reactions is 
thermodynamically favoured. This area of direct arylation is of great interest. The only limit seems to 
be predicting regioselectivity and substrate suitability.  This of course comes from understanding of 
mechanism, of which progress is being made.  Several mechanisms have been suggested but two have 
received the most support. Electrophilic aromatic substitution (SEAr) and concerted metallation 
deprotonation (CMD) and in both mechanisms oxidative addition occurs at the halide moiety. In SEAr 
the palladated aryl halide attacks pi-nucleophilic aromatics. (Fig 85) In CMD the proton at the desired 
site of reaction is made acidic by the formation of a palladacycle and abstracted followed by 
elimination of palladium.       
 
Figure 84 Diagram showing proposed transitions for SEAr, both Fagnou and Maseras' CMD palladium species. 
There have been several mechanistic studies on CMD with most groups in agreement that carboxylate 
type bases have a critical role,  the question of base/metal interaction still remains unanswered 
(García-Cuadrado et al. 2007). The SEAr pathway has all but been debunked in favour of CMD due 
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to instances of arylation reactions occurring without any directing groups present. (Lapointe and 
Fagnou. 2010). 
 
A ring Palladation  
 
Initial attempts at direct arylation were focused on forming the palladacycle on the trimethoxy A ring 
Scheme 86). The coupling precursors (148, 149) were synthesised in good yield from the reaction of 
2-iodo 3,4,5-trimethoxyphenylethanol (75) and the relevant phenol (138 = 92%, 139 = 91%)                     
 
Scheme 85 Scheme showing the attempted formation of a dibenzo[b,d]oxepine (150, 151) via intramolecular arylation. 
Precursors (148, 149) were synthesised via a Mitsunobu reaction between (75) and 138 or 139) 
 
 Using the catalytic system described by Fagnou (Campeau et al. 2004), several attempts were made 
to achieve ring closure, all unsuccessful. The deiodinated starting material was recovered, suggesting 
that oxidative addition of palladium to the carbon - halide bond had occurred. In the case of the 
fluorinated precursor (149), the major product was again the deiodinated starting material 
accompanied by a small amount of defluorinated material. Reducing the temperature to 80 
o
C resulted 
in a mixture of starting material and deiodinated material. The proto deiodination is most likely due to 
the heavily electron donating nature of the trimethoxy motif.   
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B ring Palladation 
Phenol (152) was successfully prepared in good yield (71%) by the AgNO2 catalysed iodination of 2-
fluoro 3-methoxyphenol (139). The desired precursors for ring closure (153, 154) were produced in 
good yield by reacting the phenols (110 or 152) with 3,4,5-trimethoxyphenylethanol(74) via a 
Mitsunobu reaction (153 = 77%, 154 = F 86%) (Fig 87). 
 
Scheme 86 Scheme showing the iodination of phenol (139).  The iodinated phenol (152) produced and phenol (110) were 
both coupled  with phenyl ethanol (74) to generate arylation precursors (153) and (154) respectively. Arylation of (153) gave 
oxepine (155). Arylation of (154) was unsuccessful in generating dehalogenated starting material (141, 142). 
The arylation reaction proceeded in moderate yield (~ 55% by H
 1
 NMR) under the standard Fagnou 
conditions with precursor (153). The crude material consisted of an unseparable mixture of the desired 
product and deiodinated starting material. The ring closure was attempted using the fluoro precursor 
(154) again, this was unsuccessful giving a mixture of deiodinated starting material and the ring 
closed product (by H
 1
 NMR) 
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Synthesis of Fluoro analogues of [c,e]oxepines 
The fluoro analogues were all synthesised from the common biaryl precursor (56) due to the 
ease of access via the dehydrative cyclisation of diol (157) to form oxepine and the 
nucleophilic ring closure of dibomo compound (159) to form the various hetrocyclic 
analogues as described by Edwards (Edwards et al 2011).   
 
Scheme 87 Scheme showing the synthesis of an oxepine analogue (158) from the reduction of dialdehyde (56) followed by 
acid catalysed ring closure of benzylic diol (157) 
The dialdehyde (56) was first reduced to (3-fluoro 4,4',5',6'-tetramethoxy-[1,1'-iphenyl]-2,2'-
diyl)dimethanol (157) using sodium borohydride in good yield (74%) (Scheme 88). 
Dibenzo[c,e]oxepine (158) was formed in one step from the diol (157) by acid catalysed ring 
closure. This occurred in good yield (71%). 
 
Scheme 88 Reaction scheme showing the dibromination of biaryl diol (157) to generate (159) 
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The remaining nitrogen and sulphur containing analogues were synthesised from the dibromo 
precursor. This was produced (159) in good yield (75%) from the dibromination of diol (Fig 
89).  Formation of the 8-fluoro 1,2,3,9-tetramethoxy-5,7-dihydrodibenzo[c,e]thiepine (160) 
occurred in excellent yield (94%) from the reaction of the dibrominated species (159)  with 
sodium sulfide. 
 
Scheme 89 Scheme showing the fomation of a thiepene (160) through nucleophilic ring closure of (159). 
Oxidation of the thiepine product (160) using m-CPBA gave a mixture of 8-fluoro 1,2,3,9-
tetramethoxy-5,7-dihydrodibenzo[c,e]thiepine oxide (32%) (161)  and dioxide (48%) (162) 
respectively (Fig 91) that were easily separated via column chromtography.  
 
Scheme 90 scheme showing the m-CPBA induced oxidation of thiepine (160) to form both sulfone (161) and sulfoxide (162) 
analogues  
The synthesis of 8-fluoro 1,2,3,9-tetramethoxy-6,7-dihydro 5 H-dibenzo[c,e]azepine (164) 
was attempted by multiple routes. The reaction of the dibromo biaryl precursor (159) with 
methanolic ammonia was unsuccessful, failing to yield product (164). Fig 92 shows the 
attempts to form the N-formyl derivative (163) from formic acid catalysed reaction of 
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formamide with dialdehyde (56) followed by hydrolysis to amine (164). This approach was 
also unsuccessful, resulting in decomposition of the molecule. 
 
Scheme 91 Scheme showing an attempted formation of azepine (164) from dialdehyde (56) via a ring closing formylation 
reaction followed by acid catalysed cleavage of N-formyl species (163). 
 
The reaction of 2',6-bis(bromomethyl)-3'-fluoro 2,3,4,4'-tetramethoxybiphenyl (159)  with 
benzylamine afforded the N-benzylated azepine (165) product in good yield (67%) (Fig 93). 
The many attempts to remove the benzyl group from the compound via palladium catalyzed 
hydrogenation are summarised in table (Fig 94). Increasing the amount of C/Pd had no effect. 
The reaction was also attempted with Pearlman’s catalyst (20% Pd(OH)2), this again gave 
quantitative return of starting material. 
 
Scheme 92 Scheme showing the formation of N-benzyl azepine (165) via reaction of benzylamine with dibromo biaryl 
(159). 
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Methanol (%) HCl (%) Temperature 
(
o
C) 
Pressure (atm) Yield (%) 
0 100 100 1 NR 
0 100 100 1 NR 
90 10 0 4 NR 
75 25 0 4 NR 
50 50 0 4 NR 
Table 93 Table showing the conditions attempted for the unsuccessful debenzylation of (165) via Pd catalysed 
hydrogenation 
 
Synthesis of hydroxyl analogues 
  
The synthesis of the biaryl precursor (36) for the hydroxyl analogues was achieved through 
Ullmann coupling as formation of the required imine for Ziegler coupling was low yielding.  
 
Scheme 94 Scheme showing the synthesis of Ullmann precursor (167) from (171). 
Synthesis of the B-ring precursor 6-bromo 2-methanesulfonyl-3-methoxybenzaldehyde (171) 
was produced in four steps from ortho vanilin (Fig 95, 167). The phenol group from (167) 
needed to be protected to direct the bromination to the 6 position. This was achieved in 
moderate yield (63%) by reaction with acetic anhydride in pyridine at room temperature to 
give (168). Bromination was achieved using KBr and Br2  in water to give the crude product 
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(169). Ttreatment with NaHCO3 gave the deacetylated phenol (170) which was subsequently 
mesylated to give the target (171) in excellent yield (79%) (Scheme 96).   
 
Scheme 95 Scheme showing the formation of mesylated biaryl dialdehyde (36) via copper catalysed Ullmann coupling of 
benzaldehydes (171) and (52). 
The Ullmann coupling proceeded in poor yield (33%). The dialdehyde produced (36) was 
reduced to the diol (172) using sodium borohydride in excellent yield (82%) and reaction 
with PBr3 gave the dibrominated component (173) in excellent yield (90%) (Scheme 97).  
 
 
Scheme 96 Scheme showing the synthesis of a dibrominated intermediate (173) from the reduction of dialdehyde (36) 
followed by PBr3 induced bromination of benzylic diol (172) 
The ring closure of the dibromo compound (173) with sodium sulphide was attempted in 
refluxing water/methanol (Fig 98). This produced a complex mixture. No reaction occurred at 
room temperature after 3 days. Under sonication, the reaction proceeded to give the desired 
thiepene (175) in poor yield (26%).  
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Scheme 97 Scheme showing the formation of thiepine analogue (175) from dibrominated species (173) 
Attempts to remove the mesyl group from the thiepene (Fig 99) were unsuccessful resulting 
in degradation of the product in to complex even at room temperature.  The reaction was 
repeated at room temperature. After 4 hours degradation had occurred. Attempts to oxidise 
the mesylated thiepene (175) to sulfoxide (177) and sulphone (178) with m-CPBA also 
resulted in degradation (Scheme 99).   
 
Scheme 98 Scheme showing the failed attempt to deprotect (175) to generate phenol (176). The failed oxidation of (175) to 
both thiepene oxide (177) and dioxide (178) is also described. 
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Synthesis of biaryl analogues  
 
McNulty (McNulty et al. 2015) recently reported low µM from a simplified 
NAC/Combretastatin hybrid (31) with a similar methoxy substitution to Edward’s (Edwards 
et al. 2011) oxepine analogues and CA-4 (Fig 100).   
 
Figure 99 Diagram showing the similarities between Edwards Oxepine (30), Mc Nulty’s NAC/ Combretastatin hybrid (31) 
and CA-4 (23) 
Based on McNulty’s suggested pharmacophore (31), we synthesized and tested a simplified 
series of biaryls without a central heterocyclic ring. The molecules are analogous to 
dibenzoxepines and CA-4. They were also tested to further explore the colchicine 
pharmacophore.  
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Figure 100 Diagram showing a general reaction scheme for the Suzuki coupling of aryl halides (179) with boronic acid 
(102). Molecules (181 to 187) show the series of simplified analogues synthesised for biological evaluation. 
 
These compounds were synthesised via Suzuki coupling of the appropriate aryl halide (Br or 
I) with 2,3,4-trimethoxybenzeneboronic acid (102). All reactions proceeded in excellent 
yield.  
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Aim 
The standard assays used to evaluate the in vitro biological activity of tubulin binding 
vascular targeting agents are the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay and tubulin binding assay. Combretastatin A-4 (23) was used as a standard so 
that the data obtained for tested compounds could be compared with that of existing 
antivascular compounds in the literature. All of the compounds synthesised will were tested 
using both the MTT and microtubule assembly assays. 
Introduction  
Introduction: MTT assay 
The library of synthesized target compounds was screened first using the MTT assay. This 
measures a targets ability to inhibit cell growth. For this assay, the K562 (human chronic 
myelogenous leukaemia) cell line was used as it is widely reported (Edwards et al. 2011; 
Gaukroger et al. 2003a; McNulty et al. 2015) in the literature for screening anti-cancer 
compounds.  
In the standard procedure the candidate compound was diluted in DMSO to a sub molar 
range (commonly 5 µM, 500 nM and 50 nM) and appropriate cells diluted to required 
concentration (usually 3000 cells/mL) in 10%  Feotal Calf Serum (FCS) in RPMI (Roswell 
Park Memorial Institute) media. The drug in solution was added to cell solution causing a 
1000 fold dilution in drug concentration. A series of 1:1 dilutions were carried out to give in 
total seven drug concentrations. A control consisting of the media without the drug was 
prepared to allow the validation of any growth inhibition observed in treated cells. The dosed 
cells were then incubated for 5 days at 37 
o
C in a 5% carbon dioxide in air atmosphere. 
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Scheme 101  A scheme showing the reduction of  MTT (188) to its corresponding formazan (189). 
 
After the incubation period, a solution of MTT (3-(4,5-dimethoxythiazol-2-yl)-2,5-
diphenyltetrazolium bromide (188) in Phosphate-buffered serum (PBS) was added to each 
well and the plate incubated for a further 3 hours. The assay is colourimetric in that the 
yellow MTT reagent is biochemically reduced to a purple formazan (189) precipitate by the 
mitochondrial succinate dehydrogenase enzyme present in living cells (Fig 102).  
After the 3 hours the precipitate was removed from the medium and redissolved in DMSO. 
The extent of cell growth is directly proportional to the intensity of colour, which was 
determined by measuring the optical density of the solutions using a UV/Vis spectrometer (λ-
540 nm). The measured intensity of the control sample is representative of zero cell growth 
inhibition or 100% growth. Since the control was not treated with drug, this can be compared 
against the intensities for the cells treated with drug - this allows the determination of cell 
growth inhibition.  As the degree of cell growth inhibition is determined for a range of 
concentrations for the tested compound, a graph of percentage growth inhibition versus 
concentration can be plotted. 
MTT data is usually presented as an IC50 value in the literature.  This is the drug 
concentration which inhibits cell growth by 50%.  
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Introduction: Tubulin extraction  
 
Tubulin was obtained using a standard extraction procedure involving a two stage 
polymerisation/depolymerisation method (Williams and Lee. 1982). Tubulin is a dynamic 
protein that assembles in the presence of GTP at 37 
o
C to form microtubules and 
disassembles when cooled below this temperature or in the presence of Ca
2+
 ions to tubulin 
heterodimers. This dynamic property is exploited by cycling the crude protein mix through 
cycles of assembly/disassembly collecting sequentially purified tubulin. 
The most readily available source of tubulin is the mammalian brain and nervous system. 
Cows are the most obvious choice as they have the highest level of tubulin and are farmed for 
their meat. Unfortunately issues surrounding CJD regulation have all but banned the use of 
bovine tubulin and when extracted from sheep, the protein has been found to lose its 
functional activity during storage. For our studies porcine tubulin was used. Roughly 30 
brains were acquired and transported in ice to avoid protein degradation. The brains were 
washed and blended in a buffer giving a slurry that was subjected to centrifugation at 4 
o
C to 
remove cellular debris. After the supernatant layer was removed, addition of GTP followed 
by incubation at 37 
o
C caused polymerisation of the tubulin subunits into microtubules. 
Centrifugation of these microtubules at 37 
o
C formed pellets that were suspended in fresh 
buffer. Cooling this solution to 4 
o
C again caused depolymerisation of the microtubules into 
α,β-tubulin dimers.  
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After further centrifugation the tubulin-containing supernatant was removed and incubated at 
37 
o
C with GTP again inducing formation of microtubules. The resulting pellet was once 
again acquired by centrifugation and subsequently homogenised in buffer to give a solution 
rich in protein. This liquid was added dropwise to liquid nitrogen yielding beads of purified 
tubulin that were stored in at -80
 o
C until required. 
 Introduction: Microtubule functional assay 
The tubulin functional assay was performed to find out if the extracted tubulin dimers were 
above the concentration required to form microtubules. This requires the optical density of 
the microtubules to be greater than that of the unpolymerised tubulin. Samples consisted of 
tubulin, 2-(N-morpholino)ethanesulfonic acid (MES buffer) and GTP prepared in a quartz 
cuvette at 0 
o
C. As the GTP initiates polymerisation of tubulin, it was added in last to prevent 
any premature tubulin assembly before the experiment began. The cuvettes were placed in the 
spectrophotometer and heated to 37 
o
C. As the temperature increases, so should tubulin 
polymerization, causing an increase in optical density. 
The change in optical density can be monitored and recorded using a spectrophotometer. 
Control experiments containing identical samples as before without GTP were also 
performed to rule out other temperature-dependant effects. 
Introduction: Quantification of protein  
The tubulin concentration in the purified protein solution was determined by the standard 
spectroscopic methods used by Williams (Williams and Lee. 1982). Guanidine hydrochloride 
was added to the solution and the absorbance value at 275 nm measured. This induces 
denaturation of tubulin, exposing the polypeptide chains so that the absorbance can be 
measured and the molar extinction coefficient and concentration can be calculated. 
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Introduction: Microtubule Assembly Assay  
This assay measures a target compound’s ability to inhibit microtubule formation through 
tubulin assembly. The assay bears similarity to the functional assay differing in that 
compound being tested is added before the GTP. The overall stock concentration for all 
tested compounds was chosen to be 10 µM. The samples were analysed in the 
spectrophotometer as before at 37 
o
C. If the optical density for the drug containing sample 
was less than 50% of the control the experiment was repeated at sequentially decreasing drug 
concentrations until the IC50 could be calculated. 
Results and discussion 
 
 
Figure 102 Scheme showing a series of tubulin binding agents that were tested for cytotoxicity. 
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These compounds (Fig 103) have all been subjected to the MTT assay using K562 cells. The 
results are summarised in Fig 104. 
Compound K562  
IC50 (µM)  
23 0.00053 
103 >500 
104 >500 
151 >500 
158 0.060 
160 >500 
162 >500 
165 >500 
175 >500 
190 >500 
191 >500 
192 >500 
Table 103 Table showing the IC50 values in µM for all of the compounds tested with the MTT assay against K562 
myelogenous leukaemia cells compared to CA-4 as a standard. 
From the compounds screened one entry was carried on for the tubulin binding assay. 
Compound (158) is highly cytotoxic with an IC50 value in the low nanomolar range (60 nM).   
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Compound Microtubule assembly assay 
(µM) 
23 1.3 
158 1.2 
160 >10 
151 >10 
162 >10 
165 >10 
175 >10 
103 >10 
190 >10 
191 >10 
104 >10 
192 >10 
Table 104 Table showing the IC50 values in µM for the compounds tested with the tubulin binding assay compared to CA-4 
as a standard. 
 
 
Discussion  
 
 
 
Figure 105 Scheme showing the basic structure of dibenz[c,e]oxepines and combretastatin A4 . 
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The most active compound was (158) in both MTT (K562, 60 nM) assay and MA (1.2 µM). 
This is slightly less active than the hydroxyl analogue (30) (MTT k562- 44 nM, MA – 1.0 
µM) reported by Edwards. Interestingly this activity profile occurs with CA-4 (23) and its 
fluoro analogue (194). Replacing the phenol group on (30) with a fluorine group (158) in the 
oxepine series (fig 105) results in a slightly lower inhibitory activity in the MTT assay (0.001 
to 0.01 µM) but an increase in MA inhibition (0.175 µM to 0.085 µM). The difference in 
cytotoxicity may be due to the extra degree of rotational freedom in CA-4 opposed to the 
oxepine analogues. This is due to the oxepine compounds being conformationally restricted 
by both the tethered heteroatom containing B ring and the dihedral biaryl bond. The oxepine 
where R = H (193) also exhibits significant cytotoxicity (130 nM) (Edwards et al. 2011).  
 
Figure 106 Diagram showing the two series of biaryl compounds with a central 7-membered heterocyclic ring where X is 
various heteroatom groups Listed. The symmetrical series (left) was published by Edwards (Edwards et al. 2011)and is 
analogous to the unsymmetrical fluorinated series 
 
Compounds (195 - 198) were also reported by Edwards (Edwards et al. 2011). They all had 
poor activity (MTT - IC50 > 500 µM, MA- IC50 > 10 µM). The fluorinated 
dibenzo[c,e]oxepines series (158, 161, 162, 65) of compounds were synthesised with a 
pseudo-combretastatin lower ring in an attempt to induce activity and test the effect of 
heteroatom substitution on the 7 membered central ring (Fig 107). All of the compounds 
were inactive in both MTT and MA assays.  
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Figure 107 Diagram showing a series of simplified biaryl combretastatin analogues that were for cytotoxicity 
All of these compounds (Fig 108) have all been subjected to the MTT assay tested on A2780 
cells, compounds with IC50 values less than 10 µM were subjected to further testing with 
SAOS-2 and K562 cell lines (Table 109). 
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Compound A2780 
IC50 (µM) 
 
23 0.0037 
181 60.24 
182 2.15 
183 3.73 
184 35.91 
185 58.56 
186 47.53 
187 78.24 
Table 108 Table showing the IC50 values in for a the compounds that were tested with the MTT assay against A2780 human 
ovarian cancer cells compared to CA-4 as a standard 
Compounds 182 and 183 were selected for further testing on SAOS-2 and K562 cell lines 
(Table 110) 
Compound SAOS-2 
IC50 (µM) 
K562 
IC50 (µM) 
23 0.007 0.004 
182 5.95 1.75 
183  11.21 2.32 
Table 109 Table showing the IC50 values for the compounds subjected to MTT testing on both K562 and SAOS-2 cell ines 
compared to CA-4 as a standard 
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Figure 110 Diagram showing a general structure for both Cis CA4 analogues (R3, R4) and simplified biaryl analogues (R1 
and R2) 
For this simplified series of biaryls all of the B-rings were chosen as analogues of known 
active combretastatins (111). McNulty (McNulty et al. 2015) reported µM activity from the 
simplified CA-4 (199- IC50 = 5.43 µM, MTT SAOS-2 cells)  and its regio isomer (200 - IC50 
= 1.77 µM, MTT SAOS-2 cells). Replacing the OH in (199) with fluorine (182) causes a 
slight loss in cytotoxicity (5.43 to 5.72 µM). Making this substitution on the [c,e], oxepine 
(Fig 105, 30, 158) and CA-4 (23, 194) also causes a small reduction in activity (MTT K562 
IC50 -44 to 60 nM and 1.0 to 10 nM respectively). The nitro containing compound (183) was 
also active in the low micromolar range (MTT -11.21 µM, MA - 2.32 µM). Interestingly 
when the methyl group is replaced by a methoxy (184) the compound is rendered inactive. 
This pattern of activity also occurs in CA-4 analogues. Changing the methoxy group in (202) 
to a methyl group (201) shows increased cytotoxicity (MTT on A2780, IC50 - 49 to 6.5 µM). 
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Biological experimental  
Cell culture  
 
A2780 and K562 cell lines were cultured in RPMI 1640 medium supplemented with 2 mM 
L-Glutamine and 1 0% (v/v) FBS (LabTech, UK).  SAOS-2 cell line was cultured in Mc 
Coy’s 5A medium (LabTech, UK) supplemented with 2mM L-Glutamine and 15% (v/v) 
FBS. Penicillin/Streptomycin (LabTech, UK) was added into media for MTT assay (1 mL per 
100 mL of complete medium).  
All cell lines were grown at 37 ̊ C and 5% CO2 in T25 cell culture flasks (Fisher, UK). 
 
Experimental: MTT assay 
 
All cell lines were grown to approximately 70-80% confluence before seeding into 96-well 
plates. For adherent cells flat bottomed 96-well plates were used and for suspension cells  U-
bottomed 96-well plates  were used (Greiner Bio one, UK). Adherent cells were trypsinised 
as usual and re-suspended in complete growth medium. Suspension cells were centrifuged 
(1500 rpm for 5 min) and the cell pellet was re-suspended in complete growth medium. Next 
cells were counted with the use of haemocytometer slide (LabTech, UK). Cell viability tests 
were performed with the use of Trypan blue (0.4%) (Fluka, UK).  Seeding density was as 
follows:  for K562 2 x 10
3
, for A2780: 3 x 10
3
 and for SAOS-2: 1 x 10
4
 viable cells per well 
in 100 µL of complete growth medium. After seeding the cells were incubated for 24 hr at 37 
o
C with 5% CO2 before addition of 100 µL of media with an appropriate concentration of the 
tested compound. 
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The stock solutions of the compounds were prepared in DMSO (Fisher, UK) at around 20 
mM concentration. Before MTT treatment combretastatin A-4 (CA-4) was further diluted in 
phosphate buffer saline (PBS) (Fisher, UK). The final concentration of DMSO in each of the 
wells was less than 0.2% (v/v) for each drug concentration. CA-4 was used as a control 
compound. Drug concentrations were prepared in 15 mL centrifuged tubes with a double 
final concentration (as to dose the cells, of drug solution (100 µL) was added to the well, each 
well already containing medium (100 µL) from the previous day) by serial dilution technique.  
The dosing was done in triplicate per drug concentration. Each plate had two triplicates of 
tested compound and one triplicate of a control compound. The cells were incubated for 72 hr 
at 37 
o
C with 5% CO2.  
After this period of time MTT ((3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium 
bromide; thiazolyl blue), (50 µL) (Alfa Aesar, UK) solution (3 mg/mL in PBS) was added to 
each well. The plates were incubated for 3 h. Next the liquid above the created formazan 
crystals was aspirated. Then DMSO (200 µL per well) was added and the absorbances were 
read at 540 nm and at 690 nm as a reference (blank) wavelength on an MultiScan Ascent 384 
microplate reader (Thermo Labsystems, UK). The average absorbance from triplicate 
experiments was obtained by subtraction of the blank readings from 540 nm readings.  The 
mean absorbances were used for calculation of the percentage cell survival. Absorbance of 
negative control (cells growing in medium with no drug addition) was assumed as 100% cell 
survival.   
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Experimental: Quantification of extracted tubulin 
 
Sample  Absorbance (λ = 275) nM 
1 0.171 
2 0.145 
3 0.150 
Average 0.155 
Table 111 Table showing the measured absorbance (nM) for the purified tubulin solution.   
Tubulin concentration = (Average absorbance at λ = 275 X 40) 
                                        Extinction coefficient (mL/mg/cm) 
    = 0.155 X 40 
                             1.03 
    = 6.03 mg/mL 
 
Experimental: Microtubule assembly assay  
 
All samples were prepared at 0 
o
C in quartz cells. To each was added (in order):   pH 6.6 Mes 
buffer (740 µL Mes (1 M)), 0.5 mM MgCl2, 0.1 mM EGTA), drug compound (10 µL in 
DMSO (1 mM)), tubulin 150 µL, (1 in 4 dilution in Mes from neat) and finally GTP (100 µL, 
100 mM). After thoroughly mixing and carefully drying the exterior of each cuvette they 
were placed in a UV-Vis (Varian Cary 1) that was preheated to 37 
o
C. A control cuvette 
containing DMSO (10 µL) in place of the drug compound was also used. The absorbance at 
350 nM was measured for 20 minutes and the results compared with the control to assess 
relative change in optical density. If tubulin assembly for a compound was less than 50% of 
the control, the process was repeated at lower concentrations (at increments from 1 mM) of 
the candidate compound to determine the activity.       
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Chemistry Experimental  
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Solvents and reagents 
 Both dry THF and dry diethyl ether were obtained by distillation over sodium/benzophenone 
under argon as required. Dry DCM was prepared by storage in a sealed flask over activated 
3Å molecular sieves.  
Chromatography 
Flash chromatography (Still et al 1978) was carried out using silica gel (Fluka 60 220-440 
mesh 35-70 m).  
TLC chromatography was carried out on pre-coated silica plates (0.2 mm, 60 F254) and 
observed using a UV lamp (254 nm). 
1 
H NMR  
These spectra were obtained using a Bruker AC-400 MHz NMR machine for which CDCl3 
was used as the solvent (unless stated otherwise).  Chemical shifts (H) values are displayed 
in parts per million (ppm). 
 
13
C NMR  
These spectra were obtained using the above instrument at 100 MHz with CDCl3 used as the 
solvent (unless stated otherwise). Chemical shifts (C) are quoted in parts per million (ppm). 
Infra Red 
These sprectra were obtained on a Bruker vector 22 Diamond ATR. Absorbances of 
compounds of interest are reported as wave numbers (cm
-1
). 
Melting point  
Melting points (M.p.) were recorded using a Gallenkamp melting point apparatus and were 
not corrected with standards 
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General Methods 
 
General procedure 1 
 
To a flask containing aryl iodide/bromide (1 eq), aryl boronic acid (1.3 - 1.5 eq), LiCl (2.95 
eq) in dioxane (1 mL / mmol) was added aq Na2CO3 (2 M, 4 eq) and the solution degassed 
for 20 min and an argon atmosphere established. Pd(PPh3)4 (5 mol %) was added and the 
reaction heated at 80 
o
C. After 8 hr the reaction was cooled, filtered through celite
®
, washed 
with brine, dried with magnesium sulphate and concentrated in vacuo. The crude material 
was purified by column chromatography (silica gel, hexane - ethyl acetate) 
General procedure 2 
To a flask containing aryl bromide/iodide (1.7 mmol, 1 eq), arylboronic acid (1.9 mmol, 1.1 
eq), tetra-n-butyl ammonium bromide (TBAB) (1.7 mmol, 1 eq) and K2CO3 (4.4 mmol, 2.5 
eq) was added degassed water (4 mL) and the solution degassed with argon for 20 min. A 
reflux condenser was attached, Pd (OAc)2 (0.2 mmol, 0.1 eq) added and the reaction mixture 
heated to 80 
o
C for 2 hr under an argon atmosphere. The reaction mixture was cooled to room 
temp, extracted with dichloromethane (2 X 10 mL), the organic layer was filtered through a 
plug of celite
® 
(~1 g) and washed through with dichloromethane (2 X 20 mL). After drying 
with anhydrous magnesium sulphate the solution was concentrated under vacuum and 
purified by column chromatography (silica gel, hexane - ethyl acetate). 
 
 
 
 
 125 
 
General procedure 3 
To a round bottom flask with a quickfit neck containing a solution of O-benzyl ether (g, 1 eq) 
in methanol (2 mL/ g) was added 10% palladium on activated carbon (0.1 eq). A septum was 
added, the flask purged with hydrogen for 1 min and a hydrogen filled balloon attached to 
maintain pressure. After 2 hr stirring the solution was filtered through celite
®
, washed with 
dichloromethane (40 mL), concentrated in vacuo and purified by column chromatography 
(silica gel, hexane - ethyl acetate). 
General procedure 4 
To a round bottom flask with a quickfit neck containing a solution of O-benzyl ether (x, 1 eq) 
in methanol (2 mL/g) was added Pearlman’s catalyst (0.2 eq). A septum was added, the flask 
purged with hydrogen for 1 min and a hydrogen filled balloon attached to maintain pressure. 
After 2 hr stirring the solution was filtered through celite
®
, washed with dichloromethane (40 
mL), concentrated in vacuo and purified by column chromatography (silica gel, hexane - 
ethyl acetate). 
General procedure 5 
To a solution of phenyl/hydroxyl compound (g, 1 eq) in dichloromethane (2 mL/g) at 0 
o
was 
added N,N-diisopropylethylamine (2.2 eq). After 10 min at this temperature MOMCl (1.5 eq) 
was added dropwise and the reaction allowed to stir for 2 hours warming to room temp. The 
reaction was cooled to 0 
o
sat. aq NH4Cl (10 mL/g) was added dropwise. The contents of the 
flask were separated and the aqueous phase was extracted twice with dichloromethane (2 X 
10 mL/g). The organic extracts were then combined and washed with water (10 mL/ g), brine 
(10 mL/g), dried with anhydrous sodium sulphate, concentrated in vacuo and purified by 
column chromatography (silica gel, hexane - ethyl acetate). 
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General procedure 6  
To a solution of alcohol (g, 1 eq) in dichloromethane (2 mL/g) under argon at 0 
o
2,6-lutidine 
(1.5 eq) was added followed by the dropwise addition of triethylsilyltrifluoromethane 
sulfonate (1.2 eq). The reaction mixture was stirred at 0 
o
C for 30 min and quenched with sat. 
aq NaHCO3 (10 mL/x). The aqueous layer was extracted with dichloromethane (2 X 20 mL/x 
g), the combined organic extracts dried with magnesium sulphate, concentrated in vacuo and 
purified by column chromatography. 
General procedure 7 
Dry dioxane (2 mL/g) was a added to a screw cap vial containing aryl halide (x, 1 eq) 
palladium (II) acetate (0.2 eq) and 2-(dicyclohexylphosphino)biphenyl (0.4 eq) and the 
solution was degassed with argon for 20 min. Triethylamine (3 eq) was added dropwise 
followed by pinacol borane (2 eq) and the vessel backfilled with argon, sealed and heated at 
80 
o
C for 1 hr. After cooling, sat. aq NH4Cl (15 mL/g) was added dropwise followed by 
extraction with dichloromethane (2 X 10 mL/x g) drying with anhydrous magnesium sulphate 
and concentration in vacuo. The crude product was purified by column chromatography 
(silica gel, hexane - ethyl acetate). 
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3-( methanesulfonyl)-4,4',5',6'-tetramethoxybiphenyl-2,2'-dicarbaldehyde (36) 
 
To a refluxing suspension of copper powder (0.65 g, 10 mmol, 1 eq) in dry DMF (2 mL), a 
solution of 3-bromo 2-formyl-6-methoxyphenyl methanesulfonate (35) (0.30 g, 0.10 mmol, 1 
eq) and 2-bromo 3,4,5-trimethoxybenzaldehyde (52) (0.40 g, 0.15 mmol, 1.5 eq) in DMF (2 
mL) was added dropwise. Another equivalent of 2-bromo-3,4,5-trimethoxybenzaldehyde in 
DMF (2 mL) was added after 2 hrs and  the mixture allowed to stir at reflux for a further 1 hr. 
The reaction mixture was allowed to cool, was passed through a plug of celite
®  
and 
concentrated in vacuo. The crude biaryl mixture was dissolved in diethyl ether (30 mL) and 
washed with water (4 X 20 mL), brine (50 mL), dried with anhydrous magnesium sulphate 
and concentrated in vacuo.  The residue was purified by column chromatography (silica gel, 
petroleum ether - ethyl acetate,  9:1 to 1:1) to yield an orange semi-solid. Recystallisation 
from ethyl acetate gave the title compound (36) as red solid (0.14 g, 33%), m.p. 128 - 129 
o
C 
(Lit - 129 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.23. The hexamethoxy 
homocoupled dialdehyde described by Edwards was also produced but not isolated. 
1 
H (400 MHz, CDCl3)  ppm: 10.20 (1H, s, CHO), 9.65 (1H, s, CHO), 7.38 (1H, s, Ar-H), 7.29 (1H, 
d, J = 8.5 Hz, Ar-H: p-OMs), 7.18 (1H, d, J = 8.5 Hz, Ar-H: m-OMes), 4.05 (3H, s, OMe), 4.01 (6 H, 
s, 2 X OMe), 3.59 (3H, s, OMe),  3.44 (3H, s, SOOCH3)  
 
Spectral and physical data for this compound were in accordance with the literature  
(Edwards et al. 2011). 
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2-Bromo 3,4,5-trimethoxybenzaldehyde (52) 
 
Bromine (4.7 mL, 9.2 mmol, 1 eq) was added dropwise to a stirring, refluxing solution of 
3,4,5-trimethoxybenzaldehyde  (17 g, 13.8 mmol, 1.5 eq) in chloroform (100 mL) and 
refluxed over night. The reaction mixture was allowed to cool followed by washing with 
water (100 mL), sat. aq NaHCO3 (100 mL) and drying with anhydrous sodium sulphate, 
filtered and concentrated in vacuo. The crude orange oil produced crystallised on standing 
and purification by column chromatography (800 g silica gel, hexane - ethyl acetate,  8:1 to 
6:1) gave the title compound as a pale yellow crystalline solid (16.3 g, 68%). M.p. 69 - 70 
o
C 
(Lit - 70 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.29 
 
1 
H (400 MHz, CDCl3)  ppm: 10.42 (1H, s, CHO), 7.23 (1H, s, Ar-H), 4.02 (3H, s, OMe), 
3.96 (3H, s, OMe), 3.95 (3H, s, OMe) 
Spectral and physical data for this compound were in accordance with the literature  
(Edwards et al. 2011). 
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2-Iodo 3,4,5-trimethoxybenzaldehyde (52’) 
 
To a solution of 3,4,5-trimethoxybenzaldehyde (51) (29.40 g, 150 mmol, 1 eq) in acetic acid: 
water: conc. H2SO4 (100/10/3, 700 mL) was added iodine (16.00 g, 63 mmol, 0.42 eq) 
followed by periodic acid (7.50 g, 33 mmol, 0.22 eq) and the reaction vessel warmed until 
homogeneity was achieved. The solution was heated to 65 
o
C for 4 hr with a rubber septum 
and balloon attached to the flask to retain vapours. After cooling to room temperature, solid 
sat. aq Na2S2O5  (200 mL) was added resulting in the solution turning black, water (1 L) was 
added and the cream precipitate collected by filtration, washed with water and recrystallized 
from ethanol (100 mL) to yield the title compound (52’) as a cream coloured solid (40 g, 
83%), m.p. 67 -69 
o
C (Lit - 67 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.21 
1 
H (400 MHz, CDCl3)  ppm: 10.05 (1H, s, CHO), 7.32 (1H, s, Ar-H), 3.95 (3H, s, OMe), 
3.88 (3H, s, OMe), 3.86 (3H, s, OMe) 
Spectral and physical data for this compound were in accordance with the literature  
(Nicolaus et al. 2009). 
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4-Bromo 2-fluoro 1-methoxybenzene (54) 
 
To a stirring, refluxing solution of 2-fluoroanisole (53) (73.82 g, 582 mmol, 1 eq) in 
chloroform (200 mL), bromine (45.3 mL, 877 mmol, 1.5 eq) was added dropwise and the 
reaction mixture was heated at reflux over night. After cooling, the reaction mixture was 
washed with water (100 mL), brine (100 mL), dried with anhydrous sodium sulphate and 
filtered. The solution was concentrated in vacuo to yield the title compound (54) as a brown 
liquid (101.25 g, 84.3%), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.28  
1 
H (400 MHz, CDCl3)  ppm: 7.15-6.98 (2H, m, Ar-H), 6.71 (1H, t, J = 8.95 Hz, Ar-H : o 
OMe), 3.75 (3H, s, OMe)  
Spectral and physical data for this compound were in accordance with the literature  (Kelly. 
1984). 
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6-Bromo 2-fluoro 3-methoxybenzaldehyde (55) 
 
To a argon purged flask containing diisopropylamine (9.1 mL, 64.4 mmol, 1.3 eq), anhydrous 
THF (100 mL) was added and the temperature reduced to -78 
o
C. n-BuLi (50 mL,  1.6 M in 
hexane, 69.4 mmol, 1.4 eq) was added dropwise and the temperature increased to 0 
o
C for 30 
mins. The temperature was reduced to -78 
o
C and 4-bromo 2-fluoro 1-methoxybenzene (54) 
(10 g, 49.6 mmol, 1 eq) in THF (50 mL) was added and the mixture stirred for 1 hr. DMF (10 
mL,  99.2 mmol, 2 eq) and the reaction mixture was warmed to room temperature and stirred 
at room temperature for 1 hr. The reaction was quenched with sat. aq NH4Cl solution (10 ml), 
and extracted with ethyl acetate (2x50 mL). The organic phase was washed with water (100 
mL), brine (100 mL), dried with anhydrous sodium sulphate, filtered and concentrated in 
vacuo. This yielded a dark red oil that crystallized on standing to give an orange solid. 
Recrystallisation (5:1 hexane: ethyl acetate) gave the title compound (55) as an orange solid 
(8.2 g, 71%). M.p. 81 - 82 
o
C (Lit - 82 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 
0.24 
1 
H (400 MHz, CDCl3)  ppm: 10.12 (1H, s, CHO), 7.21 (1H, dd, J = 1.89, 8.88 Hz, Ar-H : 
p-F), 7.13 (1H, t, J = 8.72 Hz, Ar-H : m-F), 3.82 (3H, s, OMe)
 
 
Spectral and physical data for this compound were in accordance with the literature  (Jarnagin  
and Akama. 2011). 
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3-Fluoro 4,4',5',6'-tetramethoxy-[1,1'-biphenyl]-2,2'-dicarbaldehyde (56) 
 
Anhydrous DMF (150 mL) was added to an argon-purged flask containing                             
2-bromo-3,4,5-trimethoxybenzaldehyde (52) (6.31g, 22.98 mmol, 1 eq), 2-bromo 5-methoxy-
6-fluorobenzaldehyde (55) (5.35 g, 22.98 mmol, 1 eq) and powdered copper (14.61 g, 229.8 
mmol, 10 eq). The mixture was heated at 170 
o
C overnight. The mixture was cooled, diluted 
with ethyl acetate (100 mL) and washed through a plug of celite
® 
(50 g) with water (100 mL). 
The organic layer was washed with brine (100 mL) and concentrated in vacuo. The crude 
brown oil produced was purified using 3 bouts of column chromatography (9:1, 1:1 and 3:7 
hexane : ethyl acetate respectively) to give the title compound (56) as a white solid (1.76 g, 
22%)  M.p 161 
o 
C TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.25 
1 
H (400 MHz, CDCl3)  ppm: 10.14 (1H, s, CHO), 9.52 (1H, s, CHO), 7.27 (1H, s, Ar-H), 7.15 (1H, 
t, J = 8.22 Ar-H : m-F), 6.92 (1H, dd, J = 1.45, 8.32 Hz Ar-H : p-F), 3.92 (3H, s, OMe), 3.90 (3H, s, 
OMe), 3.89 (3H, s, OMe), 3.51 (3H, s, OMe) 
13
Cppm: 190.1 (CHO), 187.9 (d, J = 7.31 Hz, CHO), 155.5-150.8 (bd, J = 247.92 Hz, c-F), 153.6 
(Ar-OMe), 150.8(OMe), 148.2 (d, J = 2.07 Hz, Ar-OMe:o CF), 148.1 (Ar-OMe), 147.2 (Ar), 130.4 
(Ar), 128.3 (d, J = 4.48 Hz, Ar-H) 126.3 (Ar), 124.3 (d, J = 3.92 Hz, Ar-H). 117 (d, J = 3.61 Hz, Ar), 
105.7 (Ar-H), 61.1(OMe), 60.8 (OMe), 56.5 (OMe), 56.1 (OMe)  
Λmax cm-l:  2947, 2793, 2710, 1745, 1711, 1616, 1487, 1414, 1367, 1326, 1272, 1131, 1110, 
1026, 871  
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(E)-N-(6-bromo 2-fluoro 3-methoxybenzylidene)cyclohexanamine (58)
 
To a flask containing 6-bromo 2-fluoro 3-methoxybenzaldehyde (55) (4.0 g, 17.2 mmol, 1 
eq) in methanol (20 mL), cyclohexylamine (1.70 g, 17.2 mmol, 1 eq) was added and the 
solution stirred at room temperature for 4 hr. The precipitate recovered by filtration and 
washing several times with methanol. The crude solid was recrystallized from methanol and 
dried to yield title compound (58) (3.60 g, 67%) as a white solid. M.p. 162 – 163 oC (Lit – 
162 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.26 
1 
H (400 MHz, CDCl3)  ppm: 8.31(1H, s, HC=NCy), 7.22 (1H, dd, J = 9.11, 2.27 Hz, Ar-H 
: p-F), 6.77 (1H, t, J = 8.47 Hz, Ar-H), 3.80 (3H, s, OCH3), 3.22- 3.17 (1H, m, C-H), 1.79- 
170 (4 H, m, 2 x CH2), 1.59- 1.48 (6 H, m, 3 x CH2) 
Spectral and physical data for this compound were in accordance with the literature  (Ziegler 
et al. 1980). 
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2-Iodo 3,4,5-trimethoxybenzaldehyde cyclohexylimine (59) 
 
A solution of 2-iodo 3,4,5-trimethoxybenzaldehyde (52’) (6.13 g, 19 mmol, 1 eq) and 
cyclohexylamine (2.18 mL,  19 mmol, 1 eq) in anhydrous toluene (50 mL) was heated at 120 
°C under argon in a standard Dean Stark apparatus for 4 h. Dichloromethane (40 mL) was 
added to aid solvent removal and the reaction mixture concentrated in vacuo. This yielded the 
title compound (59) as brown oil (7.76 g, 100%), TLC petroleum ether - ethyl acetate, 1:1,  
Rf = 0.21 
1 
H (400 MHz, CDCl3)  ppm: 9.98 (1H, s, N=CH), 7.28 (1H, s, Ar-H), 3.90 (3H, s, OCH3), 
3.85 (3H, s, OCH3), 3.84 (3H, s, OCH3), 3.21-3.16 (1H, m, C-H : =N-CH(CH)2, 1.78- 1.69 (4 
H, m, 2 x CH2), 1.60- 1.49 (6 H, m, 3 x CH2) 
Spectral and physical data for this compound were in accordance with the literature  (Broady 
et al. 2007). 
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2-(2-Bromo 3,4,5-trimethoxyphenyl)-1,3-dioxolane (60) 
 
 
To a flask containing 2-bromo 3,4,5-trimethoxybenzaldehyde (52) (0.74 g, 2.6 mmol, 1 eq) 
absolute ethanol (10 mL) was added. Triethylorthoformate (0.52 mL, 3.2 mmol, 1.2 eq), 
ethylene glycol (1.00 mL, 11 mmol, 4 eq) and Tetrabutylammoniumtribromide (0.08 g, 0.01 
mmol, 6 mol %) were also added and the reaction mixture allowed to stir at room temperature 
for 30 minutes. The reaction mixture was concentrated in vacuo. This was followed by 
extraction with ethyl acetate (10 mL) and washing with sat. aq NaHCO3 (10 ml). After this 
the solution was dried with anhydrous sodium sulfate filtered and concentrated in vacuo to 
yield the crude oil product. Column chromatography (20 g silica gel, hexane - ethyl acetate, 
1:1) produced the purified title compound (60) as a light brown oil that solidified on standing 
(0.84 g, 87%), m.p. 39
 o
C (Lit - 39 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.24 
1 
H (400 MHz, CDCl3)  ppm: 7.01 (1H, s Ar-H), 5.72 (1H, s, C-H : Ar-CH), 4.22- 4.15 
(2H, m, CH2) 4.02- 3.97 (2H, m, CH2), 3.83 (3H, s, CH3), 3.74 (3H, s, OMe), 3.65 (3H, s, 
OMe) 
Spectral and physical data for this compound were in accordance with the literature  (Besong 
et al. 2008). 
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2-(Tributylstannyl)-3,4,5-trimethoxybenzaldehyde (63) 
 
To a flask containing 2-bromo 3,4,5-trimethoxybenzaldehyde (52) (0.371 g, 1.3 mmol, 1 eq) 
in toluene (15 mL),  hexabutylditin (0.905 g, 1.6 mmol, 1.2 eq) was added and the solution 
degassed with argon for 10 min. Pd(PPh3)4 ( 0.750 g, 0.65 mmol, 0.5 eq) was added and the 
reaction mixture heated at refluxed under argon for 48 hrs. After cooling the solvent was 
removed in vacuo and the crude mixture was purified by column chromatography (10 g silica 
gel, hexane - ethyl acetate, 11:1) to give the title compound (63) as a colourless oil. (4.54 g, 
74%), TLC petroleum ether - ethyl acetate, 1:1, Rf = 0.20 
1 
H (400 MHz, CDCl3)  ppm: 9.82 (1H, s, CHO), 7.27 (1H, s, Ar-H), 3.92 (3H, s, OMe), 
3.89 (3H, s, OMe), 3.88 (3H, s, OMe), 1.71 - 1.25 (18 H, m, 3 X Sn-CH2CH2CH2-), 0.89 (9 
H, t, J = 7.21 Hz, 3 X butyl: CH3)   
Spectral and physical data for this compound were in accordance with the literature   
(Labruere et al. 2012)  
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(2-Iodo 3,4,5-trimethoxyphenyl)methanol (64) 
 
To a solution of 2-iodo 3,4,5-trimethoxybenzaldehyde (52’) (1.00 g, 3.1 mmol, 1 eq) in 
methanol (5 mL) at 0 
o 
C NaBH4 (0.18 g, 4.6 mmol, 1.5 eq) was added in portions over 5 min. 
After 1 hr water (5 mL) was added dropwise and the reaction mixture extracted with 
dichloromethane (2 X 10 mL). The organic phase was washed with sat. aq NaHCO3 (10 mL), 
water (10 mL), brine (10 mL), dried with anhydrous magneisium sulphate and concentrated 
in vacuo. The crude product was further purified by column chromatography (10 g silica gel, 
hexane - ethyl acetate, 8:2) to yield the title product (64) as a white low melting solid (0.910 
g, 90%), m.p 53-54 
o
C (Lit – 53 - 54 oC), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.23 
1 
H (400 MHz, CDCl3)  ppm: 6.87 (1H, s, Ar-H), 5.15 (2H, s, Ar-CH2), 3.82 (3H, s, OMe), 
3.81 (6 H, s, 2 X OMe), 3.01 (1H, s, OH)  
Spectral and physical data for this compound were in accordance with the literature  (Ruiz et 
al. 2005). 
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1-Iodo 6-triethylsilyloxymethyl-2,3,4-trimethoxybenzene (65) 
 
General procedure 6 
The crude product was further purified by column chromatography (10 g silica gel, hexane - 
ethyl acetate,  8:2) to yield the title product (65) as a colourless oil (0.295 g, 81%), TLC 
petroleum ether - ethyl acetate, 1:1, Rf = 0.21 
1 
H (400 MHz, CDCl3)  ppm: 7.05 (1H, s, Ar-H), 4.63 (2H, s, CH2), 3.88 (3H, s, OMe), 
3.86 (3H, s, OMe), 3.84 (3H, s, OMe), 1.01 (9 H, t, J = 7.81 Hz, TES: 3 X CH3), 0.70 (6 H, 
q, J = 7.81 Hz, TES: 3 X CH2)  
Spectral and physical data for this compound were in accordance with the literature  (Baudoin 
et al. 2003). 
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Triethyl(3,4,5-trimethoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-)benzyloxy)silane 
(66) 
 
General procedure 7 
The crude product was further purified by column chromatography (10 g silica gel, hexane - 
ethyl acetate, 11:1) to yield the title product as a colourless oil (66) (0.230 g, 72%), TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.28 
1 
H (400 MHz, CDCl3)  ppm: 6.94 (1H, s, Ar-H), 4.77 (2H, s, Ar-CH2) 3.88 (3H, s, OMe), 
3.87 (3H, s, OMe), 3.85 (3H, s, OMe), 1.38 (12H, s, BPIN: 4 X CH3)  0.99 (9 H, t, J = 7.97 
Hz, TES: 3 X CH3),  0.64 (6 H, q, J = 7.97 Hz, TES: 3 X CH2) 
Spectral and physical data for this compound were in accordance with the literature  (Baudoin 
et al. 2003). 
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2-Iodo 3,4,5-trimethoxy-1-((methoxymethoxy)methyl)benzene (67) 
 
General procedure 5 
The crude product was further purified by column chromatography (10 g silica gel, hexane - 
ethyl acetate, 7:3) to yield the title product as a colourless oil (67) (0.300 g, 92%), TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.28 
1 
H (400 MHz, CDCl3)  ppm: 6.64 (1H, s, Ar-H), 4.57 (2H, s, O CH2OMe), 4.57 (2H, s, 
ArCH2- O ), 3.80 (3H, s, OMe), 3.79 (3H, s, OMe), 3.78 (3H, s, OMe), 3.66 (3H, s, OMe)  
Spectral and physical data for this compound were in accordance with the literature  (Baudoin 
et al. 2003). 
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4,4,5,5-Tetramethyl-2-(2,3,4-trimethoxy-6-((methoxymethoxy)methyl)phenyl)-1,3,2-
dioxaborolane (68) 
 
General procedure 7 
(10 g silica gel, hexane - ethyl acetate,  9:1) to yield a brown oil (0.710 g, ~ 66%) as a 3:1 
inseparable mixture of the product (68) and dehalogenated starting material (by NMR), TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.23 
1 
H (400 MHz, CDCl3)  ppm: 6.63 (1H, s, Ar-H), 4.59 (2H, s, O CH2-OMe), 4.51, (2H, s, 
Ar-CH2-OMOM), 3.80 (3H, s, OMe), 3.79 (3H, s, OMe), 3.77 (3H, s, OMe), 3.63 (3H, s, 
OMe), 1.31 (12H, s, BPIN) 
Spectral and physical data for this compound were in accordance with the literature  (Baudoin 
et al. 2003). 
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2-Iodo 5-methoxybenzaldehyde (70) 
 
To a solution of 3-methoxybenzaldehyde (69) (6.38 g, 46 mmol, 1 eq) in glacial acetic acid: 
water: conc. H2SO4 (100/10/3, 350 mL) was added iodine (5.00 g, 20 mmol, 0.42 eq) 
followed by periodic acid (2.35 g, 10 mmol, 0.22 eq) and the reaction vessel warmed until 
homogeneity was achieved. The solution was heated to 65 
o
C for 4 hr with a rubber septum 
and balloon attached to the flask to retain vapours. After cooling to room temperature sat. aq 
Na2S2O5  (75 mL) was added resulting in the solution turning black, water (400 mL) was 
added and the cream precipitate collected by filtration, washed with water and recrystallized 
from ethanol (40 mL) to yield the title compound (70) as a cream coloured solid (12.26 g, 
83%), m.p 112-113 
o
C ( Lit – 112 oC), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.23 
1 
H (400 MHz, CDCl3)  ppm:  10.98 (1H, s, CHO), 7.78 (1H, d, J = 8.5 Hz, Ar-H : o 
CHO), 7.40 (1H, d, J = 3.2 Hz, Ar-H : p-CHO), 6.98 (1H, dd, J = 2.7, 8.3 Hz, Ar-H : o I), 
3.58 (H, s, OMe) 
Spectral and physical data for this compound were in accordance with the literature  (Leboeuf 
et al. 2013). 
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Methyl 2-(3,4,5-trimethoxyphenyl)acetate (73) 
 
To a round bottom flask containing 2-(3,4,5-trimethoxyphenyl)acetic acid (72) (10 g, 44.2 
mmol, 1 eq) in methanol (50 mL), H2SO4 (5 drops) was added and the reaction mixture 
stirred at 80 
o
C for 4 hrs. The reaction was allowed to cool followed by the addition of sat. aq 
NaHCO3 (5 mL). The mixture was extracted with ethyl acetate (2X100 mL) and the organic 
extracts washed with water (100 mL), dried with anhydrous sodium sulphate, filtered and 
concentrated in vacuo to give the title compound (73) as yellow oil  (10.16 g, 96%), TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.25 
1 
H (400 MHz, CDCl3)  ppm: 6.81 (2H, s, Ar-H), 3.8, (6 H, s, OMe), 3.75, (3H, s, OMe), 
3.61 (3H, s, COCH3), 3.49 (2H, s, CH2) 
Spectral and physical data for this compound were in accordance with the literature  (Sober et 
al. 1981). 
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2-(3,4,5-Trimethoxyphenyl)ethanol (74) 
 
 To a solution of methyl 2-(3,4,5-trimethoxyphenyl)acetate (73) (7.4 g, 31.0 mmol, 1 eq) and 
dry THF (75 mL) stirring at 0 
o
C under argon, LiAlH4 (1.53 g, 40.3 mmol, 1.3 eq) was added. 
After 1 hr the reaction was quenched with ethyl acetate (10 mL) and the reaction mixture 
filtered under vacuum. The filtrate was concentrated in vacuo and purified by column 
chromatography (200 g silica gel, hexane - ethyl acetate, 7:3). The title compound (74) was 
obtained as yellow oil (4.93, 75%), TLC petroleum ether - ethyl acetate, 1:1, Rf = 0.26 
 
 1 
H (400 MHz, CDCl3)  ppm: 6.92 (2H, s, Ar-H), 3.79, (6 H, s, OMe), 3.76, (3H, s, OMe), 
3.74 (2H, t, J = 6.53 Hz, CH2OH), 2.74 (2H, t, J = 6.53 Hz, Ar-CH2), 2.80 (1 H. bs, OH) 
 
Spectral and physical data for this compound were in accordance with the literature  
(Soderquist et al. 2006). 
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2-(2-Iodo 3,4,5-trimethoxyphenyl)ethanol (75) 
 
To a flask containing 2-(3,4,5-trimethoxyphenyl)ethanol (74) (5.1 g, 24.0  mmol, 1 eq) and 
silver trifluoroacetate (6.36 g, 28.8 mmol, 1.2 eq) in chloroform (20 mL), a solution of iodine 
(6.4 g, 25.2 mmol, 1.05 eq) in chloroform (130 mL) was added dropwise and the mixture 
allowed to stir for 20 min. The reaction mixture was filtered through celite
®
, concentrated in 
vacuo and purified by column chromatography (200 g silica gel, petroleum ether - ethyl 
acetate, 1:1) to yield the title (75) compound as a pale yellow solid (6.52 g, 80%), m.p. 68 
o
C 
(Lit – 68-69 oC), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.30 
 
 1 
H (400 MHz, CDCl3)  ppm: 6.82 (1H, s, Ar-H), 3.8 (6 H, s, OMe), 3.78 (3H, s, OMe), 
3.75 (2H, t, J = 7.21 Hz, CH2OH), 2.95 (2H, t, J = 7.21 Hz, CH2), 1.41 (1H, s, OH) 
 
Spectral and physical data for this compound were in accordance with the literature  (Joncour 
et al. 2006). 
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2-Iodo 3,4,5-trimethoxy-1-(2-(methoxymethoxy)ethyl)benzene (76) 
 
General procedure 5 
The crude product was further purified by column chromatography (10 g silica gel, hexane - 
ethyl acetate, 8:2) to yield the title product (76) as a colourless oil (0.201 g, 87%), TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.21 
1 
H (400 MHz, CDCl3)  ppm:  6.65 (1H, s, Ar-H), 4.59 (2H, s, O CH2-OMe), 3.79 (3H, s, 
OMe), 3.78 (3H, s, OMe), 3.77 (3H, s, OMe), 3.66, (2H, t, J = 7.44 Hz, CH2-OMOM), 3.26 
(3H, s, OMe), 2.97 (2H, t, J = 7.44 Hz, Ar-CH2) 
 
Spectral and physical data for this compound were in accordance with the literature  (Joncour 
et al. 2008) 
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4,4,5,5-Tetramethyl-2-(2,3,4-trimethoxy-6-(2-(methoxymethoxy)ethyl)phenyl)-1,3,2-
dioxaborolane (77) 
 
General procedure 6 
The crude product was further purified by column chromatography (10 g silica gel, toluene - 
ethyl acetate, 100:1) to yield the title product (77) (3:1 mixture with dehalogenated starting 
material   (0.130 g, ~75% by 
1 H
NMR), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.23 
1 
H (400 MHz, CDCl3)  ppm:  6.47 (1H, s, Ar-H), 4.55 (2H, s, O CH2-OMe), 3.78 (3H, s, 
OMe), 3.77 (3H, s, OMe), 3.75 (3H, s, OMe), 3.63, (2H, t, J = 7.38 Hz, CH2-OMOM), 3.25 
(3H, s, OMe), 2.83 (2H, t, J = 7.38 Hz, Ar-CH2), 1.31 (12H, s, BPIN)  
 
Spectral and physical data for this compound were in accordance with the literature  (Joncour 
et al. 2007). 
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Triethyl(2-iodo 3,4,5-trimethoxyphenethoxy)silane (78) 
 
General procedure 6 
The crude product was further purified by column chromatography (10 g silica gel, hexane - 
ethyl acetate, 8:2) to yield the title product (78) as colourless oil (0.312 g, 90%).  TLC 
petroleum ether - ethyl acetate, 1:1, Rf = 0.26 
1 
H (400 MHz, CDCl3)  ppm: 6.71 (1H, s, Ar-H), 3.89 (3H, s, OMe), 3.85 (3H, s, OMe), 
3.84 (3H, s, OMe), 3.80 (2H, t, J = 7.29 Hz, Ar-CH2), 2.99 (2H, t, J = 7.29 Hz, CH2-OTES), 
0.93 (9 H, t, J = 8.19 Hz, TES: 3 X CH3), 0.57 (6 H, q, J = 8.19 Hz, TES: 3 X CH2) 
Spectral and physical data for this compound were in accordance with the literature  (Joncour 
et al. 2007). 
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Triethyl(3,4,5-trimethoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenethoxy)silane (79) 
 
 
General procedure 7 
The crude product was further purified by column chromatography (10 g silica gel, toluene- 
ethyl acetate, 100:1) to yield the title product (79) as an inseparable 3:1 mixture with 
dehalogenated starting material   (0.130 g, ~65% by 
1
H
 
NMR). TLC petroleum ether - ethyl 
acetate, 1:1, Rf = 0.14 (spot has faint tail) 
1 
H (400 MHz, CDCl3)  ppm: 6.56 (1H, s, Ar-H), 3.87 (3H, s, OMe), 3.84 (3H, s, OMe), 
3.83 (3H, s, OMe), 3.76 (2H, t, J = 7.29 Hz, Ar-CH2), 2.84 (2H, t, J = 7.29 Hz, CH2-OTES), 
1.38 (12H, s, BPIN: 4 X CH3)  0.93 (9 H, t, J = 7.85 Hz, TES: 3 X CH3),  0.56 (6 H, q, J = 
7.85 Hz, TES: 3 X CH2) 
Spectral and physical data for this compound were in accordance with the literature  (Joncour 
et al. 2007). 
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(N
3
E)-N
1
,N
3
-bis(2,4,6-trimethylbenzylidene)propane-1,3-diamine (85) 
 
To a stirred solution of metsitaldehyde (84) (5.0 g, 33.73 mmol, 1 eq) in methanol (10 mL) 
1,3-diaminopropane (1.42 mL,  16.87 mmol, 0.5 eq) was added and the mixture stirred 
overnight. The reaction mixture was filtered and the solid dried.. Mp 156 
o
C (Lit - 156 
o
C), 
TLC dichloromethane - methanol,  95:5,  Rf = 0.09 
1 
H (400 MHz, CDCl3)  ppm: 6.91 (4 H, s, ArH), 6.34 (2H, s, 2 x HC=N), 3.84 (4 H, t, J = 
7.21 Hz, 2 x N-CH2), 2.42 (12H, s, 4 x CH3), 2.31 (6 H, s, 2 x CH3), 2.13 (2H, t, J = 7.2 Hz, 
CH2(CH2)2) 
 
Spectral and physical data for this compound were in accordance with the literature  
(Özdemir et al. 2005b). 
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N
1
,N
3
-Bis(2,4,6-trimethylbenzyl)propane-1,3-diamine (86) 
 
To a suspension of (N
3
E)-N
1
,N
3
-bis(2,4,6-trimethylbenzylidene)propane-1,3-diamine (85) 
(1.87 g, 5.53 mmol, 1 eq) in methanol (10 mL), NaBH4 (0.32 g, 8.38 mmol, 2.5 eq) was 
added in portions over 30 mins and after another 30 mins water (50 mL) was added. The 
mixture was extracted with ethyl acetate (2x50 mL), dried with anhydrous magnesium 
sulphate, filtered and concentrated in vacuo to give the title compound (86) as a yellow oil 
(1.72 g, 92%), TLC dichloromethane - methanol,  1:1,  Rf = 0.02 
1 
H (400 MHz, CDCl3)  ppm: 6.83 (4 H, s Ar-H), 3.74 (4 H, s, 2 XAr-CH2-N), 2.72 (4 H, t, 
J = 8.40 Hz, C-H) 2.4 (12H, s, CH3), 2.32 (6 H, s, CH3), 1.62 (2H, t, J = 8.40 Hz, 
CH2(CH2)2) 
 
Spectral and physical data for this compound were in accordance with the literature  
(Özdemir et al. 2005b). 
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1,3-Bis(2,4,6-trimethoxybenzyl)-3,4,5,6-tetrahydropyrimidinium chloride (87) 
 
 
 
N
1
,N
3
-bis(2,4,6-trimethylbenzyl)propane-1,3-diamine (86) (1.72, 5.1 mmol, 1 eq), NH4Cl 
(0.27 g, 5.1 mmol, 1 eq) triethylorthoformate (25 mL) in ethyl acetate (50 mL) were heated in 
a distillation apparatus until no more ethyl acetate was distilled. The mixture was cooled, the 
solid product collected by filtration and washed with diethyl ether to yield the title compound 
as white crystals (87) (1.43 g, 73%). M.p. 232 
o
C (Lit - 232 
o
C), TLC petroleum ether - ethyl 
acetate, 1:1,  Rf = 0.02 
1 
H (400 MHz, CDCl3)  ppm: 7.81 (4 H, s, Ar-H), 6.05 (4 H, s, CH2), 4.45 (4 H, s, CH2), 
3.70 (12H, s, CH3), 3.75 (6 H, s, CH3), 3.33 (4 H, t, J = 5.19 Hz, 2 X N-CH2), 1.96- 1.91 (2H, 
m, J = 5.19 Hz, CH2(CH2)2) 
 
Spectral and physical data for this compound were in accordance with the literature  (Yasar et 
al. 2008). 
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4,4',5,6-Tetramethoxybiphenyl-2-carbaldehyde (90) 
 
General procedure 2 
The title compound was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate,  9:1) to yield the title compound as a white solid (90) (0.710 g, 92%) m.p. 90 
o
C (Lit - 
90 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.23 
1 
H (400 MHz, CDCl3)  ppm: 9.65 (1H, s, CHO), 7.30 (1H, s, Ar-H), 7.22 (2H, d, J = 8.9 
Hz, Ar-H : m-OMe), 6.94 (2H, d, J = 8.3 Hz, Ar-H : o OMe), 3.98 (3H, s, OMe), 3.96 (3H, s, 
OMe), 3.86 (3H, s, OMe), 3.56 (3H, s, OMe) 
 
Spectral and physical data for this compound were in accordance with the literature  
(Özdemir et al. 2005b) 
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4,4',5,6-Tetramethoxybiphenyl-2-ol (101) 
 
See general procedure 3 
product was purified by column chromatography (10 g silica gel, hexane - ethyl acetate,  7:3) 
to yield the title compound as a white solid (101) that  was recrystallised from 5:1 hexane : 
ethyl acetate (0.063 g, 94%), m.p. 109 -110 
o
C (Lit - 110 
o
C), TLC petroleum ether - ethyl 
acetate, 1:1,  Rf = 0.10 
1 
H (400 MHz, CDCl3)  ppm: 7.30 (2H, d, J = 8.62 Hz, Ar-H), 7.04 (2H, d, J = 8.62 Hz, 
Ar-H : m-OMe), 6.40 (1H, s, Ar-H: o OH), 4.93 (1H, s, OH), 3.89 (3H, s, OMe), 3.88 (3H, s, 
OMe), 3.86 (3H, s, OMe), 3.65 (3H, s, OMe) 
Spectral and physical data for this compound were in accordance with the literature  (Jinno et 
al. 1999). 
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2',3',4,4'-Tetramethoxybiphenyl-2-carbaldehyde (103) 
 
General procedure 1 
The title compound was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate,  8:2) to yield the title compound as a yellow solid (103) (0.710 g, 88%) m.p. 103 - 
104 
o
C (Lit - 104 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.31 
1 
H (400 MHz, CDCl3)  ppm: 9.82 (1H, s, CHO), 7.52 (2H, d, J = 2.71 Hz, ArH : o CHO), 
7.31 (1H, d, J = 8.41 Hz, ArH : o  3’ OMe), 7.22 (1H, dd, J = 3.01, 9.41 Hz, Ar-H : m-CHO), 
6.97 (1H, d, J = 8.41 Hz, Ar-H : : m- 3’ OMe) 6.78 (1H, d, J = 8.63 Hz, Ar-H), 3.94, (3H, s, 
OMe), 3.92 (3H, s, OMe), 3.56 (3H, s, OMe) 
Spectral and physical data for this compound were in accordance with the literature  
(Mamane et al. 2004). 
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2',3',4,4'-Tetramethoxybiphenyl-2-ol (104) 
 
General procedure 3 
product was purified by column chromatography (10 g silica gel, hexane - ethyl acetate,  7:3) 
to yield the title compound as an white solid that was recrystallised from 5:1 hexane : ethyl 
acetate (0.30 g,  87%). M.p. 109 - 108 
o
C (Lit - 108 
o
C), TLC petroleum ether - ethyl acetate, 
1:1,  Rf = 0.09 
1 
H (400 MHz, CDCl3)  ppm: 7.18 (1 H d, J = 8.32 Hz, Ar-H), 7.10 (1H, bs, OH), 6.98 
(1H, d, J = 8.83 Hz, Ar-H : o  4 OMe), 6.81 (1H, d, J = 8.83 Hz, Ar-H : m- 4 OMe), 6.62 
(1H, d, J = 2.62 Hz, ar-H o  OH), 6.58 (1H, dd, J = 2.62, 8.68 Hz, Ar-H : m-OH ) 3.94 (1H, 
s, OMe), 3.91 (1H, s, OMe), 3.82 (1H, s, OMe); 3.73 (1H, s, OMe) 
Spectral and physical data for this compound were in accordance with the literature  (Kang et 
al. 1990). 
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2-Iodo 5-methoxyphenol (105) 
 
To a flask containing 3-methoxyphenol (107) (1.2 g, 9 mmol, 1 eq) and silver trifluoroacetate 
(2.2 g, 9 mmol, 1 eq) in chloroform (10 mL) was added via canula a solution of iodine (2.54 
g, 11 mmol, 1.1 eq) in chloroform (700 mL) over 4 hr. The reaction mixture was filtered 
through a plug of celite
® 
and concentrated in vacuo. The product was purified by column 
chromatography (10 g silica gel, hexane - ethyl acetate, 9:1) to give a crude solid that was 
recyrstallized from methanol to yield the title compound (105) (1.68 g, 74%) as a white 
powder. Melting range 71-72 
o
C (Lit - 72 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 
0.19 
1 
H (400 MHz, CDCl3)  ppm: 11.72 (1H, s, OH), 7.43 (1H, d, J = 8.5 Hz, Ar-H : p- OH), 
6.79 (1H, d, J = 2.4 Hz, Ar-H : o  OH), 6.73 (1H, dd, J = 2.7, 8.29 Hz Ar-H : m- OH), 3.58 
(H, s, OMe)  
Spectral and physical data for this compound were in accordance with the literature  (Dirr et 
al. 2008). 
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2-Iodo 5-methoxyphenyl benzoate (112) 
 
To a solution of 2-iodo 5-methoxyphenol (105)  (2.00 g, 7.90  mmol, 1 eq) in dry THF (1 
mL) was added triphenylphosphine (2.31 g, 8.8  mmol, 1.1 eq), benzyl alcohol (0.911 mL,  
8.8 mmol, 1.1 eq) and the mixture sonicated for 10 min.  Diisopropyl azodicarboxylate 
(DIAD) (1.75  mL,  8.8 mmol, 1.1 eq) was then added dropwise and the reaction mixture 
sonicated for 1 hr. The viscous mixture was concentrated in vacuo and the crude product was 
purified by column chromatography (10 g silica gel, hexane - ethyl acetate,  9:1) to yield the 
title product (112) (2.22 g, 81%) as a colourless oil, TLC petroleum ether - ethyl acetate, 1:1,  
Rf = 0.23 
1 
H (400 MHz, CDCl3)  ppm: 7.67 (1H, d, J = 8.7, Ar-H), 7.53- 7.48 (2H, m, Ar-H), 7.42- 
7.38 (2H, m, Ar-H), 7.35- 7.32 (1H, m, Ar-H), 6.50 (1H, d, J = 2.61 Hz, Ar-H : o  OBn), 6.36 
(1H, dd, J = 2.6, 8.6 Hz, Ar-H : m- OBn), 5.15 (2H, s, CH2), 3.79 (3H, s, OMe) 
Spectral and physical data for this compound were in accordance with the literature  (Dirr et 
al. 2008). 
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 2'-(Benzyloxy)-2,3,4,4'-tetramethoxybiphenyl (113) 
 
General procedure 1 
The title compound was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate,  9:1) to yield the title compound as an amber oil (113) (0.96 g, 88%), TLC petroleum 
ether - ethyl acetate, 1:1,  Rf = 0.24 
1 
H (400 MHz, CDCl3)  ppm: 7.46 (1H, d, J = 2.97 Hz, Ar-H: o  OBn), 7.27- 7.22 (4 H, m, 
4 X Ar-H: OBn), 7.09 (1H, dd, J = 8.31, 2.93 Hz, Ar-H: o  4’OMe), 7.05- 7.01 (2H, m, Ar-
H), 6.92 (1H, d, J = 8.57 Hz, Ar-H: o  4’OMe), 6.69 (1H, d, J = 8.57 Hz, Ar-H), 5.15 (2H, s, 
CH2: OBn), 3.90 (3H, s, OMe), 3.89 (3H, s, OMe), 3.77 (3H, s, OMe), 3.5 (3H, s, OMe)    
13
Cppm: 168.15 (Ar-OMe), 158.45 (Ar-OMe), 153.1 (Ar-OMe), 151.0 (Ar-OMe), 142.0 ( 
Ar), 135.6 (Ar), 132.6 (Ar), 132.3(Ar-H), 130.7(Ar-H), 128.2 (2Ar-H), 127.8 (Ar), 127.7 
(2Ar-H), 124.1(Ar-H), 117.5(Ar-H), 114.5(Ar-H), 107.0(Ar-H), 66.7 (CH2: OBn),60.8 
(OMe), 60.4 (OMe), 55.9 (OMe), 55.5 (OMe) 
Λmax cm-l: 2894, 2831, 1485, 1451, 1434, 1394, 1281, 1273, 1103, 984, 821, 780, 694 
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2-Bromo 3,4,5-trimethoxyphenol (115) 
 
To a solution of 3,4,5-trimethoxyphenol (114) (0.20 g, 1 mmol, 1 eq) in THF (10 mL) at 0 
o
C 
N-Bromosuccinimide (
 
NBS) (0.23 g, 1 mmol, 1 eq) was added and the reaction mixture 
stirred 1 hr, poured into ice water (10 mL) and extracted with ethyl acetate (2 X 10 mL). The 
organic layers were washed with sat. aq NaHCO3 (10 mL), water (10 mL), dried with 
anhydrous magnesium sulphate, filtered and concentrated in vacuo. The crude product was 
further purified by column chromatography (10 g silica gel, hexane - ethyl acetate,  8:2) to 
yield the title product (115) (0.286 g, 87%) as a brown oil, TLC petroleum ether - ethyl 
acetate, 1:1,  Rf = 0.17 
1 
H (400 MHz, CDCl3)  ppm: 6.46 (s, 1H, Ar-H), 5.50 (s, 1H, OH), 3.93 (s, 3H, OMe), 3.85 
(s, 3H, OMe), 3.83 (s, 3H, OMe) 
Spectral and physical data for this compound were in accordance with the literature  (Jinno et 
al. 1999). 
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2-Bromo 3,4,5-trimethoxyphenyl benzyl ether (116) 
 
To a concentrated solution of 2-bromo -3,4,5-trimethoxyphenol (115) (0.160 g, 6 mmol, 1 eq) 
in dichloromethane (1 mL) was added triphenylphosphine (0.175 g, 7 mmol, 1.1 eq), benzyl 
alcohol (0.065 mL,  6 mmol, 0.95 eq) and sonicated for 10 min. Diisopropyl azodicarboxylate 
(DIAD) (0.135 mL,  7 mmol, 1.1 eq) was then added dropwise and the solution sonicated for 
1 hr. The viscous mixture was concentrated in vacuo and the crude product was purified by 
column chromatography (10 g silica gel, hexane - ethyl acetate,  8:2) to yield the title product 
(116) (0.190 g, 90%) as a colourless oil, TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.23 
1 
H (400 MHz, CDCl3)  ppm: 7.51- 7.47 (2H, m, Ar-H), 7.42- 7.38 (2H, m, Ar-H), 7.35- 
7.29 (1H, m, Ar-H), 6.44 (s, 1H, Ar-H), 5.14 (s, 2H, CH2), 3.94 (s, 3H, OMe), 3.85 (s, 3H, 
OMe), 3.83 (s, 3H, OMe) 
Spectral and physical data for this compound were in accordance with the literature  (Jinno et 
al. 1999). 
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4,4',5,6-Tetramethoxybiphenyl-2-yl benzoate (117)
 
See general method 2  
1-(Benzyloxy)-2-bromo 3,4,5-trimethoxybenzene (116) (0.07g, 0.2 mmol, 1 eq) was purified 
by column chromatography (hexane - ethyl acetate,  9:1) to yield the title compound (117) 
(0.063 g, 90%) as an amber oil. TLC petroleum ether - ethyl acetate, 1:1, Rf = 0.21 
1 
H (400 MHz, CDCl3)  ppm: 7.29 (2H, d, J = 8.61 Hz, Ar-H : m- 4’OMe), 7.24- 7.17 (3H, 
m, Ar-H: OBn), 7.18- 7.11 (2H, m, Ar-H : OBn) 7.05 (2H, d, J = 8.61 Hz, Ar-H : o  4’OMe), 
6.44 (1H, s, Ar-H), 4.85 (2H, s, CH2), 3.89 (3H, s, OMe), 3.88 (3H, s, OMe), 3.86 (3H, s, 
OMe), 3.65 (3H, s, OMe) 
13
Cppm: 168.15 (Ar-OMe), 158.45 (Ar-OMe), 153.1 (Ar-OMe), 151.0 (Ar-OMe), 142.0 ( 
Ar), 135.6 (Ar), 132.6 (Ar), 132.3(Ar-H), 130.7(Ar-H), 128.2 (2Ar-H), 127.8 (Ar), 127.7 
(2Ar-H), 124.1(Ar-H), 117.5(Ar-H), 114.5(Ar-H), 107.0(Ar-H), 66.7 (CH2: OBn),60.8 
(OMe), 60.4 (OMe), 55.9 (OMe), 55.5 (OMe) 
Λmax cm-l: 2894, 2831, 1485, 1451, 1434, 1394, 1281, 1273, 1103, 984, 821, 780, 694 
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2-(2',3',4,4'-Tetramethoxybiphenyl-2-yloxy)acetic acid (118) 
 
To a solution of  2',3',4,4'-tetramethoxybiphenyl-2-ol (104) (0.30 g, 1 mmol, 1 eq) in ethanol 
(10 mL) was added K2CO3 (0.285 g, 2.12mmol, 2 eq) and bromo acetate (0.300 mL,  3 mmol, 
3 eq) and the reaction mixture heated at 80 
o
C for 4 hr. The mixture was cooled and 
concentrated under vacuum. A solution of 2M NaOH (50 mL) was added and stirred for 1 hr. 
The suspension was acidified to pH 1 using conc HCl , extracted with dichloromethane (2 X 
50 mL) and the organic layer washed with water (50 mL), dried with anhydrous magnesium 
sulphate, filtered and concentrated in vacuo. The crude product was recrystallised from 
methanol to yield the product as a white powder (118) (0.310 g, 89%) M.p 129 
o
C. TLC 
petroleum ether - ethyl acetate, 1:1, Rf = 0.03 (As smear) 
1 
H (400 MHz, CDCl3)  ppm: 8.88 (1H, s, COOH), 7.12 (1H, d, J = 8.41 Ar-H : m- 4 OMe), 6.87 
(1H, d, J = 8.5 Ar-H: o  Ar-O CH2), 6.73 (1H, d, J = 8.41 Ar-H : o  4 OMe), 6.56 (1H, dd, J = 2.42, 
8.41 Hz, Ar-H : m- 4’OMe), 6.39 (1H, d, J = 2.31 Ar-H : o  Ar-O CH2), 4.56 (2H, s, Ar-H : O CH2-), 
3.85 (3H, s, OMe), 3.82 (3H, s, OMe), 3.76 (3H, s, OMe), 3.58 (3H, s, OMe) 
13
Cppm: 178.1 (COOH), 162.1 (Ar-OMe), 154.5 (Ar-OMe), 153.2 (Ar-OMe), 152.4 (Ar-OMe), 
142.2(Ar), 134.3 (Ar-H), 132.2  (Ar), 125.2 (Ar), 118.8 (Ar), 115.4 (22 X Ar-H), 94.3 (Ar), 71.2 (o 
CH2), 61.4 (OMe), 60.3 (OMe), 59.2 (OMe), 56.1 (OMe) 
Λmax cm-l: 3309, 2872, 2743, 1617, 1481, 1465, 1344, 1310, 1293, 1115, 1094, 932, 892 
 
 164 
 
3,9,10,11-Tetramethoxydibenzo[b,d]oxepin-7(6 H)-one (119) 
 
2-(2',3',4,4'-Tetramethoxybiphenyl-2-yloxy)acetic acid (118) (0.110 g, 0. 35 mmol, 1 eq) was 
dissolved in a 50:50 trifluoroacetic acid /trifluoroacetic acid anhydride (5 mL) and stirred 
overnight. The solvent was evaporated and the resulting material was dissolved in 
dichloromethane (10 mL). The organic layer was washed with sat. aq NaHCO3 (10 mL), 
water (10 mL), brine (10 mL), dried with anhydrous magnesium sulphate, filtered and 
concentrated in vacuo. The mixture was purified by column chromatography (10 g silica gel, 
hexane - ethyl acetate,  8:2) to yield the title compound (119) as red crystals (0.076 g, 73%), 
m.p. 139 
o C TLC
 petroleum ether - ethyl acetate, 1:1,  Rf = 0.22 
 
1 
H (400 MHz, CDCl3)  ppm:7.58 (1H, d, J = 8.50 Hz, Ar-H : o  4’ OMe), 7.07 (1H, s, Ar-
H: o  4 OMe), 6.75 (1H, dd, J = 2.47 Hz, Ar-H : m – O CH2C), 6.69 (1H, d, J = 2,47 Hz, Ar-
H: o – O CH2C), 4.67 (2H, s : -O CH2), 3.92 (3H, s, OMe), 3.87(3H, s, OMe), 3.78 (OMe), 
3.53 (3H, s, OMe)   
13
Cppm: 200.4 (C=O), 162.7 (Ar-OMe), 158.8 (Ar-OMe), 155.2 (Ar-OMe), 148.7 (Ar-
OMe), 140.3 (Ar), 134.4 (Ar), 131.6 (Ar), 115.7 (Ar-H), 107.8(Ar), 105.1 (Ar-H), 104.5 (Ar-
H), 99.4 (Ar-H), 71.8 (CH2: Ar-CH2), 65.8 (OMe), 63.1 (OMe),  59.2 (OMe), 57.8 (OMe) 
Λmax cm-l: 2905, 2852, 1710 1617, 1481, 1465, 1412, 1270, 1243, 1171, 1143, 1047 
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2-(4,4',5,6-Tetramethoxybiphenyl-2-yloxy)acetic acid (121)
 
To a solution of 4,4',5,6-tetramethoxybiphenyl-2-ol (101) (0.05, 0.17 mmol, 1 eq) in ethanol 
(10 mL) was added K2CO3 (0.07 g, 0.51 mmol, 3 eq) and bromo acetate (0.035 mL,  0.34 
mmol, 2 eq) and the reaction mixture heated at 80 
o
C for 4 hr. The mixture was cooled and 
concentrated in vacuo. A solution of 2M NaOH (50 mL) was added and the mixture and 
stirred for 1 hr. The suspension was acidified to ph 1 with conc. HCl, extracted with 
dichloromethane (2 X 50 mL) and the organic layer washed with water (50 mL), dried with 
anhydrous magnesium sulphate, filtered and concentrated in vacuo. The crude was 
recrystallised from methanol to yield the product as a white powder (121) (0.045 g, 76%), 
m.p 135 
o 
C, TLC petroleum ether - ethyl acetate, 1:1, Rf = 0.08 (smear) 
1
 H (400 MHz, CDCl3)  ppm: 8.21-7.44 (1H, broad s, OH), 7.32 (2H, d, J = 8.21, Ar-H : o  
4’ OMe), 6.95 (2H, d, J = 8.21, Ar-H : o  4’ OMe), 6.35 (1H, s, Ar-H : o  4 OMe), 4.43 (2H, 
s, CH2 : Ar-O CH2), 3.87 (3H, s, OMe), 3.86 (3H, s, OMe), 3.84 (3H, s, OMe), 3.60 (3H, s, 
OMe) 
13
Cppm: 172.8 (COOH), 158.6 (Ar-OMe), 152.6 (Ar-OMe), 152.6 (Ar-OMe), 151.1(Ar-
OMe), 138.2(Ar), 131.7 (22 X Ar-H), 125.2 (Ar), 118.8 (Ar), 113.5 (22 X Ar-H), 95.9 (Ar), 
66.8 (o CH2), 61.1(OMe), 60.9 (OMe), 56.2 (OMe), 55.2 (OMe) 
Λmax cm-l: 3222, 2905, 2865, 1710 1617, 1481, 1465, 1347, 1310, 1253, 1204, 1143, 934 
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1,2,3,9-Tetramethoxydibenzo[b,d]oxepin-7(6 H)-one (22) 
 
 
2-(4,4',5,6-Tetramethoxybiphenyl-2-yloxy) (121) (0.115 g, 0.33 mmol, 1 eq) was dissolved in 
a 50:50 mixture of trifluoroacetic acid /trifluoroacetic acid anhydride (5 mL) and stirred 
overnight. The solvent was evaporated and the resulting material was dissolved in 
dichloromethane (10 mL). The organic layer was washed with sat. aq NaHCO3 (10 mL), water 
(10 mL), brine (10 mL), dried with anhydrous magnesium sulphate, filtered and concentrated 
in vacuo. The mixture was purified by column chromatography (10 g silica gel, hexane - 
ethyl acetate,  8:2) to yield the title compound
 
(122) as red crystals (0.082 g, 75%), m.p. 123 
o 
C, TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.25 
1 
H (400 MHz, CDCl3)  ppm: 7.60 (1H, d, J = 8.50 Hz, Ar-H: p- O CH2), 7.21 (1H, d, J = 
2.92 Hz, Ar-H : o  O CH2), 7.08 (1H, dd, J = 8.11, 2.47 Hz, Ar-H : m- O CH2 ),  6.51 (1H, s, 
Ar-H: o  4 OMe), 4.69 (2H, s : Ar-O CH2), 3.82 (9 H, s, 3 X OMe), 3.53(3H, s, OMe) 
13
Cppm: 203.2 (C=O), 162.3 (Ar-OMe), 159.1 (Ar-OMe), 153.1 (Ar-OMe), 149.4 (Ar-
OMe), 139.1 (Ar), 136.6 (Ar), 134.2 (Ar), 107.1(Ar), 106.2 (22 X Ar-H), 100.0 (Ar-H), 98.2 
(Ar-H), 74.1 (CH2: Ar-CH2), 64.8 (OMe), 60.1 (22 X OMe), 55.5 (OMe) 
Λmax cm-l: 2879, 2852, 1695, 1513, 1473, 1398, 1267, 1243, 1171, 1145, 1100, 865 
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2-Fluoro 3-methoxyphenol (139) 
 
To a purged flask containing 2-fluoroanisole (136) (0.76 mL,  6.76 mmol, 1 eq) and 
pentamethyldiethylenetriamine (1.69 mL,  8.11 mmol, 1.2 eq) in dry THF at -78
o
n-BuLi 
(5.07 mL,  1.6 M in hexanes,1.2 eq) was added followed by stirring for 3 hrs. Trimethyl 
borate ester  
(0.92 mL, 8.11 mmol, 1.2 eq) was added dropwise and the reaction was allowed to warm to 
room temperature and stirred for 1 hr. This was followed by the slow addition of glacial 
acetic acid (0.5 mL, 8.73 mmol, 1.3 eq), then 35% hydrogen peroxide (0.85 mL, 7.5 mmol, 
1.1 eq). Water (20 mL) was added and the reaction was extracted with ethyl acetate (3X50 
mL), dried with anhydrous magnesium sulphate, filtered and concentrated in vacuo to give a 
crude product. This was purified by column chromatography (200 g silica gel, petroleum 
ether - ethyl acetate,  9:1) to yield the title compound as a dark green oil (139) (0.61 g, 63%), 
TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.14 
1 
H (400 MHz, CDCl3)  ppm: 6.95- 6.89(1H, m, ArH), 6.64- 6.59 (1H, m, ArH), 6.54- 6.49 
(1H, m, ArH), 5.19 (1H, b s, OH), 3.81 (3H, s, OMe)  
 
Spectral and physical data for this compound were in accordance with the literature  (Pirrung 
and Park. 2000). 
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1,2,3-Trimethoxy-5-(2-(3-methoxyphenoxy)ethyl)benzene (141) 
 
To a concentrated solution of 3,4,5-trimethoxyphenylethanol (140)  (0.255 g, 1.2 mmol, 1 eq) 
in dry THF (1 mL) was added triphenylphosphine (0.377 g, 1.4 mmol, 1.2 eq), 3-
methoxyphenol (0.360 mL,  1.4 mmol, 1.2 eq) and the mixture sonicated for 10 min. 
Diisopropyl azodicarboxylate (0.285 mL,  1.2 mmol, 1 eq) was then added dropwise and the 
reaction mixture sonicated for 1 hr. The viscous mixture was concentrated in vacuo and the 
crude product was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate,  9:1) to yield the title product (141) (0.410 g, 92%) as a colourless oil, TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.24 
1 
H (400 MHz, CDCl3) 7.23- 7.19 (1H, m, Ar-H), 6.55 (1H, d, J = 2.4, Ar-H : o  
Ar-O CH2, o  OMe), 6.53 (2H, s, Ar-H : o  1, 3 OMe), 6.52 (1H, d, J = 8.21 Hz, Ar-H), 6.49- 
6.42 (1H, m, Ar-H), 4.18 (2H, t, J = 7.11 Hz, Ar-O CH2), 3.88 (6 H, s, OMe), 3.86 (3H, s, 
OMe), 3.81 (3H, s, OMe), 3.06 (2H, t, J = 7.11 Hz, Ar-CH2) 
13
Cppm: 160.9 (Ar-OMe), 160.0 (Ar-OMe), 153.2 (2 X Ar-OMe), 136.6 (Ar), 134.0 (Ar), 
129.9 (Ar), 106.8 (Ar), 106.3 (22 X Ar-H: o  ArCH2), 105.9 (Ar-H). 101.1(Ar-H), 68.7(Ar-O 
CH2), 60.8 (OMe), 56.1 (22 X OMe) 55.2 (OMe), 36.1(Ar-CH2)  
Λmax cm-l: 2887, 2871, 1474, 1458, 1423, 1370, 1266, 1242, 1214, 1038, 932, 899  
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5-(2-(2-Fluoro 3-methoxyphenoxy)ethyl)-1,2,3-trimethoxybenzene (142)
 
To a solution of 3, 4, 5-trimethoxyphenylethanol (139) (0.15 g, 1.2 mmol, 1 eq) in dry THF 
(1 mL) was added triphenylphosphine (0.377 g, 1.4 mmol, 1.2 eq)2-fluoro 3-methoxyphenol 
(0.360 mL,  1.4 mmol, 1.2 eq) and the mixture sonicated for 10 min. Diisopropyl 
azodicarboxylate (0.285 mL,  1.2 mmol, 1 eq) was then added dropwise and the reaction 
mixture sonicated for 1 hr. The viscous mixture was concentrated in vacuo and the crude 
product was purified by column chromatography (10 g silica gel, hexane - ethyl acetate,  9:1) 
to yield the title product (142) (0.370 g, 81%) as a colourless oil, TLC petroleum ether - ethyl 
acetate, 1:1,  Rf = 0.28 
 
1 
H (400 MHz, CDCl3)  ppm: 6.86- 6.82 (1H, m, Ar-H), 6.55- 6.51 (1H, m, Ar-H), 6.61 
(2H, s, Ar-H), 6.45-6.41 (1H, m, Ar-H), 4.20 (2H, t, J = 7.11 Hz, Ar-O CH2), 3.91 (6 H, s, 2 
X OMe), 3.86 (3H, s, OMe), 3.81 (3H, s, OMe), 3.06 (2H, t, J = 7.11 Hz, Ar-CH2) 
13
Cppm: 160.9 (Ar-OMe), 160.4-157.9 (bd, J = 243.99 Hz, C-F), 160.0 (d,   J = 12.51 Hz, 
Ar-OMe; o CF), 153.2 (2 X Ar-OMe), 135.3 (Ar), 134.0 (Ar), 112.5 (d J = 4.28 Hz, Ar), 
110.4 (22 X Ar-H: o  ArCH2), 105.9 (Ar-H). 103.2 (Ar-H), 69.2 (Ar-O CH2), 61.7 (OMe), 
56.3 (22 X OMe) 55.2 (OMe), 39.8 (Ar-CH2)  
Λmax cm-l: 2905, 2861, 1491, 1465, 1432, 1310, 1261, 1243, 1211, 1030, 935, 895, 760 
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2-Fluoro 6-iodo 3-methoxyphenol (152) 
 
To a flask containing 2-fluoro 3-methoxyphenol (139) (1.00 g, 7 mmol, 1 eq) and silver 
trifluoroacetate (1.71 g, 7.7 mmol, 1 eq) in chloroform (10 mL) was added via cannula a 
solution of iodine (1.78 g, 7 mmol, 1 eq) in chloroform (700 mL) over 4 hr. The reaction 
mixture was filtered through a plug of celite
® 
and concentrated in vacuo. The product was 
purified by column chromatography (10 g silica gel, hexane - ethyl acetate, 9:1) to give a 
crude soild that was recyrstallized from chloroform to yield the title compound (152) (1.35 g, 
71%) as a yellow powder. Melting range 91-92 
o
C (Lit - 92 
o
C), TLC petroleum ether - ethyl 
acetate, 1:1, Rf = 0.12 
 
 1 
H (400 MHz, CDCl3)  ppm: 7.37 (1H, dd, J = 2.41, 9.12 Hz, Ar-H : p- F), 6.41 (1H, t, J 
= 8.9 Hz, Ar-H : p- F), 4.72 (1H, s, Ar-OH), 3.89 (3H, s, OMe) 
Spectral and physical data for this compound were in accordance with the literature  
(Nakasato et al. 2006) 
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5-(2-(2-Iodo 5-methoxyphenoxy)ethyl)-1,2,3-trimethoxybenzene (153) 
 
To a concentrated solution of 2-iodo 3,4,5-trimethoxyphenylethanol (105) (0.25 g, 1.2 mmol, 
1 eq) in dry THF (1 mL) was added triphenylphosphine (0.377 g, 1.4 mmol, 1.2 eq), 2-iodo 
5-methoxyphenol (0.36 mL,  1.4 mmol, 1.2 eq) and sonicated for 10 min. Diisopropyl 
azodicarboxylate (0.28 mL,  1.2 mmol, 1 eq) was then added dropwise and the reaction 
mixture sonicated for 1 hr. The viscous mixture was concentrated in vacuo and the crude 
product was purified by column chromatography (10 g silica gel, hexane - ethyl acetate,  9:1) 
to yield the title product (153) (0.413 g, 77%) as a colourless oil, TLC petroleum ether - ethyl 
acetate, 1:1,  Rf = 0.23  
1 
H (400 MHz, CDCl3)  ppm: 7.63 (1H, d, J = 8.6 Hz, Ar-H), 6.61 (2H, s, Ar-H : o  1, 3 
OMe), 6.39 (1H, d, J = 2.6 Hz, Ar-H : o  Ar-O CH2, o  OMe ), 6.33 (1H, dd, J = 2.7, 8.6 Hz, 
Ar-H : m- I), 4.19 (2H, t, J = 6.41 Hz, Ar-CH2), 3.89 (6 H, s, OMe), 3.84 (3H, s, OMe), 3.78 
(6 H, s, OMe), 3.11 (2H, t, J = 6.41 Hz, O CH2) 
13
Cppm: 161.2 (Ar-OMe), 158.1 (Ar-OMe), 153.1 (2Ar-OMe), 139.1 (Ar), 136.6 (Ar), 
134.2 (Ar), 107.1(Ar), 106.2 (22 X Ar-H), 100.0 (Ar-H), 75.2 (Ar-H), 69.9 (CH2-OAr), 60.8 
(OMe), 56.2 (22 X OMe), 55.5 (OMe), 36.1(CH2: Ar-CH2) 
Λmax cm-l:  2831, 2791, 1501, 1465, 1412, 1399, 1261, 1243, 1211, 1132, 932, 833 
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2-Fluoro 4-iodo 1-methoxy-3-(3,4,5-trimethoxyphenethoxy)benzene (154) 
 
To a solution of 3,4,5-trimethoxyphenylethanol (152) (0.25 g, 1.2 mmol, 1 eq) in dry THF (1 
mL) was added triphenylphosphine (0.377 g, 1.4 mmol, 1.2 eq), 6-fluoro-2-iodo 5-
methoxyphenol (0.360mL,  1.4 mmol, 1.2 eq) and sonicated for 10 min. Diisopropyl 
azodicarboxylate (0.285 mL,  1.2 mmol, 1 eq) was then added dropwise and the reaction 
mixture sonicated for 1 hr. The viscous mixture was concentrated under reduced pressure and 
the crude product was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate,  9:1) to yield the title product (154) (0.413 g, 86%) as a colourless oil, TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.27 
1
 H (400 MHz, CDCl3)  ppm: 7.35 (1H, dd, J = 8.91, 2.3 Hz, Ar-H : p- F), 6.47 (2H, s, Ar-
H : o  1, 3 OMe), 6.44 (1H, t, J = 8.71 Hz, Ar-H : m- F), 4.25 (2H, t, J = 7.12 Hz, Ar-CH2), 
3.81(6 H, s, 2 X OMe), 3.79 (3H, s, OMe), 3.75 (3H, s, OMe), 3.05 (2H, t, J = 7.12 Hz, Ar-O 
CH2) 
13
Cppm: 160.9 (Ar-OMe), 160.4-157.9 (bd, J = 246.67 Hz, C-F), 160.0 (d,   J = 12.51 Hz, 
Ar-Ome; o CF), 153.2 (2 X Ar-OMe), 135.3 (Ar), 134.0 (Ar), 112.5 (d J = 4.28 Hz, Ar), 
110.4 (22 X Ar-H: o  ArCH2), 105.9 (Ar-H). 103.2(Ar-H), 69.2(Ar-O CH2), 61.7 (OMe), 56.3 
(22 X OMe) 55.2 (OMe), 39.8 (Ar-CH2)  
Λmax cm-l: 2912, 2831, 1608, 1517, 1494, 1465, 1412, 1399, 1258, 1222, 1135, 1132, 932, 
847 
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3-Fluoro 4,4',5',6'-tetramethoxy-[1,1'-biphenyl]-2,2'-diyl)dimethanol (157) 
 
Sodium borohydride (0.20 g, 3.6 mmol, 4 eq) was added in portions to a flask containing the 
crude dialdehyde (56) (0.32 g, 0.91 mmol, 1 eq) in methanol (5 mL) over a 1 hour period at 0 
o
C. Water (5 mL) was added to vessel and the reaction mixture was extracted with ethyl 
acetate (2 x 10 mL). The organic phase was washed with 1M HCl (10 mL), dried with 
anhydrous sodium sulphate, filtered and concentrated in vacuo. The crude diol was purified 
by column chromatography (10 g silica gel, hexane - ethyl acetate, 1:1) to give a  mixture 
title compound (157) and an unknown impurity that did not separate with further 
chromatography (0.24 g, ~75%), TLC petroleum ether - ethyl acetate, 1:1, Rf = 0.12. The 
mixture was carried on to the next step without further purification. 
1 
H (400 MHz, CDCl3)  ppm: 6.9 (1H, t, J = 8.71 Hz, Ar-H : m- F), 6.84- 6.80 (3H, m, Ar-
H), 4.5 (1H, dd, J = 1.89, 11.58 Hz, CHOH), 4.25- 4.16 (3H, m, CHOH, CH2OH), 3.8 (3H, s, 
OMe), 3.5 (3H, s, OMe), 3.2, (3H, s, OMe), 2.7(2H, s, 2 OH)     
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8-Fluoro 1,2,3,9-tetramethoxy-5,7-dihydrodibenzo[c,e]oxepine (158) 
 
To a flask containing (3-fluoro 4,4',5',6'-tetramethoxybiphenyl-2,2'-diyl)dimethanol (157) 
(0.190 g, 0.5 mmol, 1 eq), and THF (2 mL), conc HCl (2 mL) was added and the reaction 
mixture was heated at refluxed overnight. Water was added (10 mL) and the mixture was 
extracted with ethyl acetate (10 mL), dried with anhydrous sodium sulphate, filtered and 
concentrated in vacuo. Recrystallization with ethyl acetate yielded the title compound (158) 
(0.125 g, 71%) as a white crystalline solid, m.p. 151 
o
C,
 
TLC petroleum ether - ethyl acetate, 
1:1,  Rf = 0.28 
1 
H (400 MHz, CDCl3)  ppm: 7.3 (1H, dd, J = 1.52, 7.36 Hz, Ar-H : p- F), 7.1 (1H, t, J = 
8.39 Hz, Ar-H : m- F), 6.7(1H, s, Ar-H), 4.8 (1H, s, C-H), 4.2 (1H, s, C-H), 3.5 (1H, s, C-H), 
3.4 (1H, s, C-H), 3.2 (3H, s, OMe), 3.0 (3H, s, OMe), 2.8 (3H, s, OMe)     
13
C ppm: 152.1 (Ar-OMe), 150.3-147.8 (bd, J = 243.99 Hz, c-F),  149.6 (Ar-OMe), 145.6 
(d, J = 12.54 Hz, ar-OMe o C-F), 129.9 (Ar), 129.3 (d,  2.3 Hz, Ar), 124.5 (d,  1.90 Hz, Ar), 
124.0 (d J = 4.28 Hz, Ar), 122.0 (d, J = 14.21 Hz,  Ar), 111.6 (d, J = 2.30 Hz, C-H: m -CF), 
107.8  (C-H), 66.8 (CH2), 60.1 (OMe), 59.8 (OMe), 57.6 (d, J = 5.95 Hz, CH2, o C-F), 55.8 
(OMe) 
Λmax cm-l: 2912, 2831, 1608, 1517, 1494, 1465, 1412, 1399, 1258, 1222, 1135, 1158, 1034 
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2',6-Bis(bromomethyl)-3'-fluoro 2,3,4,4'-tetramethoxy-1,1'-biphenyl (159) 
 
To a flask containing (3-fluoro 4,4',5',6'-tetramethoxy-[1,1'-biphenyl]-2,2'-diyl)dimethanol 
(157) (0.50 g, 1.4 mmol, 1.0 eq) in dichloromethane (5 mL), phosphorous tribromide (0.3 
mL,  3.1 mmol, 2.2 eq) was added dropwise at 0 
o
C. After 1 hr the reaction mixture was 
allowed to warm to room temperature and stir overnight. The temperature was lowered to 0 
o
C and water (10 mL) was slowly added. The aq phase was extracted with dichloromethane 
(2 x 10 mL), washed with sat. aq NaHCO3 (2 x 10 mL), brine, dried with anhydrous sodium 
sulphate and concentrated in vacuo. The oil produced was further purified by column 
chromatography (10 g silica gel, hexane - ethyl acetate, 1:1) and recrystallized from ethanol 
to yield the title compound (159) as a white powder (159) (0.49 g, 79%), m.p 145 
o
C. TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.16 
1 
H (400 MHz, CDCl3)  ppm: 7.41 (1H, dd, J = 1.05, 7.22 Hz, Ar-H : p- F), 6.92 (1H, t, J = 8.27 
Hz, Ar-H : m- F), 6.79 (1H, s, Ar-H : o  4 OMe),  4.42 (1H, d, J = 9.88 Hz, Ar-CH2-Br), 4.25 (1H, d, 
J = 10.54 Hz, Ar-CH2-Br), 4.03 (1H, d, J = 10.54 Hz, Ar-CH2-Br), 4.03 (1H, d, J = 10.54 Hz, Ar-
CH2-Br), 3.98 (1H, dd, J = 2.66, 10.21  Hz, CH2Br; o CF), 3.88 (3H, s, OMe), 3.86 (3H, s, OMe), 
3.84 (3H, s, OMe), 3.53 (3H, s, OMe) 
13
C ppm: 150.3-147.8 (bd, J = 243.99 Hz, c-F), 152.1 (Ar-OMe),  149.6 (2 X Ar-OMe), 145.6 (d, J 
= 12.54 Hz, ar-OMe o C-F), 129.9 (Ar), 129.3 (d, J = 2.3 Hz, Ar), 124.5 (d, J = 1.90 Hz Ar), 124.0 (d 
J = 4.28 Hz, Ar), 122.0 (d, J = 14 Hz,  Ar), 111.6 (d, J = 2.30 Hz, C-H), 107.8  (C-H), 62.1 (OMe), 
61.8 (OMe), 57.4 (OMe), 57.1 (OMe) 38.6 (d, J = 6.23 Hz, CH2, o C-F), 29.4 (CH2Br) 
 
Λmax cm-l:  2894, 1598, 1481, 1471, 1453, 1369, 1306, 1293, 1124, 1112, 871, 856 
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8-Fluoro 1,2,3,9-tetramethoxy-5,7-dihydrodibenzo[c,e]thiepine (160) 
 
To a solution of 2',6-bis(bromomethyl)-3'-fluoro 2,3,4,4'-tetramethoxy-1,1'-biphenyl (159) (0.286 
g, 0.6 mmol, 1.0 eq) in methanol/water (20 mL/ 1 mL) sodium sulfide (0.43 g, 1.8 mmol, 3.0 eq) 
was added and the reaction mixture was heated at reflux overnight. The mixture allowed to cool 
and the methanol removed in vacuo. Water (10 mL) was added and the white solid produced was 
collected by filtration. The crude product was further purified by column chromatography (10 g 
silica gel, hexane - ethyl acetate, 1:1) and recrystallized from ethanol to yield the title product 
(160) (0.17 g, 81%). Mp 173 o C TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.21 
1 
H (400 MHz, Acetone-d6)  ppm: 7.02- 6.98 (2H, m, 2 Ar-H: p and m to C-F), 6.88 (1H, s, Ar-H : 
o  4 OMe), 3.87 (3H, s, OMe), 3.84 (3H, s, OMe), 3.83 (3H, s, OMe), 3.75 (1H, d, J = 12.67 Hz, C-
H), 3.53 (3H, s, OMe), 3.33 (1H, d, J = 12.67 Hz, C-H), 3.16 (1H, d, J = 13.22 Hz, C-H), 3.13 (1H, 
dd, J = 3.41 Hz, 12.61 Hz, C-H) 
13
Cppm:153.3 (Ar-OMe),  150.8 (Ar-OMe), 150.23-147.8  (bd, J = 247.13, Hz, C-F),  146.9 (d, J = 
12.81 Hz, Ar-OMe:o CF), 141.7 (Ar-OMe), 131.8 (Ar), 129.0 (d, J = 2.14 Hz, Ar), 125.5 (d, J = 4.08 
Hz, Ar), 124.6 (d, J = 2.08 Hz, Ar-H), 123.7 (d, J = 13.3 Hz, Ar)111.6 (d, J = 2.14 Hz, Ar-H), 107.3 
(Ar-H), 61.1 (OMe), 60.8 (OMe), 56.3 (OMe), 56.0 (OMe), 31.8 (Ar-CH2), 23.4 (d, J = 4.41 Hz, CH-
2:o CF). 
 
Λmax cm-l: 2894, 2831, 1485, 1451, 1434, 139, 1281, 1273, 1103, 984, 821, 780, 694 
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8-Fluoro 1,2,3,9-tetramethoxy-5,7-dihydrodibenzo[c,e]thiepine oxide  and dioxide (161, 
162) 
 
Meta-Chloroperoxybenzoic acid (m-CPBA) (0.06 g, 0.36 mmol, 1 eq) was added to a 
solution of 2',6-bis(bromomethyl)-3'-fluoro 2,3,4,4'-tetramethoxybiphenyl (160) (0.12 g, 0.36 
mmol, 1 eq) in acetone (5 mL) and stirred at 0 
o
C for 5 hrs. Water (20 mL) was added and the 
solution warmed to room temperature. The reaction mixture was extracted with ether (3 x 10 
mL), dried with anhydrous sodium sulphate, filtered and concentrated in vacuo. The crude 
mixture was dissolved in dichloromethane (10 mL) and washed with 2 M NaOH (10 mL). 
The organic layer was washed with brine (20 mL), dried with anhydrous magnesium sulphate 
and concentrated in vacuo. Further purification of the crude mixture was achieved by column 
chromatography (dichloromethane - methanol 9:1) yielding the title compounds. The 
thiepene oxide (161) was recrystallised from methanol (0.04 g, 32%), M.p. 204 
o 
C. TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.34.  Thiepene dioxide (162) was recrystallised 
from ethanol (0.06 g, 48%), m.p. 185 
o C TLC
 petroleum ether - ethyl acetate, 1:1,  Rf = 0.28 
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Thiepine oxide 
1 
H (400 MHz, CDCl3)  ppm: 7.02 (1H, dd, J = 7.78, 1.54 Hz, Ar-H : p- F), 8.62 (1H, t, J = 
8.62 Hz, Ar-H : m- F), 6.59 (1H, s, Ar-H : o  4 OMe), 3.87 (3H, s, OMe),3.84 (3H, s, OMe), 
3.83 (3H, s, OMe), 3.75 (1H, d, J = 12.38 Hz, C-H),  3.53 (3H, s, OMe), 3.33 (1H, d, J = 
13.32 Hz, C-H),  3.16 (1H, d, J = 12.38 Hz, C-H), 3.49 (1H, d, J = 13.32 Hz, C-H) 
13
C ppm:  153.3(Ar-OMe),  150.8 (Ar-OMe),150.2-147.8 (bd, J = 243.61 Hz, c-F), 146.9 
(d, J = 12.63 Hz, Ar-OMe: o C-F), 141.8 (Ar-OMe), 129.0 (d, J = 2.41 Hz, Ar), 125.6(d, J = 
3.98 Ar-H: o CF), 124.7 (d, J = 2.30 Hz, Ar), 11.6 (d, J = 2.02 Hz, Ar-H), 107.3 (Ar), 61.1 
(OMe), 60.8 (OMe), 56.3, (OMe), 56.1 (OMe), 31.8 (CH2- A ring), 23.42 (d, J = 4.48 Hz, 
CH2-o C-F) 
Λmax cm-l 2941, 2832, 1618, 1576, 1484, 1455, 1412, 1349, 1238, 1223, 1146, 1118, 1036 
Thiepine dioxide 
 1 
H (400 MHz, CDCl3)  ppm: 7.2 (1H, dd, J = 1.70, 7.77 Hz, Ar-H : p- F), 7.01 (1H, t, J = 
8.64 Hz, Ar-H : m- F), 6.71 (1H, s, Ar-H : o  4 OMe), 4.45 (1H, dd, J = 2.45, 12.31 Hz, C-
H), 3.90 (1H, d, J = 14.20 Hz, C-H)  3.91 (3H, s, OMe), 3.87 (3H, s, OMe), 3.86 (3H, s, 
OMe), 3.81 (1H, dd, J = 1.90, 10.93 Hz, C-H), 3.68 (1H, dd,  J = 2.45, 12.31 Hz, C-H),  3.58 
(3H, s, OMe) 
13
C ppm: 157.2(Ar-OMe), 155.1-151.7 (bd, J = 245.22 Hz, C-F),  149.5 (2Ar-OMe),146.9 
(d, J = 12.63 Hz, Ar-OMe: o C-F), 132.0 (d, J = 3.21 Hz, Ar), 129.6 (d, J = 4.25Ar-H: o 
CF), 126.1 (d, J = 1.92 Hz, Ar), 117.6 (d, J = 3.18 Hz, Ar-H), 107.3 (Ar), 61.1 (2OMe), 56.3, 
(OMe), 56.1 (OMe), 44.2 (CH2- A ring), 39.3 (d, J = 5.2 Hz, CH2-o C-F) 
Λmax cm-l 2955, 2784, 1633, 1554, 1465, 1434, 1390, 1341, 1222, 1190, 1123, 1112, 1059 
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N-Benzyl-8-fluoro 1,2,3,9-tetramethoxy-6,7-dihydro 5 H-dibenzo[c,e]azepine (165) 
 
Benzylamine (0.28 mL, 2 mmol, 6 eq) was added to a solution of 2',6-bis(bromomethyl)-3'-fluoro 
2,3,4,4'-tetramethoxybiphenyl (0.20 g, 0.42 mmol, 1 eq) in dry DMF (20 mL). Triethylamine 
(0.35 mL,  2 mmol, 6 eq) was added and the reaction was stired overnight at room temperature. 
The mixture was extracted with ethyl acetate ( 2 x 20 mL), the oganic layer washed with water ( 4 
x 100 mL) brine (30 mL), dried with sodium sulphate, filtered and concentrated in vacuo. The 
crude product was further purified by column chromatography (40 g silica gel, hexane - ethyl 
acetate, 7:3) and recrystallized from ethanol to yield the title product (0.12 g, 67%). Mp 140 o C 
TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.19 
1 
H (400 MHz, CDCl3) δ ppm:7.41 (2H, d, J =  7.31 Ar-H), 7.32- 7.26 (3H, m, ArH), 7.21- 
7.17 (2H, m, Ar-H), 6.92 (1H, t, J =  8.99 Hz, Ar-H : m- F), 6.62 (1H, s, Ar-H : o  4 OMe), 
3.99 (1H, d, J =  13.92 Hz, C-H), 3.92 (3H, s, OMe), 3.85 (3H, s, OMe), 3.82 (3H, s, OMe), 
3.69 (1H, d, J =  13.06 Hz, CH), 3.59 (3H, s, OMe), 3.52 (1H, d, J =  13.06 Hz, C-H), 3.44 
(1H, d, J =  11.76 Hz, C-H, N-Benzyl), 3.11 (1H, dd, J =  4.60, 16.31 Hz, C-H (α-N, o CF) 
2.85 (1H, d, J =  11.76 Hz, C-H, N-Benzyl)
 
13
C ppm: ppm:159.1-156.5(bd, J = 251.54 Hz, c-F), 154.2(Ar-OMe),  151.8 (2Ar-OMe), 
149.6 (d, J = 12.54 Hz, ar-OMe o C-F), 136.9(2Ar), 129.3 (d,  2.3 Hz, Ar), 128.1 (2Ar), 
124.5 (d, J = 1.90 Hz Ar), 124.0(d J = 4.28 Hz, Ar), 123.9 (Ar), 122.0(d, J = 14 Hz,  Ar), 
118.3 (Ar-H), 114.2 (Ar),111.6 (d, J = 2.30 Hz, C-H), 107.8  (2C-H), 66.8 (CH2), 60.1 
(OMe), 59.8 (OMe), 57.6 (d, J = 5.95 Hz, CH2, o C-F), 55.8 (OMe) 48.2 (N-Benzyl) 
Λmax cm-l : 2973, 2824, 1611, 1582, 1515, 1476, 1427, 1337, 1203, 1112, 1045, 732, 682 
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2-Formyl-6-methoxyphenyl acetate (167) 
 
Orthovanillin (167) (5.00 g, 32.7 mmol, 1 eq) was dissolved in pyridine (20 mL) and acetic 
anhydride (3.50 mL, 34 mmol, 1.2 eq) added. The mixture was stirred overnight at room 
temperature. The contents of the flask where transferred to a solution of HCl (6 M, 30 mL) 
and stirred for 10 min. The white solid formed was filtered and recrystallized from methanol 
to yield the title compound (168) (4.09 g, 63%) as a salmon coloured solid. M.p. 71 
o
C (Lit - 
71 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.29 
1 
H (400 MHz, CDCl3)  ppm: 10.12 (1H, s, CHO), 7.38 (1H, dd, J = 1.39, 8.0 Hz, Ar-H : 
m- OMe), 7.26 (1H, d, J = 8.20 Hz, Ar-H : m- OMe), 7.14 (1H, d, J = 8.0 Hz, Ar-H : o  
OMe) 3.86 (3H, s, OCH3), 2.89 (3H, s, CH3) 
Spectral and physical data for this compound were in accordance with the literature  (Dark et 
al. 1997). 
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2-Hydroxy-3-methoxy-6-bromobenzaldehyde (170) 
 
2-formyl-6-methoxyphenyl acetate (168) (4.00 g, 21 mmol, 1 eq) was added in small portions 
to a solution of KBr (7.49 g, 63 mmol, 3 eq) and bromine (1.00 mL, 41 mmol, 2 eq) in water 
(40.00 mL) over a 1 hr period. The mixture was filtered and the pink solid collected, 
suspended in 6M HCl (20 mL) and stirred for 3 hrs. The crude solid suspended in sat. aq 
NaHCO3 (20 mL, 50%) for 24 hrs. The solid collected and recrystallized from methanol to 
yield yellow crystals (169) (3.57 g, 75%), m.p. 121
o
C (Lit - 121 
o
C), TLC petroleum ether - 
ethyl acetate, 1:1, Rf = 0.19 
1 
H (400 MHz, CDCl3)  ppm: 12.22 (1H, s, OH), 10.29 (1H, s, CHO), 7.03 (1H, d, J = 8.53 
Hz, Ar-H : o  Br), 6.85 (1H, d, J = 8.53 Hz, Ar-H : o  OMe), 3.83 (3H, s, OMe) 
Spectral and physical data for this compound were in accordance with the literature  (Pettit et 
al. 2000). 
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3-Bromo 2-formyl-6-methoxyphenyl methanesulfonate (171) 
 
To a solution of 2-hydroxy-3-methoxy-6-bromobenzaldehyde (170) (0.275 g, 1.20 mmol, 1 
eq) and triethylamine (2 mL,  1.4 mmol, 1.2 eq) in dichloromethane (10 mL) at 0 
o
C 
methanesulfonyl chloride (0.18 mL,  2.4 mmol, 2 eq) was added. The reaction mixture was 
stirred at first at 0 
o
C for 10 min, then room temperature for 30 min until the development of 
a brown colour. Water (30 mL) was added and the layers separated and the aqueous layer 
extracted with ethyl acetate (2 X 30 mL). The combined organic phases were washed with 
brine (30 mL), dried with sodium sulphate, filtered and concentrated in vacuo to yield a crude 
solid. This was purified by column chromatography (silica gel, petroleum ether - ethyl 
acetate, gradient  9:1 to 1:1) to yield the title compound as a yellow solid (171) (0.290 g, 
79%), m.p. 95 
o
C (Lit - 95 
o
C), TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.26 
1 
H (400 MHz, CDCl3)  ppm: 10.23 (1H, s, CHO), 7.55 (1H, d, J = 8.81 Hz, Ar-H : o  Br), 
7.05 (1H, d, J = 8.81 Hz, Ar-H : o  OMe), 3.82 (3H, s, OMe), 2.24 (3H, s, SOOCH3) 
Spectral and physical data for this compound were in accordance with the literature  
(Edwards et al. 2011). 
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2,2'-Bis(hydroxymethyl)-4,4',5',6'-tetramethoxybiphenyl-3-yl methanesulfonate (172) 
 
NaBH4 (0.05 g, 0.96 mmol, 4 eq) was added in portions to a flask containing the crude 
dialdehyde (36) (0.10 g, 0.24 mmol, 1 eq) in methanol (10 mL) over a 1 hour period at 0 
o
C. 
Water (10 mL) was added to vessel and the reaction mixture was extracted with ethyl acetate 
(2 x 10 mL). The organic phase was washed with 1M HCl (10 mL), dried with anhydrous 
sodium sulphate, filtered and concentrated in vacuo. The crude diol was purified by column 
chromatography (10 g silica gel, hexane - ethyl acetate, 7:3) to give the purified title 
compound (172) (0.08 g, 82%), m.p 125 
o
C (Lit - 125 
o
C), TLC petroleum ether - ethyl 
acetate, 1:1,  Rf = 0.26 
 1 
H (400 MHz, CDCl3)  ppm:  7.05 (1H, d, J = 8.51 Hz, Ar-H : m- 4’ OMe), 6.99 (1H, d, J 
= 8.51 Hz, Ar-H : o  4’ OMe), 6.86 (1H, s, Ar-H : o  4 OMe), 4.59 (1H, dd, J = 4.2, 12.0 Hz, 
CHOH), 4.18- 4.11 (3H, m, CHOH, CH2OH), 3.89 (3H, s, OMe), 3.86 (3H, s, OMe), 3.82  
(3H, s, OMe), 3.56 (3H, s, OMe), 3.41, (3H, s, SOOCH3), 2.7(2H, s, 2OH)     
Spectral and physical data for this compound were in accordance with the literature  
(Edwards et al. 2011). 
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2,2'-Bis(bromomethyl)-4,4',5',6'-tetramethoxybiphenyl-3-yl methanesulfonate (173) 
 
To a flask containing 2,2'-bis(hydroxymethyl)-4,4',5',6'-tetramethoxybiphenyl-3-yl 
methanesulfonate (172) (0.05 g, 0.12 mmol, 1.0 eq) in dichloromethane (5 mL), phosphorous 
tribromide (0.07 mL,  0.36 mmol, 2.2 eq) in dichloromethane (2 mL) was added dropwise at 
0 
o
C. After 1 hr the reaction mixture was allowed to warm to room temperature and stir 
overnight. The temperature was lowered to 0 
o
C and water (10 mL) was slowly added. The aq 
phase was extracted with dichloromethane (2 x 10 mL), the organic layer was washed with 
sat. aq. NaHCO3 (2 x 10 mL), brine, dried with sodium sulphate, filtered and concentrated in 
vacuo. The solid produced was recrystallized from ethanol to yield the title product (173) as a 
white powder which was used in the next step without further purification (0.06 g, 90%), Mp 
152 
o
C,
 
TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.22 
1 
H (400 MHz, CDCl3)  ppm: 7.19 (2H, d, J = 8.51 Hz, Ar-H : m- 4’ OMe), 6.99 (1H, d, J 
= 8.51, Ar-H : m- 4’ OMe), 6.83 (1H, s, Ar-H : o  4 OMe), 4.53 (1H, d, J = 10.31 Hz, CH), 
4.27 (1H, d, J = 10.31 Hz, CH), 4.05 (1H, d, J = 10.31 Hz, CH), 3.98 (1H, d, J = 10.31 Hz, 
CH),  3.93 (3H, s, OMe), 3.87 (3H, s, OMe), 3.83 (3H, s, OMe), 3.55 (3H, s, OMe), 3.42 (3H, 
s, SOOCH3)     
13
Cppm: 153.5 (Ar-OMe), 151.2 (Ar-OMe),  150.7 (Ar-OMe), 141.6 (Ar) Me;o CMes), 
136.0 (Ar), 131.6, 131.1, 129.3(2Ar-H)124.6 (Ar), 40.0 SO2CH3) 111.1 (Ar-H), 107.2 (Ar-
H), 61.1 (OMe), 60.9 (OMe), 56.1(OMe), 56.0 (OMe), 31.7 (CH2), 25.3 (CH2) 
Λmax cm-l:  2947, 1616, 1487, 1414, 1367, 1326, 1272, 1131, 1110, 1026, 871 
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8-( methanesulfonyl)-1,2,3,9-tetramethoxy-5,7-dihydrodibenzo[c,e]thiepine (175) 
 
To a solution of 2',6-bis(bromomethyl)-3'-(methanesulfonyl)-2,3,4,4'-tetramethoxybiphenyl 
(173)  (0.592g, 0.9 mmol, 1.0 eq) in methanol/water (20:1) sodium sulfide (0.683 g, 2.7  
mmol, 3.0 eq) was added and the reaction mixture was heated at reflux overnight. The 
mixture was allowed to cool and the methanol removed in vacuo. Water (10 mL) was added 
and the white solid produced was collected by filtration. The crude product was further 
purified by column chromatography (10 g silica gel, hexane - ethyl acetate, 1:1) and 
recrystallized from ethanol to yield the title product (175) (0.121 g, 26%). Mp 141
o C TLC
 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.30 
1 
H (400 MHz, CDCl3)  ppm:  7.59  (1H, d, J = 8.71 Hz, Ar-H : m- 4’ OMe), 7.12 (1H, d, J 
= 8.71 Hz, Ar-H : o  4’ OMe), 6.93 (1H, s, Ar-H : o  4 OMe), 4.91 (1H, d, J = 11.31 Hz, C-
H), 4.61 (1H, d,  J = 11.31 Hz, C-H), 4.15 (1H, d, J = 11.46 Hz, C-H), 3.99 (3H, s, OMe), 
3.96 (3H, s, OMe), 3.92 (3H, s, OMe), 3.88 (1H, d, J = 11.46 Hz, C-H), 3.73 (3H, s, OMe), 
3.42 (3H, s, S – CH3). 
13
C ppm:153.8 (Ar-OMe), 151.3 (Ar-OMe), 150.6 (Ar-OMe), 142.8  (Ar-OMe), 137.1  
(Ar), 131.0  (Ar), 130.8 (Ar), 130.2 (Ar), 129.0  (Ar-H), 125.4 (Ar-H), 112.3 (Ar-H), 107.6 
(Ar-H), 60.9 (2OMe), 60.7 (OMe), (CH2), 56.1 (OMe), (CH2), 35.3 (-O Ms) 
Λmax cm-l: 3020, 1625, 1565, 1475, 1460, 1350, 1270, 1150, 1135, 920, 825 
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3'-Fluoro 2,3,4-trimethoxy-4'-methylbiphenyl (181) 
 
General procedure 1 
The title compound was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate,  9:1) to yield the title compound (181) as a colourless oil (0.15 g, 84%). TLC 
petroleum ether - ethyl acetate, 1:1, Rf = 0.23 
1 
H (400 MHz, CDCl3)  ppm: 7.27- 7.20 (3H, m, Ar-H), 7.05 (1H, d, J = 8.71 Hz Ar-H : m- 
4 OMe), 6.76 (1H, d, J = 8.71 Hz, Ar-H : o  4 OMe), 3.97 (3H, s, OMe), 3.91 (3H, s, OMe), 
3.73 (3H, s, OMe), 2.34 (3H, s, CH3) 
13
C ppm:162.3 (bd, J = 246.37 Hz, c-F), 159.9 (Ar-OMe), 153.4 (Ar-OMe), 151.4 (Ar-
OMe), 142.8 (Ar) 137.7 (2 Ar), 131.2 (d, J = 5.7, Ar), 124.7 (d, J = 3.11 Hz, Ar), 123.0 (C,d, 
Ar), 115.7(d, J = 24.3 Hz, ar-H, o F),107.5(Ar-H), 60.9 (2OMe),  56.0 (OMe), 14.4(Me) 
Λmax cm-l : 3071, 1316, 1211, 749, 548 
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3'-Fluoro 2,3,4,4'-tetramethoxybiphenyl (182) 
 
General procedure 1 
The title compound was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate,  9:1) to yield the title compound (182) as an amber oil (0.120 g, 92%), TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.29 
1 
H (400 MHz, CDCl3)  ppm: 7.27(1H, dd, J = 2.31, 12.28 Hz, Ar-H), 7.13 (1H, d, J = 
8.81 Hz, Ar-H), 6.92- 6.88 (2H, m, Ar-H), 6.65 (1H, d, J = 8.31 Hz, Ar-H), 3.93 (3H, s, 
OMe), 3.90 (3H, s, OMe), 3.87 (3H, s, OMe), 3.70 (3H, s, OMe) 
13
C ppm:153.2-150.8, (bd, J = 244.91 Hz, C-F), 153.1 (C- OMe),151.3(C- OMe),145.5(C- 
OMe),142.6(Ar), 131.2(d, J = 8.52 Hz, (oMe-o F), 127.2(d, J = 1.48 Hz, Ar), 124.7 (d, J = 
3.46, Ar-H), 124.4 (Ar-H), 116.9 (d, J = 19.58 Hz, Ar-H o CF), 13.0 (d, J = 2.17 Hz, Ar-H), 
107.5(Ar-H), 61.0 (OMe), 60.8 (OMe), 56.3 (OMe), 56.1 (OMe) 
Λmax cm-l : 3038, 1113, 1008, 810, 776 
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2,3,4-Trimethoxy-4'-methyl-3'-nitrobiphenyl (183) 
 
General procedure 1 
The title compound was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate, 9:1) to yield the title compound (183) as green crystals (0.210 g, 88%)  M.p. 141 
o 
C, 
TLC petroleum ether - ethyl acetate, 1:1, Rf = 0.23 
1 
H (400 MHz, CDCl3)  ppm: 8.16 (1H, d, J = 7.69 Hz, Ar-H : m- 4 OMe), 7.69 (1H, dd, J 
= 2.41, 8.46 Hz, Ar-H : o  NO2), 7.38 (1H, d, J = 7.69 Hz, Ar-H : o  4 OMe), 7.07 (1H, d, J 
= 8.12 Hz, Ar-H : m- CH3), 6.79 (1H, d, J = 8.12 Hz, Ar-H : m- CH3), 3.98 (3H, s, OMe), 
3.93 (3H, s, OMe), 3.75 (3H, s, OMe), 2.62 (3H, s, Me) 
13
C ppm:154.9 (Ar-OMe), 151.3 (Ar-OMe), 149.2 (Ar-OMe), 142.7 (ar), 137.3 (ar) 133.7 
(Ar), 132.5 (Ar), 131.74 (Ar), 125.9 (2Ar-H), 125.1 (Ar-H), 124.5(C-H, Ar-H), 60.9 (OMe), 
60.7 (OMe), 56.1 (OMe), 20.3 (CH3) 
Λmax cm-l : 3309, 2931, 1533, 130, 1293, 812, 738, 699 
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2,3,4,4'-Tetramethoxy-3'-nitrobiphenyl (184) 
 
General procedure 1 
The title compound was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate, 8:2) to yield the title compound (184) as yellow crystals (0.132, 83%), m.p. 142 
o
C,
 
TLC petroleum ether - ethyl acetate, 1:1,  Rf = 0.21 
1 
H (400 MHz, CDCl3)  ppm: 7.95 (1H, d, J = 2.31 Hz, Ar-H : o  NO2), 7.65 (1H, dd, J = 
2.32, 8.32 Hz, Ar-H : p- NO2), 7.05 (1H, d, J = 8.41 Hz, Ar-H : m- 4 OMe), 6.95 (1H, d, J = 
8.41 Hz, Ar-H : o  NO2), 6.68 (1H, d, J = 8.41 Hz, Ar-H : o  4 OMe), 3.94 (3H, s, OMe), 
3.86 (3H, s, OMe), 3.84 (3H, s, OMe),3.64 (3H, s, OMe) 
13
C ppm:153.8 (Ar-OMe),153.5 (Ar-OMe), 151.3 (Ar-OMe), 142.7(Ar), 134.8 (Ar) 130.7 
(Ar-H), 126.1(Ar-H), 125.(Ar-H), 124.4 (Ar-H), 113.3 (Ar-H), 107.2 (Ar-H), 61.1(OMe), 
61.0 (OMe), 56.6 (OMe), 56.1 (OMe) 
Λmax cm-l : 3123, 2932, 1516, 1305, 814, 749, 698 
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2,3,4-Trimethoxy-4'-methylbiphenyl (187) 
 
General procedure 1 
The title compound was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate, 10:1) to yield the title compound (187) as a colourless oil (0.122 g, 93%), TLC 
petroleum ether - ethyl acetate, 1:1,  Rf = 0.31 
1 
H (400 MHz, CDCl3)  ppm: 7.21 (2H, d, J = 8.12 Hz, Ar-H : m- CH3), 7.10 (2 H d, J = 8.12 
Hz, Ar-H : o  CH3), 6.90 (1H, d, J = 8.70 Hz, Ar-H : m- 4 OMe), 6.90 (1H, d, J = 8.70 Hz, Ar-H 
: o  CH3), 3.83 (3H, s, OMe),3.81 (3H, s, OMe), 3.55 (3H, s, OMe), 2.31 (3H, s, CH3) 
 
Spectral data was in accordance with the literature (Putta and Ghosh. 2011). 
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2',3',4'-Trimethoxy-N,N-dimethylbiphenyl-4-amine (186) 
 
General procedure 1 
The title compound was purified by column chromatography (10 g silica gel, hexane - ethyl 
acetate,  9:1) to yield the title compound as a colourless oil (0.130 g, 95%), TLC petroleum 
ether - ethyl acetate, 1:1,  Rf = 0.1 
1 
H (400 MHz, CDCl3)  ppm: 7.31 (2H, d, J = 7.62 Hz, Ar-H), 6.97 (1H, d, J = 8.34 Hz, Ar-
H), 6.71 (2H, d, J = 8.34 Hz, Ar-H), 6.61 (1H, d, J = 8.34 Hz, Ar-H), 3.86 (3H, s, OMe), 3.82 
(3H, s, OMe), 3.60 (3H, s, OMe), 2.92 (6 H, s, NMe2) 

C  ppm:152.5 (Ar-NMe2), 151.9 (Ar-OMe), 149.5(Ar-OMe), 142.58(Ar-OMe), 
129.71(2Ar-H), 128.8(Ar), 126.37(Ar), 124.5(Ar-H), 112.3(2Ar-H), 107.4(Ar-H),61.8 
(OMe), 60.7 (OMe), 56.1(OMe), 40.65 (2NMe2) 
Λmax cm-: 2930, 1532, 1471, 1345, 1139, 736, 718 
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